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Abstract
Chronic inflammation and variations in blood flow have been implicated in
the pathogenesis of cardiovascular disease. It is also possible that inflammatory
and rheological processes are involved in the development of mild cognitive im-
pairment and dementia, either through their association with vascular disease or
via some other, more direct effect on the brain. Evidence is increasing for a causal
relationship between Alzheimer’s disease and inflammation, possibly related to in-
flammatory activation of microglia. Inflammatory processes may also be involved
in the pathogenesis of cerebral small vessel disease, which in turn has been linked
to cognitive impairment and dementia. There is also evidence showing that rhe-
ological factors affect cerebral blood flow. However, despite these findings, the
associations between inflammatory and rheological markers and cognitive ability
have not been extensively studied in large groups of ageing people.
The primary aim of this thesis was to test for associations between late-life
levels of inflammatory and rheological markers (C-reactive protein (CRP), fib-
rinogen, tumor necrosis factor (TNF)-α, interleukin (IL)-6, plasma viscosity, and
haematocrit) and cognitive ability. A genetic analysis was then performed to
model single nucleotide polymorphisms (SNPs) in the genes encoding the mark-
ers against cognition in an attempt to determine the weight of evidence for a
causal inflammation-cognition association.
Four studies were used to test these aims with the majority of the analysis
being performed on the Aspirin for Asymptomatic Atherosclerosis (AAA) Trial
(n = 3,350), and the Edinburgh Type 2 Diabetes Study (ET2DS) (n = 1,066).
The Edinburgh Artery Study (n = 534), and the 1936 Lothian Birth Cohort (n
= 1,091), were used as replication cohorts for the genetic analysis. All cohorts
comprised community-dwelling, elderly citizens (aged around 70 years) living
in central Scotland. With the exception of the ET2DS, all data used were for
secondary analyses.
Cognitive ability was assessed in all studies using comprehensive batteries
of neuropsychological tests that included a measure of crystallised intelligence
in the form of a vocabulary test. As performance on such tests varies little
across a lifespan, adjusting for these scores in the late-life models enabled the
determination of estimated lifetime cognitive change. In the case of the 1936
Lothian Birth Cohort an actual age-11 IQ measure was available in addition to
the cognitive follow-up scores recorded at age-70.
Linear regression showed small but significant associations between CRP, fib-
rinogen, and plasma viscosity, and cognition and estimated lifetime cognitive
decline in the AAA Trial. Similar results were observed in the ET2DS for CRP,
IL-6, and TNF-α. These associations tended to be of a magnitude whereby the
markers explained 1% of the variance of the cognitive test scores. The cognitive
domains most consistently associated with the markers were processing speed,
and a data derived general intelligence factor.
A novel genetic analysis was then undertaken to model SNPs against cognitive
ability and decline. Most of the results generated were null findings. However,
strongly significant associations were found between the rs2227412 fibrinogen beta
gene SNP and the cognitive test scores in the ET2DS. Furthermore, the genotype
associated with the lowest cognitive scores was also related to higher levels of
plasma fibrinogen.
Whilst replication of the association between the fibrinogen SNPs and cog-
nition was not found across all cohorts, these results still indicate a potentially
causal role for this haemostatic/inflammatory marker. To date, the majority
of inflammation-cognition associations have focussed on the acute-phase protein
CRP. The main outcomes from this thesis suggest that its close correlate, fib-
rinogen, is an equally, if not more important factor in the complex process of
cognitive ageing.
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Chapter 1
Inflammation, cognition, Type 2
diabetes, and genetics.
1.1 Introduction
Decline in memory and other cognitive abilities is one of the most feared conse-
quences of growing old. Given our generally ageing population, the public health
consequences of such age-related cognitive decline are likely to increase over the
coming years. It has been well established that by the time we observe clinical
symptoms of cognitive deficits, much cerebral damage has already been done (Fil-
lit & Butler 1997). There is thus an urgent need to identify preclinical markers
of future cognitive decline in order to develop effective interventions aimed at re-
ducing neurotoxicity before irreversible neural damage and dementia can occur.
One potentially fruitful area in the search for such markers is the inflammatory
system, which is thought to be involved in the development of Alzheimer’s disease
and may also be important in the development of vascular dementia (Jones 2001,
Schmidt et al. 2002).
The main aims of this thesis were to use data from four large, prospective co-
hort studies based in central Scotland to test the associations between biomarkers
of inflammation and rheology and cognitive ability. In addition to modelling the
late-life biomarker levels against cognitive ability and decline, genetic analyses
were used as a measure of causal inference.
This chapter reviews briefly some of the key background details that were
required prior to conducting the main literature review and analysis. Specifi-
cally, a general overview of inflammation is provided, including some details of
its immunological processes. A large section is then devoted to introducing cog-
nitive ability, including general intelligence, and normal cognitive ageing and its
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determinants. The cognition section closes with a brief description of both Mild
Cognitive Impairment and dementia along with some of the neurological hall-
marks associated with these conditions. The penultimate section of the chapter
introduces Type 2 diabetes – using textbook information and current medical
guidelines to define the disease, its diagnosis, and its risk factors, before two
short literature review sections on its association with both inflammation and
cognition. The chapter closes with an introductory section on genetics, which
describes DNA structure and some of the types of genetic information commonly
used for analyses in genetic epidemiology studies.
Chapters 2 to 4 then provide a detailed description of the specific biomark-
ers analysed in this thesis. Much of the analysis concentrates on the inflam-
matory biomarker, C-reactive protein (CRP), and the inflammatory/rheological
biomarker, fibrinogen. Chapters 2 and 3 provide information on the history, pro-
duction, structure, and genetic determinants of these respective markers. Fur-
thermore, summaries of their associations with cognitive ability and cognitive
decline were investigated by means of a literature review. A similar approach is
taken in Chapter 4, which presents a concise review of the inflammatory markers
tumor necrosis factor (TNF)-α and interleukin (IL)-6. Moreover, this chapter
also introduces several markers of inflammation and cognition that were assessed
as part of the genetic analysis.
A short section describing the main aims of the thesis is then presented before
Chapters 5 to 7 introduce the studies and populations that were analysed. The
two main studies, the Aspirin for Asymptomatic Atherosclerosis (AAA) Trial
and the Edinburgh Type 2 Diabetes Study (ET2DS), are reviewed separately in
Chapters 5 and 6, whilst the replication cohorts, the Edinburgh Artery Study
(EAS) and the 1936 Lothian Birth Cohort (LBC1936), are reviewed together in
Chapter 7.
The results of the biomarker-cognition analyses are provided in Chapter 8,
with the results from the genetic analyses featuring in Chapter 9. A discussion
of these findings is given in Chapter 10, which also includes a summary of the
implications of this work and recommendations for future research.
1.2 Inflammation
Inflammation occurs as the initial response of the body’s immune system to in-
fection or irritation (Kumar et al. 2003). It attempts to remove an offending
stimulus before instigating the healing process for the affected tissue. Inflamma-
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tion can be divided into two categories: acute inflammation, which occurs in the
short term (minutes, days, weeks), and chronic inflammation, which is ongoing
and can last for months or even several years. The symptoms that characterise
an acute inflammatory response are heat (calor), pain (dolor), redness (rubor),
swelling (tumor), and/or loss of function (functio laesa). The first four of these
were described by Celsus with the latter being attributed to Virchow (Hurley
1983).
At a microscopic level, inflammation involves a complicated sequence of events
that includes:
• the dilation of arteries and capillaries, which results in increased permeabil-
ity and blood flow,
• the flow of fluids, such as plasma proteins, from the circulatory system into
the area of inflammation (exudation),
• a migration of white blood cells (leukocytes) into the inflammatory focus
(Gallin et al. 1983, Kumar et al. 2003).
Immunologically, the inflammatory process is activated by the recognition of
the material that is to be eliminated (the antigen). This can occur via specific or
non-specific means. Specific recognition is mediated by antibodies or by receptors
on white blood cells (T lymphocytes) whilst non-specific recognition relies on the
identification of broken down (denatured) proteins by the complement pathway
or by phagocytes (McGeer & McGeer 2002). During the non-specific process,
a recognition component binds to the antigen, which initiates the production
of pro-inflammatory substances (Kumar et al. 2003). These mediators result in
the microscopic events described above although it is the job of phagocytes to
actually destroy antigens through immune mechanisms (Gallin et al. 1983).
Whilst many immune processes are ongoing, resolution with the removal of
antigens often occurs without displaying detectable signs of inflammation. If
clinically apparent inflammation is present then this tends to indicate that:
• the immune system has encountered an unusually large amount of antigen,
• the antigen is presented in an unusual location,
• the antigen was difficult to digest (Gallin et al. 1983).
Inflammation and tissue injury at the immune level are characteristics of a
wide variety of human diseases such as rheumatoid arthritis, chronic asthma, al-
lergic reactions, and inflammatory bowel disease (Hurley 1983). The aetiology of
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inflammation is complicated and studies have also implicated it with other health
conditions and diseases including impaired cognitive function and dementia (Dik
et al. 2005, Gunstad et al. 2006, Ravaglia et al. 2005, Schmidt et al. 2002, Schram
et al. 2007, van Oijen et al. 2007, Yaffe et al. 2003). Whilst it has been peripheral
levels of inflammatory markers that have been associated with these cognitive
disorders, there are several pathways through which cytokines and inflammatory
mediators can communicate directly with neurones in the brain (Strachan et al.
2008). This may result in the activation of cerebral endothelial cells and trans-
portation processes across the blood-brain barrier (Konsman et al. 2002, Perry
2004). Moreover, macrophages in the brain are also capable of producing inflam-
matory cytokines (Strachan et al. 2008).
More details of the inflammatory response system and some of the individual
proteins involved in these processes are discussed at length in Chapters 2 to 4.
1.3 Cognition
The neurobiology of cognitive ageing is a complicated process and understanding
changes in cognition can be demanding for many reasons. One of the most notable
challenges is the discrimination of normal ageing from neural pathologies (Whal-
ley 2002). Given the increased risk of developing conditions such as Alzheimer’s
disease (AD), Parkinson’s disease, diabetes, hypertension, and atherosclerosis
with age, it is ever more likely that elderly adults will experience some form of
neuropathologies (Hedden & Gabrieli 2004). Cognitive ageing research is also
hampered somewhat by study design with longitudinal studies being expensive
and time consuming to conduct. Only a handful of studies have followed up indi-
viduals from childhood or early adulthood into old-age although follow-up studies
of elderly individuals (> 60 years) are becoming more common place.
1.3.1 Defining ‘intelligence’
Before compartmentalizing cognition into sub-units responsible for different func-
tions, scientists attributed intellectual ability to a single ‘general intelligence’
component (Lezak 2004). This was postulated to increase during formative years
with future tissue loss resulting from ageing, accident and disease. However,
refinements to cognitive testing have facilitated greater precision and control
over measurements of intellectual behaviour. Subsequently, cognitive ability is
now recognised as a multi-factorial component that requires a combination of
tests to target its specific domains. Nevertheless, there tends to be strong inter-
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correlations between individual tests, reflecting the presence of a general intelli-
gence factor (Deary & Batty 2007).
Two common approaches to defining intelligence and intellectual function are
those of Lezak and Carroll. Lezak comes from a neuropsychological tradition,
in which the aim is to devise tests for cognitive domains; Carroll comes from
a psychometric tradition, in which the emphasis is to examine how tests of dif-
ferent domains are related to each other. The former approach tends to use
case studies and case-control designs. The latter uses correlational designs with
samples/cohorts to study individual differences in continua.
Lezak’s approach
Lezak defined intellectual function into four major classes (Lezak 2004):
• receptive functions, which involve the acquisition, classification, integration,
and processing of information.
• memory and learning for the obtainment and recall of information.
• thinking, which involves the organization and reorganization of information.
• expressive function, via which information is conveyed or acted upon.
Within these groupings it is possible to differentiate between functions that me-
diate verbal/symbolic information from those that involve data that cannot be
described by words or symbols, such as complex visual or sound patterns.
Carroll’s Three Stratum Theory
A compelling argument of intelligence is also presented in Carroll’s Three Stratum
Theory (Carroll 1993) whereby he identifies, via factor analyses, three layers
representing narrow, broad, and general cognitive ability. The general ability
stratum consists of the general intelligence factor with the broad stratum being
separated into seven separate domains: crystallised intelligence, fluid intelligence,
general memory and learning, broad visual perception, broad audio perception,
broad retrieval ability, broad cognitive speediness and processing speed. The
narrow stratum includes 69 abilities, each of which can be allocated into one of
the seven categories within the broad stratum.
Within the seven broad categories of cognition, crystallised intelligence refers
to retained knowledge that is accumulated over time. By contrast, fluid intelli-
gence can be thought of as the information processing abilities, or the actual use
of knowledge as opposed to its acquisition. Measures of fluid intelligence are less
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robust to physiological adaptations such as ageing and physical damage to the
brain than their crystallised counterparts (Deary & Batty 2007). For example,
certain tests of vocabulary and verbal ability tend to remain preserved through-
out the majority of a person’s lifetime. This conservation can even remain during
the initial stages of dementia whilst other, fluid abilities are showing significant
signs of decline.
Central to intelligence capabilities are an individual’s capacity to memorise
and learn new information. Clinically, three types of memory can be defined:
registration; short-term memory; and long-term memory (Lezak 2004). In the
registration stage, information is held in a sensory store for a very brief period of
one or two seconds. Despite its purported role defined above, Lezak notes that
registration is “neither strictly a memory function nor a perceptual function but
rather a selecting process by which perceptions enter the memory system.” The
details that are processed during this short registration phase are then passed on
to short-term memory, otherwise they decay rapidly.
Short-term memory encompasses the fixation of the information retained dur-
ing the registry process. It behaves “as a limited capacity store from which in-
formation is transferred to a more permanent store” and “as a limited capacity
retrieval system”. This working or primary memory stage will retain information
for between thirty seconds and two minutes unless it is reiterated via rehearsal.
Rehearsal is defined as “any repetitive mental process that serves to lengthen the
duration of a memory trace.”
The final segment of the memory system is that of long-term or secondary
memory. Items committed to long term memory are consolidated as quickly
as half-a-second after they enter short-term storage (Lezak 2004). Long-term
memory can also be separated into recent and remote memories. These can
span from memories amassed in the last few hours, days, weeks, or months, back
to older memories from childhood. Moreover, in the majority of cases, long-
term memories can be thought of as being a continuum with no definite cut-off
between recent and remote events. This dichotomisation only becomes apparent
and meaningful when investigating persons with problems of amnesia (Lezak
2004).
The category of cognitive speediness and information processing speed mea-
sures the ability to assimilate, process, and output new information. Theories
suggesting processing speed as a measure of performance in simple and complex
cognitive tasks have been proposed since the first days of cognitive testing (Deary
et al. 2001). There is some evidence to support this with reaction time scores
6
being shown to correlate significantly with intelligence test scores (Deary 2000);
the higher the cognitive function, the faster and less variable the reaction time.
For the remaining broad categories, visual and audio perception defines the abil-
ity to interpret information from visible light and audible sounds to the eyes and
ears, respectively. Finally, broad retrieval ability denotes “a capacity to readily
call up concepts, ideas, and names from long-term memory. (Lezak 2004)”
Moving further ‘downstream’ beyond the third stratum yields the individual
cognitive tests that are used to assess the cognitive domains identified within each
stratum. Due to the complex nature of cognitive function it is very difficult to
devise a test or group of tests to measure a single domain without tapping abilities
from other areas. Nevertheless, classification of tests into general domains is still
possible, although caution must be exercised when using results of individual
tests to make inferences on the broader domains.
1.3.2 Cognitive change
Thus far just some of the difficulties in defining and measuring cognitive abil-
ity have been discussed. A further layer of complexity is added if one considers
cognitive change and the identification of factors involved in cognitive decline.
As already mentioned, one of the main difficulties in assessing cognitive decline
is the discernment of normal ageing from pathological decline. This subsection
addresses normal cognitive ageing and its determinants with Mild Cognitive Im-
pairment and dementia being discussed in subsections 1.3.3 and 1.3.4.
Whilst performance on many cognitive tasks declines over time, the age at
onset and the rate of decline can vary substantially across domains (Hedden &
Gabrieli 2004). Much of the change in cognition may be attributed to a de-
cline in the general factor although domain specific deficits can also be described
(Whalley et al. 2004). Cross-sectional and longitudinal studies have both shown
declination from early adulthood in the following domains: delayed recall of verbal
information; working memory; short-term recall; and processing speed (Hedden
& Gabrieli 2004). Several studies note processing speed to be the domain showing
the most prominent changes across the adult lifespan (Hedden & Gabrieli 2004,
Yankner et al. 2008). This may suggest why older persons require more time to
absorb new information. It has also been hypothesised that specific candidate
domains, such as processing speed, are the main focus of age-related changes and
thus, mediate the effects of age on other domains (Whalley et al. 2004). However,
despite these findings the evidence is far from conclusive with different patterns of
decline in cognition being observed for different domains within different studies.
7
Estimated lifetime cognitive change
Although many areas of cognition decline over time, some abilities remain rela-
tively stable throughout a lifetime’s duration. Most notably these include well
practised tasks or tasks involving knowledge. Long-term memory of life history,
implicit memory, attention span, vocabulary, and semantic knowledge also show
relative stability over time (Hedden & Gabrieli 2004, Yankner et al. 2008).
Given that performances on vocabulary-based tests tend not to vary, studies
have used this information to help estimate lifetime cognitive change (Rafnsson
et al. 2007). Scores from validated tests such as the Mill Hill Vocabulary Scale
and the National Adult Reading Test can be used to estimate pre-morbid or prior
cognitive ability (Deary et al. 2004). This is particularly useful in that very few
studies have measures of cognition ranging from early adulthood to old age. It
has been shown that late-life cognitive scores adjusted for a late-life vocabulary-
based estimate of pre-morbid ability correlate highly with actual cognitive change
measured across a lifetime (Crawford et al. 2001). The methodology applied by
Rafnsson et al. to estimate cognitive change was to enter the vocabulary-based
test scores as covariates in a regression model where late-life cognitive ability was
the dependent variable. This technique was applied to the estimated lifetime
cognitive change models in this thesis.
In addition to the stability of vocabulary-based measures of cognition, there is
evidence to suggest that some processes, such as emotional stability, may improve
with age (Yankner et al. 2008). The preservation of these facets may aid older
persons to derive more efficient or effective strategies when performing tasks that
younger persons rely on processing abilities for.
The change or lack of change in cognition across time has been assessed using
both cross-sectional and longitudinal study designs. There are pros and cons to
both methods with longitudinal studies having the obvious advantage of assessing
change amongst the same group of individuals. However, they can also under-
estimate the actual associations due to practice effects and sample attrition, with
the most severely impaired being more likely to be censored. The main problem
involved in collecting cross-sectional data is the possibility of cohort differences
between study groups.
Determinants of normal cognitive ageing
There are several factors that influence individual differences in normal cognitive
ageing (Deary & Gow 2008, Hendrie et al. 2006). These include modifiable and
non-modifiable determinants such as:
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• genetic variation,
• brain white matter pathology and integrity,
• education,
• cardiovascular risk factors,
• depression,
• psychosocial factors (e.g. socio-economic status, social networks, stress),
• physical activity,
• chronic illness,
• lifestyle factors (e.g. diet).
1.3.3 Mild Cognitive Impairment
During the ageing process, trajectories of cognitive decline can differ markedly
between individuals. Whilst some experience negligible change in cognitive func-
tion, others may deteriorate dramatically (Christensen 2001). Furthermore, many
who go on to develop dementia will experience a transitional phase of decline prior
to clinical diagnosis. This period of decline provides a window of opportunity for
intervention and clinical treatment in the attempt to postpone or prevent further
deterioration (Bischkopf et al. 2002).
A prominent concept in age-related cognitive decline is that of mild cogni-
tive impairment (MCI). This accounts for the stage between normal ageing and
dementia where a patient shows decreased performance on memory tasks but
not sufficiently so as to be clinically diagnosed with dementia (Petersen et al.
1999). Although widely used as a diagnostic entity of sub-clinical cognitive im-
pairment (Davis & Rockwood 2004), no unique MCI definition currently exists.
The original proposal for MCI required the presentation of the following quartet
of conditions:
• a memory complaint, preferably confirmed by an informant.
• an objective memory impairment for age.
• a relative preservation of other cognitive functions.
• no dementia. (Petersen et al. 1999)
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In recent years, adaptations and refinements have been made to the criteria
to include forms of mild dysfunction other than memory loss (Portet et al. 2006).
The conversion rate of MCI into dementia is around 10-15% per year (Petersen
et al. 1999) with the annual incidence of newly diagnosed cases of MCI being
between 3-5% (Rusinek et al. 2003). Neurologically, the symptoms of MCI include
an increased number of neurofibrillary tangles in an area of the brain associated
with memory (the temporal lobe) (Hedden & Gabrieli 2004).
1.3.4 Dementia
At the opposite end of the cognitive spectrum from normal ageing is dementia.
As previously mentioned, this state can be reached via declination in cognitive
function in persons with MCI or by more direct means. The term dementia
refers to a syndrome, not a single disease, and is characterised by chronic loss
of cognitive function (van der Flier & Scheltens 2005). Over the next 40 years,
the expected number of persons in the UK with dementia is expected to rise over
two-fold from 700,000 to 1.7 million (Strachan et al. 2008).
The most common causes of dementia are Alzheimer’s disease and through
vascular complications (Vascular Dementia – VaD). Most commonly diagnosed
in persons aged over 60, the neurological hallmarks of AD are amyloid plaques
and neurofibrillary tangles. The former consist of an aggregation of insoluble β–
amyloid proteins, which are thought initiate the deterioration of neuronal synapse
function, composition, and function. Neurofibrillary tangles are described by
Rosenzweig and Leiman (Rosenzweig & Leiman 1982) as “abnormal whorls of
filaments which formed a tangled array inside the cell”.
In comparison, VaD is a term for many different processes that result in






The most common form of VaD results from cerebral small vessel disease,
which is associated with the presence of lacunar infarcts (lesions caused by the
occlusion of arteries) and white matter lesions (damage to the myelin) (Bruce
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et al. 2003, Munshi et al. 2006). By contrast, large vessel cognitive impairment
tends to be embolic with cerebral damage via numerous infarcts that are widely
distributed throughout the brain, or via a single infarct in a critical area of the
brain (Strachan et al. 2008). Ischaemic-hypoperfusive VaD occurs via reduced
blood flow to the brain (Román 2004) whilst haemorrhagic VaD describes bleeds
in the brain-ruptured blood vessels (Meyer et al. 2000).
Presently, several criteria can be used in the diagnosis of VaD (Graves 2004,
Wetterling et al. 1996) although it is often not possible to distinguish between
VaD and AD (van der Flier & Scheltens 2005). Complicating matters further, it is
also possible for VaD and AD to co-exist in what is termed mixed dementia, and
for both conditions to share underlying risk factors and neuropathological features
(Ritchie & Lovestone 2002). Within normal ageing, a combination of oxidative
stress, inflammation, and alterations to cerebral microvascular structure have
been credited as the cause of cognitive impairment (Riddle et al. 2003) Although
much of MCI and pathological ageing can also be attributed to these reactions,
most healthy brains display a varying degree of neuropathological features that
are typical of AD (Whalley et al. 2004).
In summary, the neuropathology of age-related cognitive decline is compli-
cated and its biological basis remains largely unknown. Whilst current thinking
is opposed to a widespread loss of neurons in favour of restricted loss to specific
cortical regions (Rasmussen et al. 1996), the presence of neurofibrillary tangles
and amyloid plaques in seemingly healthy brains makes clinical diagnoses of men-
tal health complications extremely complex.
1.4 Diabetes
Diabetes Mellitus is a chronic metabolic disorder that is characterized by in-
creased plasma glucose. There are two types of diabetes that can be diagnosed:
insulin dependent (Type 1 diabetes), and non-insulin dependent (Type 2 dia-
betes). There are approximately 2.5 million people with diabetes in the UK and
a further 500,000 with undiagnosed diabetes (Diabetes UK 2009). In the UK,
Type 2 diabetes accounts for between 85–95% of all sufferers. Type 1 diabetes
usually occurs before the age of 40 with Type 2 diabetes more likely to be present
after this age (Diabetes UK 2009). However, it is becoming increasingly common
for Type 2 diabetes to be diagnosed in people from as young as the age of seven.
There is also an increased prevalence of Type 2 diabetes in some younger eth-
nic populations, for example South Asian and African Caribbean persons are
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often diagnosed from 25 years upwards (Diabetes UK 2009). Moreover, by the
year 2030 it has been projected that 366 million people worldwide (4.4% of the
population) will have diabetes (Strachan et al. 2008).
Type 1 diabetes occurs via the destruction of beta cells in the pancreas
(Williams & Pickup 1999). These cells are responsible for the production of
insulin, an essential hormone in the metabolism of glucose. As a result, the body
is forced to use its fat stores as a source of energy. Presently, the main treatment
for Type 1 diabetes is the administration of insulin shots.
By contrast, Type 2 diabetes is characterised by high blood glucose levels
resulting from insulin resistance (Williams & Pickup 1999). Insulin levels initially
rise in an attempt to drive glucose into the cells. However, the pancreas ultimately
struggles to keep up with the production and insulin levels fall. This leads to
elevated blood glucose levels and symptoms of the condition.
1.4.1 Diagnosis
The following diagnostic criteria are described using information from the Second
Edition of the Handbook of Diabetes (Williams & Pickup 1999) and from the
World Health Organisation website1.
Diabetes is diagnosed through the identification of chronic hyperglycemia. If
a patient is presented with classic symptoms such as thirst, passing large volumes
of urine (polyuria), or weight loss then a test of random blood glucose will provide
an instant indication as to whether he/she has diabetes. If the patient’s blood
glucose level is slightly elevated or if there are no classical symptoms or signs
then a formal test of oral glucose tolerance will be conducted. For the oral
glucose tolerance test the subject is given a morning blood test after an overnight
fast. After blood withdrawal, 75g of glucose is given by mouth before a further
blood sample is taken two hours later. A diagnosis of diabetes is made if the
fasting plasma glucose level is in excess of 7.0mmol/l or the value of the second
test exceeds 11.1mmol/l. The international measurement criteria, which is set by
the World Health Organisation also recognises an intermediate stage of abnormal
plasma glucose levels, called impaired glucose tolerance (IGT). This is diagnosed
when the fasting plasma glucose level is less than 7.0mmol/l and the two hour
repeat measure is between 7.8–11.1mmol/l. Persons diagnosed with IGT are
reviewed and retested periodically.
Once a diagnosis of diabetes has been made, the next stage is classification into
Type 1 or Type 2 diabetes. It is more likely to be the former if the symptoms
1http://www.who.int/diabetes/en/
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presented include weight loss and sustained ketosis (elevated levels of ketone
bodies in the blood, which are used as an alternative energy source to glucose)
although further tests can be carried out to aid a formal diagnosis.
1.4.2 Risk factors and management of diabetes
Whilst both types of diabetes are currently incurable, simple changes to diet and
physical activity can help to control the effects of Type 2 diabetes (Diabetes UK
2009). Some of the strongest risk factors associated with the condition include
obesity, old age, ethnicity, physical inactivity, previous gestational diabetes, and
having one or more parent or sibling with Type 2 diabetes (Mayo Clinic Staff
2009).
As we get older, insulin production decreases due to age-related impairment of
the pancreatic beta cells. Most persons that are diagnosed with Type 2 diabetes
are over the age of 40 with the peak age of onset being around 60 years (Diabetes
UK 2009, Williams & Pickup 1999). However, it is becoming increasingly more
common for young adults and children to be diagnosed with diabetes (Diabetes
UK 2009). This is mostly linked to increasing rates of obesity and decreased
physical activity. The visceral fat that is present in truncal obesity is more
metabolically active than peripheral fat and also circulates large quantities of
non-esterified fatty acids (Williams & Pickup 1999). These acids have several
properties that can lead to insulin resistance including inhibition of glucose uptake
in muscles. The relationship between a lack of physical exercise and diabetes is
thought to be due to exercise increasing insulin sensitivity and preventing obesity
(Williams & Pickup 1999).
There is also variation in the prevalence of Type 2 diabetes by ethnicity (Di-
abetes UK 2009, Mayo Clinic Staff 2009, Williams & Pickup 1999). Higher rates
are found in populations that come from a South Asian background. In the
United States, African Americans, Mexican Americans, and Native Americans
have particularly high incidence rates of the disease.
1.4.3 Association with cognition
There is longitudinal evidence to implicate Type 2 diabetes as a risk factor for
age-related cognitive decline and dementia (Biessels et al. 2006, Cukierman et al.
2005, Strachan et al. 1997). Compared to a non-diabetic population, the risk of
dementia is 1.5–2.5 times greater in persons with Type 2 diabetes (Price et al.
2008a). However, the exact mechanisms underpinning the association are unclear.
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In addition to its relationship with hyperglycemia and hypoglycaemia, Type 2 di-
abetes is known to be a cause of microvascular disease, retinopathy, nephropathy,
and macrovascular disease - including coronary heart disease and stroke (Starr &
Convit 2007). Consequently, vascular dementia is common amongst older persons
with Type 2 diabetes. Whilst it is likely that diabetes-related cognitive dysfunc-
tion has a multi-factorial pathogenesis, there is growing evidence to implicate a
role for diabetes specific risk factors e.g. metabolic derangements and a range of
circulating biomarkers and genetic risk factors (Price et al. 2008a).
The association between Type 2 diabetes and cognitive decline is well de-
scribed and summarised concisely in a review paper by Kodl and Seaquist (Kodl
& Seaquist 2008). They describe strong evidence for decreased cognitive per-
formance in persons with Type 2 diabetes in the following domains: memory,
psychomotor speed, executive function, verbal fluency, visual retention, atten-
tion, and complex motor functioning. Despite many studies examining the link
between diabetes and cognitive function, there are inconsistencies in controlling
for covariates. Age is almost always adjusted for although the same cannot be
said for other covariates. Amongst the potential confounders and comorbidities,
severe hypoglycemic events have been related to cognitive impairment in younger
persons, although these tend to have less influence in ageing persons with diabetes
(Kodl & Seaquist 2008). In addition to its association with other cardiovascular
complications, those with diabetes are twice as likely to suffer from depression,
which is similarly associated with impaired cognitive function. They are also at
greater risk of developing vascular dementia and Alzheimer’s disease (Kodl &
Seaquist 2008).
One of the complications that precedes diabetes, impaired glucose tolerance
(IGT) has been associated with poorer cognition across the domains of work-
ing memory, verbal declarative memory, and executive function (Messier 2005).
These decrements were observed in older persons under fasting conditions but di-
minished after re-testing post consumption of a glucose solution. The relationship
between IGT and cognitive dysfunction was also present but reduced in younger
persons. Subsequently, it would seem natural to assume that progression from
IGT to Type 2 diabetes would result in a concomitant change in cognition. How-
ever, this does not appear to be the case. Messier hypothesises that this may be
due to confounding factors modulating the relationship (Messier 2005). As previ-
ously commented, Type 2 diabetes is a disease that often occurs in combination
with other conditions leading to increased risk of cardio and cerebrovascular dis-
ease, which themselves are independent predictors of cognitive dysfunction.
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Furthermore, short-term variation in blood glucose concentration may have a
significant effect on cognitive function in those with diabetes. One study (of just
20 subjects) found an increase in blood glucose levels to 16.5mmol/l for one hour
to have a negative impact in the working memory, attention, and mood (Som-
merfield et al. 2004). In addition, a multi-centre randomised trial found strict
glycemic control over a 26 week period in 145 persons with Type 2 diabetes to
improve performance in working memory (Ryan et al. 2006). Finally, a one year
follow-up study of 156 persons found elevated post-prandial glucose to associate
significantly with poorer executive function and attention performance (Abbate-
cola et al. 2006). To observe significant associations over such short follow-up
periods perhaps indicates that functional consequences of hyperglycemia e.g. al-
tered cerebral blood flow, may cause cognitive dysfunction. Moreover, in a pop-
ulation of nearly 2,000 post-menopausal women, it was found that those with a
HbA1c (glycated haemoglobin, which is a measure of glucose control over the past
6-8 weeks) of more than 7.0% had a 4-fold increase of developing mild cognitive
impairment (Yaffe et al. 2006).
For those with good glycemic control who are under the age of 70, Type 2
diabetes has little impact upon cognitive function (Messier 2005). By contrast,
those with poor glycemic control and underlying micro or macrovascular disease
may be at risk of impaired cognition. Beyond the age threshold of 70 years, it
is likely that accelerated cognitive decline is a result of Type 2 diabetes and its
interaction with vascular dementia and Alzheimer’s disease. The domains most
affected in younger persons are processing speed and verbal episodic memory
with extension to most domains beyond the age of 70. The severity of decline is
noticed most for those with concurrent vascular disease (Messier 2005).
In terms of describing the mechanisms that correspond to the cognitive de-
cline, one study forwards three potential pathways (Biessels et al. 2006). The
first focuses on decline via ischemic vascular disease as Type 2 diabetes is closely
involved in the pathology of both large and small blood vessels. Secondly, they
propose the toxic effects of high glucose concentration, which is equivalent to the
role of irregular glucose metabolism in other long-term complications of diabetes.
Finally, it is possible that cognitive dysfunction is a result of affected insulin
homeostasis in the brain. It appears that insulin, in accordance with insulin-
degrading enzyme, modulates cognition, possibly through cerebral amyloid and
tau metabolism.
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1.4.4 Association with inflammation
In addition to its implication in the development of atherosclerosis, inflammation
has been studied in relation to insulin resistance and Type 2 diabetes. Several
studies have since reported that chronic, low-grade inflammation may induce
insulin resistance and that it might be part of the pathway leading to diabetes.
Furthermore, around 90% of persons with Type 2 diabetes show insulin resistance,
which normally precedes the first symptoms of the disease (Sjohölm & Nyström
2006).
It is well recognised that cardiovascular disease is one of the main complica-
tions of insulin resistance and Type 2 diabetes. However, it may be possible that
inflammation is not only a consequence of atherosclerosis but that it also plays an
active role in the initiation of insulin resistance. Prospective studies have found
elevated levels of acute-phase proteins (including C-reactive protein) to predict
the development of insulin resistance and Type 2 diabetes (Nesto 2004).
One mechanism by which inflammation and insulin resistance are related is
obesity (Barzilay & Freedland 2003). Persons with obesity and, in particular,
truncal obesity tend to secrete an increased concentration of inflammatory cy-
tokines and proteins. Some of these cytokines, such as TNF-α and IL-6 affect
the sensitivity of insulin and its secretion. In addition, they also act on the liver,
increasing the synthesis of other inflammatory proteins e.g. CRP and fibrinogen.
A second possible mechanism of association is during hyperglycaemia, which
yields an increased concentration of glycation end products (Coppola et al. 2006).
These activate the macrophages, increase oxidative stress, and thus up-regulate
the synthesis of the IL-1, IL-6, and TNF-α, which in turn augments the produc-
tion of CRP.
Conversely, it may be that chronic inflammation occurs as a by-product of
the insulin resistance syndrome (Nesto 2004). Insulin is known to have acute
anti-inflammatory properties that include the ability to suppress the synthesis of
acute-phase proteins. Therefore, it is plausible that increased production of CRP
and fibrinogen are a consequence of insulin resistance.
Whether inflammation lies on the causal pathway towards Type 2 diabetes
is not yet clear although recent studies have developed methodologies to try and
test this hypothesis. One such approach is Mendelian randomisation. Briefly, this
models the exposure variable against the outcome whilst stratifying for genetic
variants which control the synthesis of the exposure phenotype. As genetic infor-
mation is determined at conception, this method helps to reduce for confounding
effects that may arise from basic association studies. A detailed description of
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Mendelian randomisation and the statistical methods used in its application is
provided in Chapter 9.
One study that used this methodology investigated the association between
CRP and insulin resistance and Type 2 diabetes (Brunner et al. 2008). Using
genetic and physiological information from 4,674 men and women with Type 2
diabetes from the Whitehall Study (mean age 49 years), the authors tested the
relationship between haplotype-stratified CRP levels against HOMA-IR (a mea-
sure of insulin resistance) and HbA1c. The findings from these analyses found
it unlikely that CRP is causally associated with either of the factors. Similarly,
a pooled analysis of CRP haplotypes and diabetes in the Whitehall Study and
a replication cohort, the Northwick Park Heart Study II, showed no association
between CRP variants and diabetes risk (Type 2 diabetes prevalence = 7.4%, n
= 522). Finally, data from the Wellcome Trust Case Control Consortium also
showed no association between CRP haplotypes and diabetes risk. In conclusion,
the authors report that the CRP–diabetes relationship may be due to confound-
ing from upstream effectors of inflammation as opposed to downstream markers.
They suggest future investigations should examine cytokines at the start of the
inflammatory cascade, for example IL-6 and TNF-α.
1.5 Genetics
Despite many epidemiological studies providing evidence for a relationship be-
tween a phenotype and disease outcome, it is often very difficult to determine if
the association is causal. One of the most challenging aspects in such a situa-
tion is to account for all potential confounders and mediators within the model.
Such complications can be partially resolved by a genetic epidemiology approach,
whereby genetic variants can be modelled directly, or via an intermediate phe-
notype, against the outcome variable. The main advantage of considering DNA
variation is that a person’s germline is fixed at conception. This means that mod-
elling with genetic data bypasses some of the problems of confounding. However,
genetic association studies do require that the variant under investigation affects
the intermediate phenotype or outcome variable. If the genetic variant is actu-
ally a proxy marker for the true causal variant or if there are multiple variants
that affect the phenotype or outcome then it becomes much harder to annotate
the causal mechanism and subsequently, develop interventions. The introductory
material presented in the following subsections is common knowledge. Three
textbooks were used to reference the majority of the content (Carey 2002, Fal-
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coner & MacKay 1995, Plomin et al. 2000); individual references are included for
descriptions of the more complex issues.
1.5.1 DNA
The genetic blueprint for life which regulates cell growth, division, and function
is stored in a person’s DNA. DNA is comprised of two long polymer strands that
are made up of individual units called nucleotides. The genetic code is written
using four nucleotides: adenine, cytosine, thymine and guanine (A, C, T, and
G). These nucleotides form complementary base pairs (A–T and C–G) when the
two polymer strands align, bond, and twist to give DNA its classic double helical
shape.
Within eukaryotes DNA is organised into 46 entities known as chromosomes.
There are 22 pairs of autosomal chromosomes and two sex chromosomes. Chro-
mosomes are organised structures of DNA, sections of which are grouped together
to form genes. Genes contain coding information for specific proteins, which sub-
sequently correspond to a variety of biological traits.
When a gene is active a copy of it is made by a process called transcription.
Transcription begins when the gene unwinds into two strands. Free RNA nu-
cleotides then form complementary base pairs with one strand of DNA bases,
and the mRNA strand is synthesised before it peels off from the DNA and moves
from the cell nucleus into the cytoplasm. Translation of the mRNA into proteins
then takes place in the cytoplasm. The mRNA strand attaches to a ribosome
before tRNA molecules are used to read its coding triplets. Peptide bonds then
form between the adjacent amino acids to form proteins.
The regions of the gene that are translated into proteins are known as ex-
ons with the non-translated regions referred to as introns. The number of and
length of both introns and exons varies by gene. This main section of the gene
is flanked at the front and back by the 5’ and 3’ untranslated regions (UTRs),
respectively. Several roles in gene expression have been attributed to the UTRs,
including mRNA stability, and translational efficiency (the rate of mRNA trans-
lation into proteins). In terms of location, genes are situated at fixed points on
the chromosome called loci.
1.5.2 Genotypes, phenotypes, and haplotypes
As diploid organisms, humans have two copies of each gene in their somatic cells.
Each copy of the gene is referred to as an allele and the combined information
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from both alleles represents an individual’s genotype. If the two copies of the
gene are identical then the alleles will also be the same and the genotype is said
to be homozygous. However, if there is allelic variation then the genotype will
be heterozygous. The physically expressed form of the gene (the phenotype) is
determined by the alleles and depending on the combination of alleles, recessive
or dominant traits may be exhibited.
It can also be informative to consider groups of alleles on the same chromo-
some that are inherited together in blocks. The formal name for such a group
is a haplotype – a contraction of the phrase ‘haploid genotype’. Haplotypes are
built using the details of consecutive alleles and are perhaps better markers of
phenotypes than genotypes given that they reflect blocks of inherited information
as opposed to single variants. Unfortunately, as humans are diploid organisms,
haplotype inference is not guaranteed to be 100% accurate. Where a person is
heterozygous for a genotype, it is not possible to determine for certain which
allele should go with which haplotype. The alleles in this situation are described
as being phase ambiguous (Spinka et al. 2005). In order to generate haplotypes,
statistical methods such as the Expectation–Maximization (EM)–algorithm are
used to impute haplotype frequencies at the population level. Computer software
packages such as SimHap2 can generate such haplotypes and then test for asso-
ciations with outcome phenotypes, whilst incorporating the uncertainty around
inferred haplotypes into the modelling procedure.
1.5.3 Genetic variation
There are numerous ways in which the DNA sequence of a gene can be altered.
Depending on the location of the mutation and whether it alters the protein
structure, genetic variants can have varying health effects. There are several
different types of mutation that alter genetic structure such as small-scale and
large-scale mutations.
Small-scale mutations incorporate alterations that affect a gene in one or a
few nucleotides. These include:
• Single nucleotide polymorphisms (SNPs) - as the name would suggest, a
SNP is DNA sequence variation whereby a single nucleotide in the genome
varies between members of a species. This difference may result in a synony-
mous (silent) or non-synonymous (non-silent) mutation. A silent mutation
is when there is a change in the DNA sequence but no change in the protein
2http://www.genepi.org.au/simhap.html
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that is coded - hence there is no noticeable difference in the biological trait
for which that particular gene is responsible for programming. By contrast,
non-synonymous SNPs tend to be more dangerous in that the nucleotide
alteration results in a different protein being coded, which could potentially
cause serious damage.
• Insertions - this is where one or more nucleotides are added to the DNA. The
normal causes of an insertion are transposons (sequences of DNA that are
capable of moving within a cell) and errors during replication of repeating
elements.
• Small deletions - this is when one or more nucleotides are removed from the
DNA. They occur at random and generally tend to be irreversible.
Large-scale mutations can result from
• Amplifications - whereby duplicate copies are made of chromosomal regions,
which increases the expression of the genes located in situ.
• Inversions and translocations - an inversion is where there is a reversal of the
nucleotide information on a portion of the chromosome whereas transloca-
tion is the rearrangement of parts of between non-homologous chromosomes.
• Large deletions – this is when a deletion or recombination event causes the
loss of an allele, resulting in a homozygotic site where before there were two
alleles and either hetero or homozygosity.
1.5.4 Linkage, Linkage Disequilibrium, and TagSNPs
It is often of interest to consider allelic information from different loci on the
same chromosome that are close enough together to be inherited as a unit. Loci
that are inherited in such a manner are said to be linked. Therefore, knowing an
allele at one point of the chromosome enables inference of the other alleles.
Furthermore, it is also possible for a non-random association of alleles that
could potentially be located on different chromosomes. The strength of these as-
sociations can be quantified using a measurement of linkage disequilibrium (LD).
There are several different statistics to consider when assessing LD, such as D’ (a
measure of the independence of the two alleles) and r2 (how well one allele can
predict another). In areas where there is evidence of high LD it is possible to infer
information from across the region by typing a solitary SNP, called a tagSNP.
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1.6 Summary
This chapter provided an introduction to the key fields reported in this thesis:
inflammation, Type 2 diabetes, cognition, and genetics. An in-depth review of
specific inflammatory biomarkers is provided in the following three chapters. This
includes information on the function of the markers, the genes that encode the
markers, the inter-relationship between the markers and the genetic variants, and






Building on the brief description of inflammation in Chapter 1, this chapter
provides a detailed overview of the inflammatory biomarker C-reactive protein
(CRP). It begins by charting the history of CRP, its molecular structure, and
its function. This is followed by a literature review to determine the association
between plasma CRP levels and cognitive ability. Finally, a summary of the CRP
gene is presented with SNP variants being reported in relation to both plasma
CRP levels and cognition function.
2.2 History
Discovered by Tillett and Francis in 1930, C-reactive protein (CRP) was found
in the serum of patients with pneumococcal pneumonia (Tillett & Francis 1930).
These patients’ sera were found to be precipitating with a soluble extract, labelled
fraction C, which was later identified as a polysaccharide of the cell wall of the
pneumococcal bacteria. After resolution of the pneumonia, the precipitation
was no longer found to occur between the sera and fraction C. However, in the
instances where the pneumonia resulted in a fatal outcome, the precipitate could
still be formed.
Future studies by Tillett and Francis showed similar test results for the follow-
ing conditions: staphylococcus osteomyelitis, rheumatic fever, sub-acute bacterial
endocarditis, and lung abscesses. However, negative test results were found for
the precipitation reaction in patients suffering from viral infections, malaria, and
tuberculosis (Ablij & Meinders 2002).
It was the work of Rachel Welsh in 1933 that helped to define the precipitation
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phenomenon as a non-specific physiochemical reaction to bacterial infection as
opposed to a specific antigen-antibody reaction. Eight years later in 1941, Avery
and Abernethy established that the substance responsible for the precipitation
reaction with fraction C was the protein CRP. (Gotschlich 1989)
2.3 Production
CRP is an acute-phase protein that is primarily synthesised and secreted into the
circulation from the hepatocytes in the liver (Ablij & Meinders 2002) although
studies have also shown that production can occur in adipocytes (Yeh 2005).
An acute-phase protein is a protein whose plasma concentration increases or
decreases by over 25% during an inflammatory attack (Kushner 1982). Healthy
individuals generally have CRP levels less than 3mg/l (Pearson et al. 2003). These
can increase as much as 1000-fold during acute inflammation (Ridker 2003) to a
potential peak of around 400mg/l (Pepys & Berger 2001).
The mechanism that causes this proliferation of CRP is mostly driven by a
rise in concentration of the cytokine interleukin (IL)-6 which is used to recruit
CRP to the site of inflammation (Yudkin et al. 1999). Circulating levels of both
interleukin (IL)-1β and tumor necrosis factor (TNF)-α have also been shown
to regulate CRP mRNA transcription (Yudkin et al. 1999). Removal of CRP
from the bloodstream is mono-exponential with a biological half-life of 19 hours
(Koenig et al. 2003). As the half-life is unaffected by the relative level of CRP,
the only significant determinant of plasma CRP is its rate of synthesis. This, in
principal, justifies its clinical use to monitor inflammatory activity.
2.4 Structure and function
CRP is a protein from the pentraxin family with binding sites for ligands on each
of the five sub-units of the molecule (Kuo et al. 2005). After binding with phos-
phocholine or a number of similar ligands such as damaged cell membranes, na-
tive or oxidised plasma lipoproteins, and various components of micro-organisms,
the ligand-complexed CRP is recognised by the complement sub-component C1q
(Ablij & Meinders 2002). This in turn leads to the formation of the C3 sub-
component complex, and subsequently, to the activation of the human comple-
ment system – a biochemical cascade of the immune system that aids the removal
of pathogens from the body (Feuerstein et al. 2003). Activation of the comple-
ment pathway enables the elimination of the ligand-CRP complex by causing it
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to be engulfed (opsonized) and destroyed by phagocytes, such as macrophages.
CRP is also able to bind to receptors on antibody or immunoglobin (IgG)
molecules, which themselves bind to many kinds of pathogens (Gewurz et al.
1995). IgG protects the body against viral and bacterial infection by comple-
ment activation. The effect of the CRP-IgG binding is to stimulate the action
of phagocytic cells and to augment the phagocytosis of micro-organisms or dam-
aged/dead host cell material.
It has also been hypothesised that CRP is involved in anti-inflammatory pro-
cesses through a modified version of CRP (mCRP) (Ablij & Meinders 2002).
The formation of mCRP occurs via the proteolysis of CRP, which dissociates
into monomeric sub-units before structural change (denaturisation) leads to the
creation of new molecules (Zouki et al. 2001). mCRP has the ability to bind to a
low-affinity IgG receptor on the neutrophil (a type of white blood cell which re-
moves pathogens via phagocytosis) (Zouki et al. 1997). This elicits the shedding
of the adhesion molecule, L-selectin, from the neutrophil and prevents bonding
to the endothelial cell. This process may provide an explanation as to why neu-
trophils are missing in atherosclerotic lesions (Rattazzi et al. 2003).
2.5 Measurement
Whilst CRP levels greater than 10mg/l are widely regarded as being associated
with acute inflammation (Pearson et al. 2003), variation at lower levels of CRP
is also of great interest. This is particularly the case when assessing chronic
inflammatory conditions. Until the last 5-10 years, accurate and consistent mea-
surement of low CRP levels was not possible. However, the introduction of high
sensitivity CRP assays has resulted in a relatively inexpensive and reliable method
to measure CRP levels from as low as 0.15mg/l (Yu & Rifai 2000). CRP samples
are stable at room temperature and high sensitivity assays yield near identical
results in both fresh and frozen plasma samples (Koenig 2005). Nonetheless,
there is conflicting evidence on CRP measurement stability with some describing
no diurnal variation and relatively stable results over a three month period (Li
& Fang 2004). Another study found that 63% of CRP measurements in healthy
adults fell into the same quartile when re-measured three months later (Ockene
et al. 2001). By contrast, Riese et al. advocate re-sampling healthy persons with
‘high’ values (> 1.75mg/l for males, > 1.00mg/l for females not using oral con-
traceptives, and > 2.00mg/l for females using oral contraceptives) (Riese et al.
2002). Multiple measures of CRP are also strongly recommended when the par-
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ticipants under investigation are suffering from cardiovascular disease (Koenig
2005, Stigant et al. 2005).
In my view, the crux of the single sample versus multiple samples debate
surrounds the cardiovascular health of the participants. Li and Fang provide
a clear and articulate argument to support the reliability of a single measure in
healthy persons. Although it is possible that some participants may have an acute
infection at the time of measurement, a large sample size should dominate these
potential effects and provide an accurate and true reflection of CRP variability.
2.6 Factors influencing CRP levels
Plasma CRP levels can vary according to both modifiable and non-modifiable
factors. Most commonly these include age, sex, BMI, smoking, and ethnicity. It
has been well documented that CRP levels rise gradually throughout life in both
men and women with females having slightly higher levels (Pankow et al. 2001),
especially those receiving HRT (Eklund et al. 2005, Yu & Rifai 2000, Miller et al.
2005) or taking the contraceptive pill (Dreon et al. 2003, Döring et al. 2004).
Where studies stratify by ethnicity they hoped to reduce the heterogeneity
across ethnic groups. There is far greater genetic variation in persons of African
origin compared to those of European origin (Crawford et al. 2006b, Wang et al.
2006). Wang et al. reported 84 SNPs in the CRP gene, 37 of which had a minor
allele frequency (MAF) > 5%. Of these 37 SNPs one was Caucasian-unique,
15 were African-American unique with the remaining 21 SNPs common to both
populations.
BMI and smoking status are common indicators of cardiovascular disease with
higher levels of both strongly associated with raised CRP levels (Brull et al.
2003, Casas et al. 2006, D’Aiuto et al. 2005, Lau et al. 2005, Wang et al. 2006,
Yu & Rifai 2000). According to one group, the association between BMI and
CRP implies a state of low-grade systemic inflammation in overweight and obese
persons (Visser et al. 1999). This association is quite substantial with Kathiresan
et al. and Tchernof et al. finding 15% and 18% of CRP variation to be explained
by BMI. In total, the portion of plasma CRP levels explained by non-genetic
variables varies between 16% and 30% (Table 2.1). Some of the other common
adjustable covariates included in these studies were alcohol intake, systolic and
diastolic blood pressure, LDL/HDL/total cholesterol, and statin use.
Finally, recent studies of older people have found socioeconomic status (SES)
in adult life to predict mid/late-life levels of inflammatory markers, including
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Author Adjustment Variables % CRP Explained
Crawford et al.
(2006b)
age, sex, ethnicity, smoking, edu-
cation, CHD, BMI, total choles-
terol, HDL cholesterol, triglyc-




age, sex, BMI, HRT, smoking, to-
tal/HDL cholesterol ratio, hyper-
tension, lipid lowering therapy,
prevalent cardiovascular disease,





age, sex, waist circumference, lep-
tin level, IGT, smoking
16%
Miller et al. (2005) age, BMI, smoking (PRINCE
study)
21%
Miller et al. (2005) age, BMI, smoking (PHS study) 20%
Pankow et al. (2001) age, education, smoking, alcohol, 30% (women)
HRT, obesity, diabetes 22% (men)
Tchernof et al. (2002) BMI in post-menopausal women 18%
Table 2.1: Percentage of variation in plasma CRP levels explained by covariates.
CRP and fibrinogen (Pollitt et al. 2007, Tabassum et al. 2008). These associa-
tions were weakened when comparing the biomarker levels with childhood SES.
Furthermore, adjustment for adult cardiovascular disease risk factors strongly
attenuated the associations between CRP and early life SES. Nonetheless, both
studies showed decreased SES to predict elevated marker levels. Specifically, the
Atherosclerosis Risk in Communities (ARIC) study found a 17% increase in CRP
level between the lowest and highest socioeconomic groups (n = 12,681) (Pol-
litt et al. 2007). These findings were more pronounced in whites than in blacks.
Similarly consistent findings were also noted between fibrinogen and SES. The
second study was the 1958 British Birth Cohort, which had measures on SES at
birth, age 23, and age 42 in 5,951 persons (Tabassum et al. 2008). Comparing a
cumulative score for SES with biomarker levels at age 44–45 the authors found
significant associations with both fibrinogen and CRP (p < 0.001). Finally, one
other study found adult but not childhood socioeconomic status to be linked to
CRP levels of 1,484 persons from the Young Finns Study (Gimeno et al. 2007).
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2.7 Association with disease
2.7.1 General
Although uncertainty surrounds the specific role of CRP in disease, it has con-
sistently been associated with many conditions. High-sensitivity CRP is a strong
predictor of vascular disease across a large cross-section of clinical populations
that includes “individuals without CVD, patients presenting with acute coronary
syndromes, patients with stable angina or in the stable phase after MI, and pa-
tients with the metabolic syndrome, diabetes, or renal disease” (Bassuk et al.
2004). In addition to being a marker and predictor of cardiovascular and inflam-
matory disease, CRP levels have also been associated with dementia (Schmidt
et al. 2002) and a variety of cancers, including lung (Siemes et al. 2006) and col-
orectal (Erlinger et al. 2004). However, as already mentioned, it is unclear if CRP
is actually functional in the development and progression of these conditions or
if it is simply a marker of underlying inflammation.
2.7.2 Atherosclerosis
The presence of complement and CRP in atherosclerotic lesions via the oxidisation
and phagocytosis of the LDL–CRP complex indicates a role for inflammation in
atherosclerosis (Bhakdi et al. 2004). Furthermore, the continual production of the
pro-inflammatory cytokines TNF-α, IL-6, and IL-1, by macrophages and T lym-
phocytes provides evidence that atherosclerosis is an inflammatory process (Ablij
& Meinders 2002). These cytokines are released from atherosclerotic plaques into
the blood, resulting in increased hepatic production of the inflammatory medi-
ators CRP, serum amyloid P component, serum amyloid A, and fibrinogen. Of
the markers, CRP is the quickest to react to an inflammatory stimulus, mak-
ing it a good candidate to determine the inflammatory role in plaque formation
(Ablij & Meinders 2002). Nevertheless, whether CRP plays a causal role in the
inflammatory response surrounding atherosclerosis remains unresolved.
Immunohistochemical investigations have reported the presence of CRP in
coronary arteries and its association with lipids within the artery walls (Zhang
et al. 1999). Quantitative recombinant polymerase chain reaction (PCR) showed
a 10-fold increase in CRP mRNA in athero-arterial tissue compared to normal
arterial tissue (Yasojima et al. 2001). CRP has also been detected in atheroscle-
rotic lesions from the earliest to the most advanced stages (Sun et al. 2005). Sun
et al. conclude that the presence of CRP in lesions is derived from the circulation
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instead of de novo synthesis by vascular cells due to the lack of CRP mRNA in
atherosclerotic lesions and macrophages. However, a review study of CRP’s role
in vascular disease noted several novel cell types were able to produce CRP and
complement within atherosclerotic plaques (Mazer & Rabbani 2004).
There is substantial evidence from in vitro laboratory studies of endothelial
cells to indicate a pro-atherogenic role for CRP (Jialal et al. 2004). However,
conflicting evidence from in vivo mouse models has failed to conclusively identify
a causal relationship between CRP and vascular disease (Stenvinkel 2006). Where
CRP has been shown not to be causally involved, its presence in atherosclerosis is
hypothesised to be indirectly related to vascular damage with other inflammatory
mediators being the main culprits (Stenvinkel 2006).
Inconsistent proof of a causal role is also described in a selection of epidemio-
logical studies. There seems little doubt over the ability of CRP to predict future
myocardial infarction and other vascular events, although recent studies question
whether its predictive power is as strong as first thought (Sattar & Lowe 2006).
Furthermore, there has been an increase in evidence questioning the projected
causal function of CRP in atherogenesis. However, others note that CRP ele-
vation precedes clinically symptomatic atherosclerosis and testing plasma CRP
level is the only widely available clinical test that provides a tangible link between
inflammation and atherosclerosis (Mazer & Rabbani 2004).
2.8 Association with cognition
In recent years, population-based epidemiological studies have been undertaken
to ascertain the relationship between CRP levels and cognitive ability. A com-
prehensive search of the online medical databases PubMed1, Embase, and Ovid
Medline (through the University of Edinburgh library website2) was undertaken to
identify large-scale, cross-sectional or longitudinal studies with extensive cognitive
testing, that described the association between CRP levels and cognitive ability.
Search terms were carefully selected to try and reduce the selection of studies that
focussed on dementia diagnoses instead of milder forms of cognitive impairment.
In addition to the database searches, when suitable papers were found, their refer-
ences were also reviewed. Specifically, the terms used for the medline search were
(‘exp C-reactive protein’ | ‘C-reactive protein.mp’ | ‘CRP.mp’) & (‘exp cognition’




cline.mp’). The search dates were set from 1950 to December 2008 and papers
were limited to those written in English. Equivalent search terms/notation were
used for the retrieval of papers from the PubMed and Embase databases.
During the search a single systematic review of the relationship between CRP
and cognitive disorders was uncovered (Kuo et al. 2005). This paper assimilated
information on CRP level and its association with stroke, cognitive disorders, and
depression in the general population. Six studies were identified that described
the association between CRP and cognitive impairment or dementia. However,
all six of these papers were also retrieved in the main search.
Many of the studies identified in the literature search suffered from small
sample sizes and/or a limited cognitive test battery. In addition, several stud-
ies considered a dementia or MCI diagnosis as opposed to a measure of late-life
normal cognitive ageing. This is possibly due to dementia and MCI being more
straightforward conditions to diagnose as there are formal criteria for their defi-
nitions.
2.8.1 Key papers
Of the papers reviewed, four included a comprehensive battery of cognitive tests
administered to a large, population-based cohort over a substantial follow-up
period (Alley et al. 2008, Dik et al. 2005, Schram et al. 2007, Weuve et al. 2006).
Chronologically, the oldest report was from 2005 where Dik et al. looked at
inflammatory protein levels and cognitive decline in an elderly Dutch population.
The study involved 998 participants from the Longitudinal Aging Study Ams-
terdam, mean age 74.6 years (s.d. 6.2). Cognition was assessed at both baseline
and at 3 year follow-up on the domains of general cognition, memory, fluid intel-
ligence, and information-processing speed. Serum measurements of four inflam-
matory markers were taken at baseline: CRP, α1-antichymotrypsin (α1-ACT),
albumin, and IL-6.
The results of the study found increased levels of α1-ACT to be associated
with cognitive decline in general intelligence (measured using the Mini-Mental
State Examination). No other significant associations were found with α1-ACT
or any of the other inflammatory markers and cognitive change. A secondary
finding of the study was that carriers of the Apolipoprotein ε4 allele had lower
CRP levels than non-carriers (p < 0.001).
A second Dutch study, this time by Schram et al., combined data from two
independent, population-based cohort studies: the Rotterdam Study, and the
Leiden 85-plus Study. The Rotterdam Study contained 3,874 participants of
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mean age 72 who were followed up for an average of 4.6 years. The Leiden 85-
plus Study contained 491 individuals all aged 85 who were followed up for 5 years.
Both studies assessed global cognition, executive function, and memory. Linear
regression was used to investigate the associations between inflammatory markers
and cognitive function and decline.
The results from the Rotterdam study showed higher levels of CRP and IL-
6 to be cross-sectionally associated with poorer global cognition and executive
function (difference in cognitive test score per s.d. of CRP –0.03, 95% CI (–0.05,
–0.02), p < 0.001 and –0.04, (–0.07, –0.02) , p<0.001; difference in cognitive
test score per s.d. of IL-6 –0.08, 95% CI (–0.14, –0.02), p = 0.009 and –0.10,
(–0.17, –0.03), p = 0.008). Associations of a similar magnitude were observed in
the Leiden study although these were non-significant. However, when assessing
cognitive decline, higher IL-6 levels were related to a steeper decline in memory
in the Leiden group (annual decline per s.d. –0.123, (–0.233, –0.013), p = 0.03).
The authors also looked at the effect of APOε4 on the associations and found
that the presence of the ε4 allele resulted in a significant association between IL-6
and decline in memory (Leiden only) and global cognition.
The penultimate study reviewed was a 2006 investigation by Weuve et al.,
which focussed on CRP and cognitive ability in older women. The cohort com-
prised 4,231 older participants of the Women’s Health Study (age range 60–90)
who had a CRP measurement taken between 1992 and 1996. From 1998 to 2000
a five test cognitive battery was administered to assess ability in the domains
of general cognition, verbal memory, and category fluency. Regression modelling
was used to compare mean cognitive test scores by quintile of CRP after adjust-
ment for potential confounding variables. The results provided no indication for
a difference in cognitive performance between the top and bottom CRP quintiles.
For example, the adjusted mean difference between upper and lower quintile for
a global cognitive score that combined results from all of the tests was 0.04, 95%
CI (–0.02, 0.11), p for trend across quintiles = 0.38.
The most recent paper reviewed was from 2008 by Alley et al. Using growth
curve modelling they investigated the association between IL-6 and CRP levels
with cognitive change, which was assessed three times over a 7 year period. The
population for the study consisted of 851 persons aged 70–79 at baseline who
were participating in the MacArthur Study of Successful Aging. Cognition was
assessed using five domain specific tests, a summary score of the five tests, and
a general ability test. Scores were obtained at baseline and at a 3 year and 7
year follow-up. Cross-sectionally, the investigators found inverse relationships
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between both inflammatory markers and cognition. However, upon adjustment
for potential confounder variables, no significant effect was observed between
either marker and baseline cognition or the rate of longitudinal cognitive change.
Nonetheless, the authors did find an increased risk in incident decline in general
ability for persons in the top tertile of IL-6 (p < 0.05).
Overall, these longitudinal data provide contrasting evidence to support the
hypothesis that increased inflammation, measured by CRP, has a negative impact
upon cognitive ability. Dik et al. suggest that their null findings may be due to
the sensitivity of the assay used to measure the serum marker levels, or selective
non-response and loss to follow-up of frail, elderly subjects. Their results may
also have been affected by the follow-up period of 3 years, which is possibly too
short a period in which to observe substantial cognitive decline. There may also
have been evidence of a practice effect in their cognitive test results – something
that might have affected the data for the study by Alley et al. In spite of the large
sample size and battery of cognitive tests, Weuve et al. only focussed on CRP’s
ability to predict future cognitive ability (but not decline) in women. Therefore,
I would be inclined to apply greatest weight to the findings of Schram et al.,
who reported some evidence for an association between elevated CRP levels and
impaired cognitive performance but not cognitive decline. Finally, it should be
noted that the effect sizes across all studies are modest. However, as Schram
remarks, this does not imply that the involvement of systemic inflammation in
the pathology of cognitive decline is modest as well.
The remainder of the papers identified in the systematic search are sum-
marised below by study design type. An additional section is provided to de-
scribe the CRP and dementia papers that were uncovered despite the attempts
to exclude them from the search.
2.8.2 Prospective cohort studies
Of the other studies reviewed, the main body of evidence points towards CRP
being able to predict cognitive ability in both cross-sectional and longitudinal
data. As with the results of the key papers, there is scant evidence to imply a
predictive role for CRP in measures of cognitive change.
Five prospective cohort studies were retrieved in the literature search with
all successfully relating CRP levels prospectively to follow-up cognition. These
studies found baseline CRP to predict
• a 5 year follow-up association with a four point or greater decline on the
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MMSE in 650 men and women (239 persons aged 75 years, 212 aged 80,
and 199 aged 85): relative risk of decline for CRP > 5mg/l = 2.32, 95% CI
(1.01, 5.46) (Tilvis et al. 2004).
• a 12 year follow up association with decreased memory capacity in 97
women, aged 60-70 years: standardised β = -0.842, 95% CI (-1.602, 0.083),
p = 0.030 (Komulainen et al. 2007).
• a 6 year follow-up association with decrements in word learning in 92 men
and women, mean age 55 years (s.d. 11), unstandardised regression coeffi-
cient β = -0.27, 95% CI (-0.45, -0.08), p < 0.05 (Teunissen et al. 2003).
• a 1 year follow-up association with attention-executive-psychomotor perfor-
mance in 78 men and women, mean age 70.6 years (s.d. 7.4): standardised
β = -0.22, p = 0.04 (Hoth et al. 2008).
• a 2 year follow-up association with a five point or greater decline on the
modified MMSE in 3,031 men and women, mean age 77 years (s.d. 2.9):
odds ratio for cognitive decline in highest versus lowest CRP tertile = 1.41,
95% CI (1.10, 1.79) (Yaffe et al. 2003).
Some criticisms that could be directed at the studies include measuring cog-
nition using a single, generic test (Tilvis et al. 2004, Yaffe et al. 2003), having a
short follow-up period (Yaffe et al. 2003) and performing analyses on very small
samples (Komulainen et al. 2007, Teunissen et al. 2003). Specifically, Tilvis et al.
assessed cognition using the MMSE, which is not a sensitive measure for subtle
changes cognitive function. The studies by Komulainen and Teunissen, whilst
having extensive cognitive testing and lengthy follow-ups, failed to have more
than 100 subjects tested. This is going to affect the possibility of chance findings
as well as the ability to generalise the results to other populations. Furthermore,
it is confusing that both Yaffe and Tilvis split CRP levels into tertiles or high
versus low. By taking such an approach, both studies are failing to fully use the
continuous data collected, which subsequently is going to reduce the power to
detect differences in cognition.
Nonetheless, the design of these four studies are far superior to that of Hoth et
al. who cognitively assessed just 78 adults with cardiovascular disease at baseline
and one year follow-up. Whilst they used a comprehensive 24 test battery, to re–
test a relatively young cohort (age range 56–84) within one year is undoubtedly
going to affect scores due to a practice effect. The primary analysis in the study
was to create a composite z–score for five cognitive domains and to model the
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baseline CRP levels against the change in z-scores over the one year period. They
analysed the association between baseline CRP levels and change in z–scores for
each domain after adjusting for age and baseline cognitive z–score. As the changes
in z–scores (z–baseline – z–follow-up) are going to be highly correlated with the z–
baseline scores, to adjust the model for the latter variable is highly questionable.
Given the lack of consideration for appropriate statistical analyses, I would be
inclined to interpret the findings from this study with caution.
2.8.3 Cross-sectional studies
In studies with a cross-sectional design, several significant associations between
CRP and cognitive ability were found. Mangiafico et al. studied 164 persons
with asymptomatic peripheral arterial disease (APAD) versus 164 healthy con-
trols (Mangiafico et al. 2006). Both samples had a mean age of 70 years and
contained 74% and 73% men, respectively. Linear regression results showed that
those with APAD had significantly poorer cognitive test scores. Poorer cog-
nition was also significantly predicted by CRP levels for patients with APAD
(attention and verbal working memory: unstandardised β = –0.175, s.e. 0.046,
p = 0.0002; attention and mental flexibility: β = 10.792, s.e. 2.946, p = 0.0003;
visuo-constructive skills and visual memory: β = –0.337, s.e. 0.170, p = 0.0496).
These findings support a hypothesis of CRP contributing to atherothrombotic
lesions via complement activation, which subsequently leads to brain damage.
However, the authors note that raised CRP levels may merely reflect the un-
derlying inflammatory component of sub-clinical atherosclerotic cerebrovascular
disease.
Another study investigated homocysteine and CRP levels with cognitive func-
tion in persons with cardiovascular disease (Gunstad et al. 2006). This study used
an extensive 22 test battery to assess six major cognitive domains as well as ob-
taining MRI scans for 37 of its 126 participants. The gender distribution of the
sample was 59% male and the mean age of participants was 69.2 years (s.d. 7.6).
The results showed significant associations between CRP levels and several of
the tests under each cognitive domain (p < 0.05). There were no associations
between homocysteine and cognition or between either marker and white matter
disease or whole brain volume from the MRI data.
The final study reviewed, used only the MMSE to assess cognition. The prob-
lem in using this test as a measure of cognitive ability is that its most common
application is as a screening test for dementia. Subsequently, it exhibits a ceiling
effect in healthy samples and is insensitive to small changes in cognition. Never-
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theless, Ravaglia et al. investigated 540 well functioning, healthy, and cognitively
normal Italian men and women (mean age 73 years (s.d. 6)) and found elevated
CRP levels to be associated with lower MMSE scores (Ravaglia et al. 2005). In
a similar approach to the studies of Yaffe and Tilvis, they split CRP into deciles
and found the highest compared to the lowest (> 7mg/l) to have increased odds
of 3.07, 95% CI (1.2, 7.9) for an MMSE score between 24–25 (out of 30).
2.8.4 CRP and dementia
The studies that investigated CRP levels with dementia gave mixed results.
Schmidt, Arai, Engelhart, and Dimopoulos showed positive associations but van
Oijen, and Haan found no relationship between the marker levels and dementia
status (Arai et al. 2006, Dimopoulos et al. 2006, Engelhart et al. 2004, Haan
et al. 2007, Schmidt et al. 2002, van Oijen et al. 2007). However, the Haan study
did show APOε4 stratified CRP levels to be associated with decreased dementia
rates. Further, despite not finding an association between CRP and dementia
(the odds ratio per s.d increase in CRP was 0.95, 95% CI (0.84 to 1.06)), van
Oijen et al. did report an association between plasma fibrinogen levels and both
vascular dementia and Alzheimer’s disease. This study measured fibrinogen and
CRP levels in 2,835 and 6,713 persons from the Rotterdam study and followed
them up for mean of 5.7 years to obtain a dementia cohort of 395 cases. In their
discussion, they argue that the association with fibrinogen but not CRP implies
a haematological over an inflammatory mechanism for dementia – based on the
fact that fibrinogen is a biomarker of both inflammation and haematosis.
In addition to the work by van Oijen, the study by Schmidt et al. is also of
particular interest and importance – most notably due to its impressive study
design and extensive follow-up period of 25 years. The study contained 1,050
Japanese-American men from the Honolulu-Asia Aging Study who were in their
mid-fifties when they had CRP levels measured. Twenty five years later, these
mid-life levels of CRP were found to be associated with dementia and all its
major sub-types (VaD and AD). The odds ratio for dementia for those in the
upper compared to lower quartile of CRP was 2.8, 95% CI (1.6, 5.1) with p <
0.002 for a trend across quartiles.
2.8.5 Summary
When considering the mixed results from the prospective cohort and cross-sectional
studies, it appears that the time of measurement for CRP may be critical when
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trying to associate it with impaired cognition. For example, CRP levels in late-life
could potentially be affected by underlying vascular disease or other age-related
medical conditions.
Nonetheless, there does appear to be some evidence linking CRP levels to
both late life cognitive ability and dementia although the associations between
CRP and late-life cognitive change are less well investigated. There is thus a need
for large-scale prospective cohort studies, like that presented by Schram et al.,
with extensive cognitive testing and a long-term follow-up. This will help add to
the growing literature for the cross-sectional and prospective associations. Well
designed studies with multi-wave data will also help determine the relationship
between baseline CRP levels and cognitive change, which will aid researchers




CRP is located on the long arm of chromosome one (1q21-q23) and covers a 2.3kb
area3. The gene is composed of two coding exons separated by a single intron
and is flanked by a short (104bp) 5 prime untranslated region (5’ UTR) and a
longer (1.2kb) 3 prime untranslated region (3’ UTR) (Miller et al. 2005).
2.9.2 CRP SNPs
The results from studies on the CRP gene provide indisputable evidence that it
is polymorphic (Hage & Szalai 2007). One study systematically re-sequenced the
CRP gene and identified as many as 40 different SNPs that contribute to the
formation of up to 29 different haplotypes (Crawford et al. 2006b). High linkage
disequilibrium between all known CRP SNPs has resulted in the usage of tagging
SNPs to identify CRP haplotypes (Carlson et al. 2005, Hage & Szalai 2007,
Stram 2004). In persons of European origin there are four common haplotypes
describing the variation across the CRP gene, which can be identified using three
tagging SNPs (Kardys et al. 2006). However, as noted in the review paper by
Hage et al. many studies have established associations between CRP levels and
both CRP haplotypes and disease risk but few have found a relationship between
the CRP gene and disease risk. They conclude that as the CRP polymorphisms
3http://genome.ucsc.edu/cgi-bin/hgTracks?position=chr1:157948707-157950383
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explain just a moderate proportion of serum CRP variation (∼10%) it would take
extremely large studies to observe direct associations between SNPs/haplotypes
and actual clinical events. In contrast to the CRP gene explaining only a modest
amount of serum CRP levels, CRP levels are shown to be 30–50% heritable (Wang
et al. 2006). This suggests a potential polygenic effect on the heritable aspect of
CRP levels with multiple genes being responsible for its variation.
2.9.3 Association with CRP levels
The association between CRP SNPs and CRP levels has been extensively studied
using polymorphisms from across the CRP gene. The majority of research has
focussed primarily on five tagging polymorphisms; rs3091244 (a tri-allelic SNP
located in the 5’ UTR); rs1417938 (located in the first intron); rs1800947 (a
synonymous SNP located in the second exon); and rs1205 and rs1130864 (located
in the 3’ UTR). The relationships between these SNPs and CRP levels have been
largely consistent across different studies with conflicting results occurring in just
a handful of investigations (Table 2.2).
Moving systematically across the genome, the first SNP under frequent inves-
tigation is the tri-allelic flanking SNP, rs3091244. Of the seven papers reviewed
that studied this SNP, all found increased CRP levels in carriers of the T allele.
The next SNP along the genome is rs1417938, which is situated in the first and
only intron. Its minor allele was associated with significantly lower CRP levels in
three studies (Lange et al. 2006, Miller et al. 2005, Suk Danik et al. 2006), and
with significantly higher CRP levels in two studies (Mart́ınez-Calatrava et al.
2007, Suk et al. 2005). Another paper reported a significant association between
rs1417938 and CRP levels but failed to state in which direction and with which
allele the relationship was (Kathiresan et al. 2006a). Finally, a null finding was
reported in the study by Crawford et al. (Crawford et al. 2006a)
The only SNP that was frequently investigated and that features in a coding
region was rs1800947 in the second exon. Twelve papers were found comparing
its allelic variants with CRP levels with eight showing an increase in CRP levels
in carriers of the minor allele. Of the remaining papers, two failed to find a
significant association (Crawford et al. 2006a, Morita et al. 2006), one found
an inverse association with the minor allele (Balistreri et al. 2006), and as with
rs1417938, Kathiresan et al. found a significant association but failed to report
its direction.
The final two SNPs (rs1205 and rs1130864) are located in the 3’ UTR and
were reported in nine and eleven papers, respectively. Inverse associations were
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described for the minor allele of rs1205 and positive associations for the minor
allele of rs1130864 with CRP levels. None of the respective studies found associ-
ations in the opposite direction although some reported null associations (Morita
et al. 2006, Paik et al. 2007, Wang et al. 2006). Furthermore, the Kathiresan
paper once again identified both SNPs as being significant but failed to report
the direction of the associations.
The study design and population characteristics varied across the individual
studies and they have been summarised in Table 2.3. One criticism that can be
directed at many of the studies is a small sample size. The number of participants
ranged from 55 (D’Aiuto et al. 2005) to 7,159 (Crawford et al. 2006b) with six
of the eighteen studies having a sample population of fewer than 1,000. These
small sample studies make it difficult to generalise the results and increase the
possibility of chance findings.
In the middle of 2008 a systematic review by Verzilli et al. provided a compre-
hensive report on the genetic variants that affect plasma CRP levels (Verzilli et al.
2008). They identified twenty-six studies of note (total n = 32,802), which had
reviewed the associations of eight SNPs in the CRP gene (rs3093059, rs2794521,
rs3091244, rs1417938, rs1800947, rs1130864, rs1205, and rs3093077) with CRP
concentration. Although no SNP was typed in every study there were several
partial overlaps.
Using a Bayesian regression model, they combined data from all sites and ad-
justed the associations for possible correlations with the remaining variants. This
approach helps to extricate the effects at causal sites from the effects at the sites
in LD with the causal variant(s). Of the SNPs investigated, rs1130864, rs1205,
and rs3093077 held the strongest independent association with plasma CRP lev-
els. One other SNP (rs1800947) was also deemed to be important although its
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.9.4 Association with cardiovascular disease
As mentioned previously, raised CRP levels have been implicated as risk fac-
tors for many different cardiovascular complications. Although there is evidence
connecting CRP polymorphisms with CRP levels, few studies have positively as-
sociated CRP gene variants with cardiovascular risk. Most notably, data from
prospective cohort studies such as the Physicians Health Study, the Framing-
ham Heart Study, the NHLBI Family Heart Study, and the Rotterdam Study
have found no associations between CRP genotype, CRP levels, and MI or stroke
(Kardys et al. 2006, Miller et al. 2005, Kathiresan et al. 2006a, Wang et al. 2006).
However, one study did find a genetic link between CRP and cardiovascular
events in two different ethnic populations aged ≥ 65 (Lange et al. 2006). In a
study of 3,941 white subjects, the rs1417938 SNP was found to significantly pre-
dict stroke and cardiovascular mortality (hazard ratios 1.40, 95% CI (1.06, 1.87),
1.40 (1.10, 1.90), respectively). In 700 black participants, the rs3093058 poly-
morphism was a significant predictor of increased risk of MI and stroke (hazard
ratios 4.08, 95% CI (1.58, 10.53), 3.64 (1.41, 9.39), respectively).
Other studies that noted associations between CRP genotype and disease
status showed a history of acute MI to be linked to the C allele of the rs1800947
SNP (Balistreri et al. 2006). One study also found an association between the
same SNP and atherosclerosis, as presented by a measurement of pulse wave
velocity (Morita et al. 2006). A weak association was found with the rs1130864
SNP and non-fatal MI with an odds ratio for the TT genotype and an event
being 1.25, 95% CI (1.09, 1.43) using records from over 4,000 males from six
separate European studies (Casas et al. 2006). Furthermore, some researchers
found SNPs that were not associated with CRP levels but were directly related
to disease status. A 2005 study by Chen et al. showed the A allele of rs2794521 to
be linked with coronary heart disease in a Han Chinese population (Chen et al.
2005). This finding was confirmed in the Physicians’ Health Study where the
SNP variant was related to a decreased risk of MI (Miller et al. 2005). Finally,
the functional, tri-allelic rs3091244 SNP has been linked to both CRP levels and
increased coronary heart disease in 7,159 American participants of the NHANES-
III, Third National Health and Nutritional Examination Study (Crawford et al.
2006a).
These findings add to the evidence for CRP being both a marker of and active
participant in cardiovascular disease. It is therefore possible that CRP genotypes
influence CRP levels, which then affect the onset and progression of cardiovascular
events.
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2.9.5 Association with cognition
To my knowledge there are not currently (as of 25th March 2009) any studies of
CRP genetic variants and non-pathological cognitive ability or decline. However,
studies have looked at the relationship between CRP haplotypes and dementia
(van Oijen et al. 2007), and between CRP SNPs and six week cognitive decline
post cardiac surgery (Mathew et al. 2007).
The study by Van Oijen et al. tested the association between three CRP SNPs
(rs1205, rs1130864, and rs3093068), their haplotypes, and incident dementia in
the Rotterdam Study population. During a mean follow-up of 9.2 years, 607
cases of incident dementia were identified from the baseline population of 5,972.
The mean age of the sample at baseline was 68.9 (s.d. 8.7). Results from Cox
proportional hazard models showed the T allele of rs1205 to associate with both
lower plasma CRP levels and lower risk of dementia (hazard ratio 0.73, 95% CI
(0.53, 0.98)) and AD (hazard ratio 0.73, 95% CI (0.53, 0.98)).
The second of the studies monitored cognitive ability in 513 persons pre and
post coronary artery bypass graft (CABG) surgery and modelled cognitive decline
against several inflammatory marker SNPs (including two CRP SNPs: rs1205 and
rs1800947). Cognition was assessed the day before surgery and six weeks after
surgery using a five test battery. Information from the five tests was combined to
derive four underlying traits: verbal memory and language comprehension (short-
term and delayed); attention, psychomotor processing speed, and concentration;
abstraction and visuo-spatial orientation; and figural memory. Cognitive decline
was defined as a one standard deviation or greater decrease in performance on at
least one of the domains. The results of the logistic regression analysis showed
the minor allele of rs1800947 to associate with a reduction in cognitive deficit in a
European-American population: odds ratio 0.37, 95% CI (0.16, 0.78), p = 0.013.
2.10 Summary
There is evidence to associate raised plasma CRP levels with cardiovascular dis-
ease and cognitive dysfunction. Findings for the latter condition varied, particu-
larly in relation to CRP’s association with cognitive decline. Nonetheless, there
is sufficient support for a small but significant association between CRP and late-
life cognitive ability. In addition, several studies have related SNP variants within
the CRP gene to raised CRP levels. As of yet, no studies have looked directly at





Similar to the previous chapter on CRP, this chapter provides a summary of
the inflammatory/haemostatic biomarker fibrinogen. A short section describes
the history of fibrinogen, its structure and its function, before a longer review
reports its association with cognitive ability. Brief mentions are also given to the
haemostatic markers plasma viscosity and haematocrit. The chapter closes with
a description of the three fibrinogen genes that encode the biomarker, including
a review of the association of their SNP variants with plasma fibrinogen levels
and cognitive ability.
3.2 History
The study of haematology has been documented from the year 400 BC and is a
topic that has even featured in the works of the Philosophers Plato and Aristotle
(Doyle & Addis 2006). In his Timaeus, Plato hypothesised that during the cooling
of blood, fibres in the blood were active in the clotting process. Further, Aristotle
believed that these fibres were solids composed of earth and that their removal
from the blood inhibited clotting.
It wasn’t until the 1770s and the work of William Hewson that major devel-
opments were made in understanding the clotting process (Doyle et al. 2006).
Hewson showed the source of the fibres to be the coagulable lymph, now referred
to as blood plasma. The use of the term fibrin to describe the clotting fibres
was first presented by Jean-Antoine Chaptal towards the end of the 18th century
(Doyle & Addis 2006). His theories centred on the belief that a continual removal
of fibrin, possibly for nutritional requirements, kept the blood in a fluid state.
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In the latter half of following century, the production of fibrin was described
in multiple studies as resulting from a precursor molecule as opposed to being a
constituent of blood. Buchanan and Schmidt then managed to identify thrombin
as the agent which converted this molecule, fibrinogen, to fibrin (Doyle & Addis
2006).
Today, fibrinogen levels reflect the thrombotic potential of blood; as a haema-
tological factor it has been of interest to those studying cognitive decline since
such factors are related to cerebrovascular disease, which in turn has been linked
with cognitive function (Kritchevsky et al. 2005).
3.3 Production
As with CRP, production and synthesis of fibrinogen mainly occurs through
hepatocytes in the liver although production is also possible in megakaryocytes
(Pulanić & Rudan 2005). These bone marrow cells are mainly responsible for
the production of blood platelets, which are requisite for normal blood clotting
(Kaushansky 2008). Plasma levels of fibrinogen are less prone to acute changes
than CRP. A normal range is defined as being between 150-450mg/l (Kamath &
Lip 2003) with levels above this associated with an increased risk of cardiovas-
cular disease (Banks et al. 2006). The production and synthesis of fibrinogen is
controlled by a host of cytokines and other molecules. Notably, IL-1, IL-6, and
TNF-α have been shown to stimulate fibrinogen production whilst IL-4, IL-10,
IL-13, and high plasma albumin suppress its synthesis (Pulanić & Rudan 2005).
Fibrinogen has a biological half-life of around 100 hours (Kamath & Lip 2003).
3.4 Structure and function
Fibrinogen is a hexamer that consists of two symmetric half molecules that con-
tain one of each of the alpha, beta, and gamma polypeptide chains (Kant et al.
1985). Through the action of the enzyme, thrombin, it is converted into the in-
soluble protein, fibrin (Reinhart 2003). The primary function of fibrin is to form
an interlacing, mesh-type network that helps to reduce bleeding around a wound
site in conjunction with the bone marrow cell-derived platelets. In addition to
its vital function as a clotting factor in the blood coagulation system, fibrino-
gen is involved in numerous pathophysiological processes such as inflammation,
atherogenesis, and thrombogenesis (Pulanić & Rudan 2005). The exact means by
which fibrinogen is implicated in these often related processes is unclear although
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a variety of mechanisms have been postulated regarding thrombogenesis. These
include fibrinogen infiltration of the cell wall, haemorrhaging due to increased
blood viscosity, and increased platelet aggregation (Kamath & Lip 2003).
Fibrinogen is also the main determinant of plasma viscosity. Together with
red blood cell deformation, red blood cell aggregation, and the volume fraction
of red blood cells (haematocrit) these comprise blood viscosity – the intrinsic
resistance of blood to flow in vessels (Lowe et al. 1997). Moreover, increased
viscosity may lead to impaired microcirculatory flow, endothelial damage and
thrombosis predisposition (Koenig 2003).
3.5 Factors influencing fibrinogen levels
Showing a similar pattern to CRP, fibrinogen levels are influenced by several
physiological, pathological, and lifestyle factors (Fibrinogen Studies Collaboration
2007, Kamath & Lip 2003, Lowe et al. 2004, Pulanić & Rudan 2005). Of the
non-modifiable factors, increased age and female gender, particularly during post-
menopausal years, are again linked with increased marker levels. Women using
oral contraceptive medication are reported to have further raised levels.
Several studies have investigated variability in fibrinogen levels across different
ethnic groups. This information has been summarised by Heinrich and Assmann,
who comment that lower fibrinogen levels are found in Asian persons and higher
levels in African Americans and Native Americans compared to those in white
populations (Heinrich & Assmann 1995). Whilst raised levels are generally asso-
ciated with increased risk of cardiovascular complications, two ethnic groups for
whom this does not apply are rural Africans and Greenland Eskimos.
Factors that are positively associated with fibrinogen levels include a selec-
tion of common cardiovascular risk factors: BMI, waist-hip ratio, diabetes, LDL-
cholesterol, and smoking (Kamath & Lip 2003, Lowe et al. 2004, Pulanić & Rudan
2005). Of these, smoking appears to be the strongest determinant of plasma fib-
rinogen levels. It has been estimated that half of smoking related cardiovascular
damage is meditated through proliferation of fibrinogen levels (Heinrich & Ass-
mann 1995, Pulanić & Rudan 2005). Whilst there is a dose-dependent response
between the number of cigarettes smoked and age-adjusted fibrinogen levels, the
cessation of smoking results in a rapid reduction of fibrinogen levels (Heinrich &
Assmann 1995). However, it can take up to ten years or more for the levels to
return to those of a healthy individual who has never smoked (Pulanić & Rudan
2005).
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Some of the factors inversely associated with fibrinogen levels include HDL-
cholesterol, exercise, alcohol consumption, and a host of pharmacological inter-
ventions (Kamath & Lip 2003, Pulanić & Rudan 2005, Reinhart 2003). The most
contentious of these associations is probably for alcohol intake. Several studies
have shown linear associations with fibrinogen levels, even at the stage where
alcohol intake is damaging liver cells. By contrast, other studies have reported
U-shaped associations or sometimes no relationship at all.
3.6 Association with disease
3.6.1 General
Similar to the associations found with CRP, raised fibrinogen levels have been
implicated in several physiological complications. Most commonly, it has been
linked to coronary heart disease, MI, and major cardiovascular diseases (Kamath
& Lip 2003, Pulanić & Rudan 2005, Reinhart 2003, Welsh et al. 2008) although
studies have also reported increased levels to be associated with Type 1 and Type
2 diabetes (Pulanić & Rudan 2005). Furthermore, there is evidence to implicate
elevated fibrinogen levels in persons suffering from both vascular and non-vascular
dementia (van Oijen et al. 2005). However, despite the discovery of positive
associations with many diseases, the mechanisms driving these relationships have
not been fully determined. Several possibilities have been postulated, particularly
with regards to atherosclerosis and these will be discussed in more detail below.
3.6.2 Atherosclerosis
As described in the corresponding section of the CRP review, there is substantial
evidence linking inflammatory processes with atherosclerosis. However, in con-
trast with CRP, there is more support to causally implicate fibrinogen in both
atherogenesis and thrombogenesis.
In a review paper of fibrinogen, its biochemistry, epidemiology, and determi-
nants, Kamath and Lip comment that there can be little doubt over fibrin deposits
initiating and being an active factor in the development of atherosclerotic plaques
(Kamath & Lip 2003). Given the close relationship between atherogenesis and
thrombogenesis it is likely that fibrinogen, a key component in the latter process,
will also be active in the formation of atherosclerotic lesions. Heinrich and Ass-
mann add support to this claim, noting that it has been known for many years
that thrombosis contributes to atherogenesis (Heinrich & Assmann 1995).
46
To help understand the role of fibrinogen in atherogenesis, Heinrich and Ass-
mann suggest a cyclical process to describe atherothrombosis formation. Initially,
they propose a mild acute-phase reaction in response to vessel-wall alteration re-
sulting from a chronic stimulus. This yields an increase in fibrinogen levels which
in turn leads to increased fibrin deposits, pushing the haemostatic balance to-
wards thrombogenesis.
As fibrin is an adsorptive surface for LDL cholesterol, its breakdown dur-
ing fibrinolysis leads to lipid aggregation and plaque growth. Eventual fissure
of the plaque results in an inflammatory response and a return to the start of
the atherothrombotic cycle. Subsequently, Kamath and Lip propose fibrinogen
to be a more useful acute-phase protein to measure than CRP due to its more
specific relationship with vascular disease. In addition to being a strong predic-
tor of cardiovascular events in persons with recognized atherosclerotic vascular
disease, fibrinogen levels are also elevated prior to the onset of stroke and acute
myocardial infarction in patients with transient ischemic attack, and chronic sta-
ble angina pectoris, respectively. This implies that raised fibrinogen levels are an
independent risk factor for acute cardiovascular and cerebrovascular events.
The epidemiological evidence relating plasma fibrinogen levels to cardiovascu-
lar events is best summarised in a comprehensive meta-analysis from 2005 (Fib-
rinogen Studies Collaboration 2005). A previous meta-analysis of 18 prospective,
long-term studies showed an increased risk ratio for coronary heart disease of
1.8, 95% CI (1.6, 2.0) per 1g/l increase in plasma fibrinogen levels (Danesh et al.
1998). However, the nature of the data collected prevented a thorough review
of the independent associations between fibrinogen, CHD and other vascular or
non-vascular outcomes.
By contrast, the Fibrinogen Studies Collaboration report included information
on 154,211 persons from 31 prospective studies each with a 1 year minimum of
follow-up. The summary statistics for the data reported a total of 6,944 non-
fatal myocardial infarction or strokes and 13,210 deaths across all cohorts. The
overall findings of the meta-analysis were presented as hazard ratios for disease
outcome per 1g/l increase in fibrinogen. The age and sex-adjusted ratios were
2.42, 95% CI (2.24, 2.60) for CHD, 2.06 (1.83, 2.33) for stroke, 2.76 (2.28, 3.35)
for other vascular mortality, and 2.03 (1.90, 2.18) for non-vascular mortality. The
ratios for CHD and stroke were reduced to around 1.8 after adjustment for several
cardiovascular risk factors.
In summary, there is compelling epidemiological evidence for an association
between increased fibrinogen levels and cardiovascular disease. The literature also
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suggests several mechanisms through which fibrinogen might be causally involved
in atherosclerosis.
3.7 Association with cognition
After uncovering a substantial body of evidence for an association with atheroscle-
rosis and cardiovascular disease, a database search was conducted to identify pa-
pers looking at the relationship between plasma fibrinogen levels and cognitive
ability. The search strategy was very similar to that used in Section 2.8 for
the report on CRP and cognition. Briefly, terms were included to incorporate
fibrinogen, fibrin and other similar derivatives along with cognitive ability and
decline but not dementia. The list of Medline search terms read (‘exp Fibrinogen’
| ‘fibrinogen.mp’ | ‘Fibrin’) & (‘exp cognition’ | ‘exp cognition disorders’ | ‘cogni-
tion.mp’ | ‘cognit$ impair$.mp’ | ‘cognitive decline.mp’). The search dates were
again set from 1950 to December 2008 and papers were limited to those written
in English. Equivalent terms were used in the search of the PubMed and Embase
databases. Of the reviewed studies, the predominant approach taken was that of
a cross-sectional design with just a solitary large-scale, long-term follow-up pa-
per with a large battery of cognitive testing being identified. To my knowledge,
there are no systematic reviews currently available summarising the relationship
between fibrinogen and cognition.
3.7.1 Key papers
The single key paper identified followed up 452 people from the Edinburgh Artery
Study over a period of 16 years (Rafnsson et al. 2007). Cognitive information
was obtained using a battery of four tests that assessed the domains of verbal
declarative memory (Logical Memory Test – LM), nonverbal reasoning (Raven’s
Standard Progressive Matrices – RAVENS), executive function (Verbal Fluency
Test – VFT), and information processing speed (Digit Symbol Test – DST). A
general cognitive factor, g, was derived by taking the standardised scores from
the first unrotated component of a principal components analysis. Biomarker
information including plasma fibrinogen and IL-6 levels was collected at baseline
whilst cognitive measures were assessed at both 11 year and 16 year follow-up.
In an age and sex-adjusted linear regression analysis, fibrinogen levels associ-
ated inversely with two of the four 16 year follow-up cognitive tests (VFT and
DST), and also with g. Further adjustments were made to control for base-
line cognitive scores and for peak cognitive ability, measured using the National
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Adult Reading Test (NART). These resulted in no significant associations except
for RAVENS (baseline adjusted) and LM (NART adjusted). IL-6 associated sig-
nificantly with RAVENS and g for both the unadjusted and adjusted models.
Age and sex-adjusted associations were also found with DST and VFT with the
former remaining significant after adjustment for NART scores.
These results suggest that late-life inflammatory biomarker levels are associ-
ated with late-life cognitive ability and to a lesser degree with late-life cognitive
change and estimated lifetime cognitive decline. The short length of the cognitive
follow-up may have reduced the potential effect sizes for cognitive change due to
practice effects and/or too short a window in which to observe change - even in
a elderly cohort who were a mean age of 73.1 years at baseline cognitive testing.
Rafnsson et al. postulate several mechanisms via which fibrinogen may be
involved in the process of cognitive decline. These include an increase in plasma
viscosity leading to reduced cerebral blood flow. In their study, the fibrinogen–
cognition association was retained after adjustment for prevalent and incident
CVD, suggesting a relationship independent of vascular complications. How-
ever, they noted that the association may be mediated by cerebral lesions, which
have been shown to associate with both fibrinogen levels and cognitive decline
(Knuiman et al. 2001, Schneider et al. 2004, 2003). Furthermore, fibrinogen lev-
els were shown to correlate strongly with D-dimer levels (a degradation product
of fibrinolysis that is used to help diagnose thromboses) even though the latter
didn’t associate significantly with cognition. This implies a role for fibrinogen
over and above its coagulant properties in cognitive decline. Nonetheless, an in-
dependent study showed a strongly significant association between D-dimer levels
and cognitive decline over a 4 year period in 1,723 elderly people (mean age 77.6
years (s.d. 5.4)) (Wilson et al. 2003).
3.7.2 Cross-sectional studies
Of the other studies reviewed all were cross-sectional in design with date of pub-
lication ranging between 1997 and 2008 (Table 3.1). The majority of evidence
from these investigations points towards no association between fibrinogen and
cognition. However, these conclusions need to be interpreted with caution as
there are several limitations that may be influencing the relationships reported.
In accordance with the studies describing the associations between CRP and cog-
nition, these are centred around sample size concerns and limited or unsuitable
cognitive testing.
Sample size ranged from 270 to 15,800 although only two studies assessed more
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than 1,000 persons. Moreover, none of the smaller studies report the effect sizes
they were expecting or were powered to detect. It is clear from the prospective
studies on CRP and cognition that the associations discovered for inflammatory
markers are likely to be small, accounting for only a small proportion of the
variation in cognition. Subsequently, it is of critical importance for authors to
declare what effect sizes they are expecting and are able to detect.
The largest of the studies sampled 15,800 middle-aged-to-elderly persons from
four separate US communities (Cerhan et al. 1998). Cognition was assessed using
tests of memory, processing speed, and executive function. Fibrinogen measures
were taken on all participants but were split into quintiles for the analysis. AN-
COVA adjusting for age, education, occupation, race, and study trial centre found
significant differences between fibrinogen quintiles and both memory and process-
ing speed scores (p < 0.05 and p < 0.005). In both situations, the upper quintiles
corresponded to poorer cognitive scores.
With regards to the rest of the literature, many studies used a single, generic
test to assess late-life cognitive ability. Two studies used the MMSE for their
analysis (Fischer et al. 2006, Kostka et al. 2008). The flaws in taking this approach
have been discussed at length previously. Another study used the Alice Heim
(AH)-4 Test to assess general ability and the choice reaction time to measure
decision speed (Elwood et al. 2001). Although a single test, the AH-4 provides
a fairly extensive evaluation of general ability with 65 test items of increasing
difficulty that alternate between mathematical and verbal reasoning. In their
report, Elwood et al. found no consistent trends to associate higher fibrinogen
levels with poorer performance although there is evidence to relate levels in the
highest quartile with slower reaction times. Significant results were presented
for the associations between plasma viscosity and AH4 and reaction time scores
(age and social class-adjusted regression p-values 0.001 and 0.003, respectively).
Given that fibrinogen is the main constituent of plasma viscosity this remains
consistent with the hypothesis of cerebral blood flow being directly linked to
cognitive function rather than through atherosclerosis or other disease processes.
A significant U-shaped relationship was also found between haematocrit and age
and social class-adjusted reaction times (p < 0.05).
There was no strong evidence for an association between fibrinogen and cog-
nition in the papers presented by Kilander et al. and Stewart et al. Despite this,
the latter study found an inverse relationship between cognitive ability and the
quintile with the lowest fibrinogen levels. However, no obvious pattern of results
was present for those in the upper quintiles.
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3.7.3 Summary
In conclusion, there have been very few comprehensive studies investigating the
associations between fibrinogen and late-life cognition. The literature available
suggests a similar pattern of results to those of CRP and cognition i.e. small
but significant associations between higher marker levels and decreased cognitive
ability. There is also a need to explore and understand the role of fibrinogen
and the mechanisms through which it may relate to cognition. The arguments
reviewed indicate a potential association through decreased blood flow and in-




























































































































































































































































































































































































































































































































































































































































































































































































































































































































Fibrinogen is encoded by three genes that represent its different polypeptide
chains: fibrinogen alpha (FGA)1, fibrinogen beta (FGB)2, and fibrinogen gamma
(FGG)3. The genes are located on the long arm of chromosome four (4q23-q33)
(Kant et al. 1985) and cover a 50kb area (Carty et al. 2008). The FGG gene
contains 10 exons and is aligned 10kb upstream from the FGA which contains 6
exons (Uitte de Willige et al. 2005). The FGB gene is located downstream from
the FGA gene and contains 8 exons (Tuddenham & Cooper 1994).
3.8.2 Fibrinogen SNPs
All three fibrinogen encoding genes have been investigated with respect to poly-
morphisms that may explain fibrinogen levels or disease status. The function
of these genes varies with the alpha and gamma chains believed to affect clot
structure with the beta gene being involved in fibrinogen synthesis (Lim et al.
2003). Due to evidence from in vitro research implicating FGB polymorphisms
in fibrinogen production, it has been the most extensively studied of the trio of
genes. Studies have also shown fibrinogen synthesis to be affected by the other
two chains yet, despite this fact, variants in the promoter regions of the FGA and
FGG genes are infrequently investigated (de Maat 2005). In accordance with re-
sults from genetic epidemiology studies of the CRP gene, SNPs across the three
fibrinogen genes have been significantly associated with fibrinogen levels but to
a much lesser degree with disease outcomes.
Variation in fibrinogen levels has been reported to be between 20-51% her-
itable (Pulanić & Rudan 2005) yet only a small fraction of this variance can
be explained by the fibrinogen genes. Indeed, a genome wide association study
for variants affecting fibrinogen levels failed to identify any significant polymor-
phisms within the fibrinogen encoding genes (Yang et al. 2003). The highest LOD
scores (base 10 logarithm of the odds) for the scan were found on chromosomes
two and ten but no specific genes could be established on either segment. Twin
studies have also shown environmental effects to have greater influence on plasma





3.8.3 Association with plasma fibrinogen levels
The association between fibrinogen SNPs and fibrinogen levels has been studied
using polymorphisms from across all three fibrinogen genes. To date, research
has focussed primarily on variants in the beta chain due to its role in fibrinogen
synthesis. Studies have attributed 4.2% and between 5-9% of plasma fibrinogen
variation to the alpha and beta genes, respectively (Humphries et al. 1987, 1992).
One of first SNPs to be identified in the beta gene was the Bcl-I (or 6638ins28)
polymorphism (Humphries et al. 1987). This variant was discovered to be in com-
plete linkage disequilibrium with the -455G/A SNP (rs1800790) and has gone on
to be one of the most widely studied fibrinogen SNPs. Consistent reports from
multiple studies have associated it with fibrinogen levels – the most commonly
quoted effect size is a 7-10% increase for carriers of the A allele (approximately
20% of the population) (Pulanić & Rudan 2005). Although it is a non-coding
polymorphism, some authors propose -455G/A to be functional due to its proxi-
mal location to other cytokines which have been associated with fibrinogen levels
(de Maat 2001). A study that investigated fourteen SNPs from across the beta
gene in 1,811 participants from the Framingham Heart Study found nine to as-
sociate significantly with plasma fibrinogen levels (Kathiresan et al. 2006b). In
order to account for correlations and linkage between them, a stepwise regression
was performed to identify the SNPs of most importance. This approach identified
the -455G/A polymorphism as the single most important predictor of fibrinogen
levels. In accordance with the figures from the review studies, the A allele was
associated with increased plasma levels, explaining around 1% of the variation.
In a separate study of fibrinogen SNPs with fibrinogen levels, just under 2% of
the total fibrinogen variation was explained by a collection of 22 polymorphisms
from across the three fibrinogen genes (Reiner et al. 2006).
In addition to the -455G/A SNP two of the most commonly reported non-
coding polymorphisms are the -148C/T (rs1800787) and the -854G/A (rs1800791)
variants (de Maat 2001, Kamath & Lip 2003, Koenig & Ernst 1992). Both are
located in the promoter region of the beta gene, which is the section towards the
5’ UTR that initialises the transcription process. There is also a suggestion that
-148C/T is functional due to its location being very close to the IL-6 responsive
element (de Maat 2001).
Two coding polymorphisms have also been identified and described in detail
(Scott et al. 2004). The first is the Thr312Ala variant which is located in the alpha
chain and is important in the interaction with Factor XIII, which determines the
stiffness of the blood clot. The second variant is in the beta chain and is labelled
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Arg448Lys. This polymorphism is involved in clot permeability by determining
the tightness and fineness of the clot structure.
Given the relatively large size of the fibrinogen genes and the high LD between
many of the SNPs, some studies have taken a haplotype or tagSNP approach
for their analysis. One such study typed 44 SNPs across the three genes and
found three main haplotype blocks, each of which could be represented by 4-
6 common haplotypes (Kathiresan et al. 2006b). In total, 16 tagSNPs were
required to predict all haplotypes with a frequency above 5%. The association
of the haplotypes with fibrinogen levels matched the findings for the individual
SNPs; haplotypes with the -455G/A and -148C/T allele resulted in increased
levels whilst those with the -854G/A allele resulted in decreased levels.
One study notes that despite fibrinogen heritability being relatively high, the
overall explanatory contribution of individual SNPs towards intermediate pheno-
types such as plasma fibrinogen level is typically small (Scott et al. 2004). This
may, in part explain the inconsistent findings between genetic variants and clin-
ical outcomes. Pulanić and Rudan reaffirm this in the specific context of the
beta gene, noting the modest effect sizes and difficulties in replicating positive
associations. They suggest a shift in focus towards gene-environment interactions
to attain a more precise measure of plasma fibrinogen levels.
3.8.4 Association with cardiovascular disease
There is a substantial body of evidence associating fibrinogen levels with cardio-
vascular disease. In the previous subsection genetic variants of the three fibrino-
gen genes were reviewed in relation to fibrinogen levels. In this subsection the
relationships between fibrinogen SNPs and cardiovascular disease outcomes are
explored.
On the whole, the evidence for associations with cardiovascular disease favours
null findings. As with the studies of SNPs and fibrinogen levels, the main SNP
reported was the -455G/A variant. The review studies reporting a positive asso-
ciation with disease outcome described significant findings with the development
of coronary artery disease (CAD) in persons with Type 2 diabetes, with the pro-
gression of atheroma, CAD, and the development of cerebral infarcts for carriers
of the A allele (Scott et al. 2004). Although this highlights numerous significant
associations, these findings are by no means replicated across all studies. A re-
view study also noted an association between this SNP and risk of CHD – odds
ratio 1.77, 95% CI (1.08, 2.90). However, in contrast with the other studies this
increased risk was for carriers of the major G allele (Koenig & Ernst 1992).
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The other polymorphisms associated with disease status included the Bcl-I
variant with CAD (Scott et al. 2004), CHD (Koenig & Ernst 1992), and MI
(de Maat 2005) but in the latter case, only in the additional presence of a sec-
ond risk factor such as Helicobacter Pylori infection. The two coding polymor-
phisms introduced previously were significantly associated with post-stroke mor-
tality in subjects with atrial fibrillation, pulmonary embolism in DVT sufferers
(Thr312Ala), and with some forms of macrovascular disease (Arg448Lys) (Scott
et al. 2004). However, it must be noted that in the case of the Arg448Lys asso-
ciations, positive findings were not observed in all of the reviewed studies.
Haplotype associations with CVD were also investigated, again with mixed
results. A three SNP haplotype including the -455G/A and -854G/A variants,
associated the minor allele haplotype with lower mortality in patients with sepsis
(Manocha et al. 2007). This haplotype was also associated with increased fibrino-
gen levels, implying a beneficial impact of high fibrinogen in persons with sepsis.
Other haplotype studies associated fibrinogen gene variation with ischemic stroke
in men (a twelve SNP haplotype covering all three genes) (Carty et al. 2008), MI
(a two SNP alpha-gamma haplotype) (van Oijen et al. 2008), and small vessel
disease (an eight SNP alpha-gamma haplotype) (Mannila et al. 2007). Two of
these papers failed to find associations with individual SNPs emphasising that
a haplotype approach to genetic epidemiology may yield increased power to de-
tect associations. However, a large-scale study of 1,811 Framingham Heart Study
participants by revealed no relationship between either SNPs or haplotypes with
CVD (Kathiresan et al. 2006b).
To summarise, in accordance with the studies investigating CRP SNPs with
CVD, there is inconclusive evidence as to the relationship between fibrinogen
SNPs, fibrinogen levels, and CVD. These inconsistent findings suggest the need
for further large-scale epidemiological studies to help decipher the exact role of
fibrinogen in cardiovascular disease outcomes.
3.8.5 Association with cognition
There have been very few studies conducted to test the association between fib-
rinogen SNPs and cognitive ability. A literature review found no directly relevant
papers on this topic. However, some studies have investigated the association be-
tween fibrinogen SNPs/haplotypes and cerebral small vessel disease (Martiskainen
et al. 2003, van Oijen et al. 2008).
The largest and most comprehensive of these studies was by Van Oijen et
al. who used logistic regression models to analyse the association between fib-
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rinogen levels and haplotypes with silent brain infarcts and white matter lesions
(van Oijen et al. 2008). The cohort for the analysis was 1,077 persons (mean
age 72) from the Rotterdam Study undergoing cerebral MRI. Haplotypes were
generated using seven tagging SNPs from the FGA and FGG genes. These hap-
lotypes explained the common variation in the two genes. In addition, they also
genotyped the functional 2148C/T polymorphism (rs1800787) in the FGB gene
that has been shown to directly affect FGB promoter activity (Verschuur et al.
2005). The results of the study found small but significant associations between
two of the FGA-FGG haplotypes and the presence of silent brain infarcts and
periventricular white matter lesions on brain MRI. Conversely, no associations
were observed between the FGB promoter SNP or plasma fibrinogen levels and
the MRI output. There were also null findings between the FGA-FGG haplotypes
and plasma fibrinogen levels. These findings provide evidence for a relationship
between the common variants in the fibrinogen genes and cerebral small vessel
disease. The authors propose structure of the fibrin clots as opposed to plasma
fibrinogen levels as a potential causal factor in the pathogenesis of cerebral small
vessel disease.
3.9 Summary
This chapter has presented extensive background details on plasma fibrinogen and
the three genes that encode it. Despite a lack of studies investigating fibrinogen
levels with cognitive ability, there does seem to be a degree of evidence pointing
in the direction of small but consistently inverse associations. There is currently
a lack of papers focussing on the relationship between the genes that encode
fibrinogen and cognitive ability, although associations have been found between




and inflammatory marker genes
4.1 Introduction
In addition to CRP and fibrinogen, several other inflammatory markers and
marker genes have been posited as predictors of cognitive ability. In this short
chapter, the relationship between plasma levels and SNP variants of interleukin-6
and tumor necrosis factor-α and cognition are discussed. A short summary is also
presented for four other genes related to inflammatory pathways and cognitive
ability: TCF-1, F13A1, IL-1, and APOε.
4.2 Tumor Necrosis Factor-α and Interleukin-6
During inflammation the levels of CRP and fibrinogen are regulated by several
factors including the cytokines tumor necrosis factor-α and interleukin-6 (Ablij
& Meinders 2002). These inflammatory cytokines have also been studied inde-
pendently with regard to their associations with cognitive ability, cardiovascular
disease, and inflammatory disease. TNF-α and IL-6 are released by white blood
cells in response to an inflammatory stimulus, resulting in increased synthesis
of acute-phase proteins in the liver (Gallin et al. 1983). This pro-inflammatory
response is vital in stimulating the immune system and thus, in the removal of
pathogens and post-infection healing.
59
4.3 Production and function
4.3.1 Tumor Necrosis Factor-α
TNF-α was first named in 1975 because of its ability to destroy malignant tumor
tissue in mice (Carswell et al. 1975). In modern times it is recognised primarily
as a regulator of the immune system. The main production of TNF-α takes place
in macrophages although synthesis occurs in several other cells, including glial
cells in the brain (Frei et al. 1987). Whilst it is vital in maintaining immunity, an
excess concentration of TNF-α can cause a deleterious effect on neurons (Allan &
Rothwell 2001, Viviani et al. 2004). In addition, as TNF-α is a promoter of the
inflammatory response, it is a key factor in chronic inflammatory diseases such as
rheumatoid arthritis (Feldmann et al. 1996). Functionally, TNF-α is often found
to operate in conjunction with interleukin-1 and interleukin-6. The TNF-α gene
covers approximately a 3kb region and is located on the short arm of chromosome
six (6p21.3)1. It contains four exons with the last one responsible for coding more
than 80% of the secreted protein (Nedwin et al. 1985).
4.3.2 Interleukin-6
IL-6 is a cytokine that can induce both a pro and anti-inflammatory response. It is
produced by macrophages and T cell lymphocytes and its presence helps stimulate
the production of a large number of liver-based acute-phase proteins (Pradhan
et al. 2001). The production of IL-6 is part of the immune response to harmful
stimuli such as infections, burns, and trauma. Its primary pro-inflammatory
functions include activation of the acute-phase response, and the growth and
differentiation of B and T cells (Maggio et al. 2006). The anti-inflammatory
properties of IL-6 are mediated through its ability to inhibit the production of
pro-inflammatory cytokines such as TNF-α (Maggio et al. 2006). The IL-6 gene
is located on the short arm of chromosome seven (7p21)2 and contains six exons






4.4 Association with cognition
4.4.1 Prospective evidence
Several studies have investigated the relationship of plasma IL-6 and TNF-α lev-
els with cognition. Of the prospective evidence reviewed, three studies were in
relation to IL-6 with one also investigating TNF-α. Chronologically, the oldest of
these was from 2003 where the authors studied 3,031 African-American and white
men and women (mean age 74 years) from the Health, Aging, and Body Com-
position Study (Yaffe et al. 2003). Serum levels of three inflammatory markers
(IL-6, TNF-α, and CRP) were measured and modelled against two year cognitive
change in scores on the modified MMSE (3MS). After age-adjustment the odds
ratios for cognitive decline (a 5 point or greater decline in 3MS score) in the high-
est versus lowest tertile of marker level were significant for IL-6 (odds ratio 1.34,
95% CI (1.06, 1.69)) but not for TNF-α (odds ratio 1.12, 95% CI (0.88, 1.43)).
Further adjustment for other demographic variables and comorbidities rendered
the associations non-significant although the magnitude of the point estimates
remained similar. The results for CRP have been reported in Section 2.8.2. Also
discussed previously, the limitations of this study surround the short follow-up
period and the use of a single, general ability measure to assess cognition.
The second paper reviewed was a 2007 report that studied 290 persons aged
55-75 years over a three year period (Jordanova et al. 2007). Baseline levels of
the inflammatory markers, IL-6, CRP, and serum amyloid A were measured and
cognition was assessed at both time-points with decline in individual tests and
a composite outcome used as indicators of cognitive change. Upon adjustment
for potential confounding factors, raised IL-6 levels but not CRP levels were
associated with cognitive decline (odds ratio for decline in g for high versus low
IL-6 quartile was 2.9, 95% CI (1.1, 7.5)). Strong associations were also found
between IL-6 levels and decline in orientation, immediate verbal recall tasks, and
to a lesser degree with delayed recall and psychomotor speed. Although this paper
used an extensive cognitive battery and assessed multiple inflammatory markers,
as it focused solely on Afro-Caribbean persons it is difficult to generalise these
findings to a wider population. Further, splitting the marker levels into quartiles
and then comparing top and bottom categories is going to compromise the power
to detect an effect in what is already a relatively small and heterogeneous (by
age) sample.
The most recent paper reviewed was from 2008 (Alley et al. 2008). This paper
was reviewed as part of the literature search for CRP. To recap, growth curve
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modelling showed there to be little evidence for an association between IL-6 and
CRP levels with cognitive change, which was assessed three times over a seven
year period in 851 persons aged 70-79 years at baseline who were participating
in the MacArthur Study of Successful Aging.
Of the three papers, this study presents the most rigorous argument for the
evidence of a longitudinal association between IL-6 and cognition. Due to its
reasonably large sample size and comprehensive assessment of cognitive ability
at three separate waves I would provide greater weight to their null findings than
to the positive results reported by Jordanova and Yaffe.
4.4.2 Cross-sectional evidence
As with the longitudinal studies, three cross-sectional studies were found that
investigated the association between IL-6 and TNF-α levels and cognitive ability.
The most relevant of these was a report by van Exel et al. who measured a ratio of
the pro-inflammatory cytokine TNF-α by the anti-inflammatory cytokine IL-10
in 599 members of the Leiden 85-Plus Study (van Exel et al. 2003). An indication
of atherosclerosis was assessed using self-reported CVD and an electrocardiogram
(a graphical recording of the cardiac cycle) to report MI or myocardial ischemia.
Cognition was measured using the MMSE and a four test cognitive battery; a de-
mentia diagnosis was also made where appropriate. A linear regression analysis
found the inflammatory ratio to associate inversely with all of the measures of
cognition, including dementia, but only in those with cardiovascular disease. The
associations remained after adjustment for confounders such as sex, education,
non-steroidal anti-inflammatory drug (NSAID) use, total cholesterol, HbA1c, his-
tory of hypertension, and history of stroke. As to a mechanism, the authors hy-
pothesise that atherosclerosis causes a pro-inflammatory response, which in turn
leads to neurodegeneration, cognitive decline, and dementia.
Of the two other studies reviewed, the paper by Wright et al. found an inverse
association between IL-6 levels and MMSE scores in 269 stroke free participants
in the Northern Manhattan Study (mean age 66.7 years (s.d. 8.4)) (Wright et al.
2006). However, this was a small study on a racially diverse population who were
assessed with a single measure of cognitive ability. The final paper analysed IL-6
levels in relation to cognitive function in a group of 500 middle aged persons
(mean age 44.6 years (s.d. 6.7)) (Marsland et al. 2006). This study used an
extensive battery from the Wechsler Memory Scale to assess memory and two
individual tests to assess executive function. Despite the cohort being much
younger than the others reported, an inverse relationship was found between IL-6
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and cognition, which was independent of a number of health factors such as BMI,
smoking and hypertension. These findings raise the possibility that IL-6 may
represent a biomarker for risk of future cognitive decline.
In summary, there is mixed evidence from both cross-sectional and longitudi-
nal studies as to the relationship between IL-6 and TNF-α with cognitive ability
and cognitive decline. Whilst some studies have used an extensive battery of tests
to measure cognition, and had a reasonably long follow-up period, the number of
participants in the studies has been quite small. As with the CRP/fibrinogen as-
sociations with cognition, there is a need for large-scale prospective cohort studies
that can confirm or deny the existence of these small effects.
4.5 Association between SNPs and cognition
Further to the studies analysing TNF-α and IL-6 levels with cognitive ability, a
study by Bernhard Baune investigated the relationship between SNPs of the TNF-
α, IL-6 and IL-1β genes with cognition (Baune et al. 2008). Using a relatively
small study of 369 elderly participants of the Memory and Morbidity in Augsburg
Elderly (MEMO)-study, they assessed the relationship between a single SNP from
each of the three genes with measures of memory, processing speed, and motor
function.
The SNPs selected for the analysis were rs1800269 (TNF-α) due to previous
associations with dementia in centenarians (Bruunsgaard et al. 2004), rs1800796,
(IL-6 ) which has been associated with detrimental effects on cognitive develop-
ment in children (Harding et al. 2005), and rs16944 (IL-1β). Linear regression
models yielded significant associations between the IL-1β SNP and memory per-
formance (p = 0.003) and between the TNF-α SNP and processing speed (p =
0.004) after adjustment for age, sex, education, and MMSE score. In the case
of the IL-1β SNP, the CC genotype was consistently but not significantly associ-
ated with increased performance across the other cognitive domains whereas the
GA/AA genotypes for the TNF-α SNP were associated with poorer performance
on the two tests where significance was not attained. Whilst it is possible that
this implies a domain specific effect for the SNP it is also plausible that the re-
sult is a false positive. Given the small sample size for the analysis and limited
number of SNPs typed in each gene, additional follow-up studies are required to
replicate the findings.
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4.6 Additional inflammation/cognition genes
4.6.1 Transcription Factor Gene 1
Located on chromosome twelve (12q24.31)3 Transcription factor gene-1 (TCF-1 )
- also known as HNF1A - encodes the transcription factor hepatocyte nuclear
factor (HNF)-1α (Reiner et al. 2008a). The Hepatocyte Nuclear Factor (HNF )
genes regulate the transcription of proteins involved with blood clotting factors,
enzymes, and transporters involved with glucose, cholesterol, fatty acid transport
and metabolism (Armendariz & Krauss 2009). HNF-1α is expressed predomi-
nantly in the liver and has been associated with transactivation (increased gene
expression triggered by endogenous cellular or viral proteins) of CRP (Toniatti
et al. 1990).
The relationship between TCF-1 genetic variants and CRP levels has been
described in detail (Reiner et al. 2008a). By combining data from the Cardiovas-
cular Health Study (CHS) (n = 4,333) and the Pharmacogenomics and Risk of
Cardiovascular Disease (PARC) (n = 909 + 773), Bayes factors were computed
to identify SNPs with the strongest evidence of association with CRP levels.
The PARC study included data from two separate groups of of late-life men and
women (mean age 62 years (s.d. 14) and 63 years (s.d. 13), respectively). The
characteristics of these groups were similar with 32% and 25% of the samples be-
ing female and with mean CRP levels being 0.89 mg/l (s.d. 1.52) and 0.69 mg/l
(s.d. 1.27). By contrast, the CHS demographics differed substantially (mean age
73 years (s.d. 6), 57% female, mean CRP 3.5 mg/l (s.d. 5.9)).
In the first stage of analysis, SNPs from a variety of genes were modelled
against CRP levels in both studies. This identified strong predictors in the CRP
and APOε genes. Modest Bayes factors were observed for variants in the TCF-1
gene across both studies. Given the previous reporting of CRP/APOε variants
and CRP levels, Reiner and colleagues decided to focus their investigation on
variations in the TCF-1 gene. Combining the SNP information from the two
studies with information on multimarker LD from HapMap, they assessed the
strength of evidence for phenotypic association with typed and untyped SNPs in
the TCF-1 region. Of the 193 SNPs in this region, the strongest evidence of an
association was with a cluster of five untyped SNPs in perfect LD (rs7310409,
rs2393775, rs7979473, rs2393791, and rs7979478).




gene and CRP levels, the heterogeneity between the two populations in Reiner’s
paper could be a cause for concern. However, as age, gender, BMI, and smoking
are adjusted for in the analyses, it would appear that the major influences on
CRP have been accounted for.
A 2005 study by Soria et al. conducted a genome-wide scan on 21 Span-
ish families to search for determinants of plasma fibrinogen levels (Soria et al.
2005). The study participants were part of the Genetic Analysis of Idiopathic
Thrombophilia (GAIT) Project and included 398 persons belonging to pedigrees
of 3-5 generations. The age of participants ranged from < 1 to 88 years. In an
age and sex-adjusted analysis, fibrinogen levels were significantly associated with
three of the ten TCF-1 SNPs included in the analysis: rs1169292, rs1169301,
and rs2464196. However, no associations were found between any of the TCF-1
haplotypes that were generated, leading the authors to conclude it was likely that
the functional variant was not typed in the analysis. One problem with the SNP
analysis was the conclusion of a positive association at the nominal significance
level of 0.05. Had a correction for multiple testing been applied then the TCF-
1 –fibrinogen association would have been null. Secondly, the authors failed to
investigate the LD structure of the SNPs in question. It is therefore possible that
the three positive SNP associations are actually being tagged by each other and
that the multiple positive findings are simply a replication.
4.6.2 Coagulation factor XIII, A1 polypeptide
The F13A1 or Coagulation factor XIII, A1 polypeptide gene is located on chro-
mosome six (6p25.3-p24.3)4 and encodes coagulation factor XIII. After the con-
version of fibrinogen into fibrin via the enzyme thrombin, factor XIII stabilises
the newly formed mesh of fibrin by cross-linking the molecules. This process
results in the formation of clots.
A pair of studies yielded similar, null associations between the rs5985, F13A1
variant and fibrinogen levels (Mannila et al. 2006, 2007). However, as the primary
aim of both studies was to consider the association between SNPs and fibrinogen
levels in MI patients, this reduces the ability to generalise the results to healthy
subjects.
The first study comprised 327 Swedish persons who were survivors of a first
MI, and 60 controls (selected by rs1049636 genotype - a FGG SNP that has been
associated with altered fibrin clot structure). Significant epistasis (gene-gene
4http://genome.ucsc.edu/cgi-bin/hgTracks?position=chr6:6089310-6265923
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interaction) on plasma fibrinogen concentration was detected between rs2070011
(FGA) and rs5985.
In the second study, 1,213 men and women diagnosed with an MI were com-
pared with 1,561 healthy controls of similar age, sex and area of residence. Plasma
fibrinogen and IL-6 levels were assessed for differences by fibrinogen SNPs and
haplotypes, and the F13A1 rs5985 SNP. Concordant with their previous findings,
the F13A1 SNP did not appear to exert any influence upon plasma fibrinogen
concentration.
4.6.3 Interleukin-1
One of the first cytokines to be discovered, interleukin-1 is composed of two
distinct proteins IL-1α and IL-1β. Both proteins are coded for on chromosome
two (α 2q12-q21, β 2q13-q21)5,6 and are pro-inflammatory components of the
immune system. Functionally, IL-1 facilitates the movement of leukocytes to
sites of infection in addition to regulating the hypothalamus, which raises body
temperature (Dinarello 1994). These processes complement the immune system
and help the body to combat pathogens and fight infection.
Several studies have investigated the relationship between plasma levels of IL-
1, its genetic variants and cognition but with mixed results (Holmes et al. 2003,
Trompet et al. 2008, van den Biggelaar et al. 2007). Van den Biggelaar et al.
investigated whether inflammation precedes depressive symptoms and cognitive
decline in 267 persons, aged 85 years from the Leiden 85-Plus study. Partici-
pants were prospectively followed up for five years until age 90 when they were
assessed for depressive symptoms (Geriatric Depression Scale) and cognitive abil-
ity (MMSE). Whilst higher levels of IL-1β were associated with an increase in
depressive symptoms, no associations were observed with cognitive dysfunction.
Moving from biomarker levels to genetic markers, Trompet et al. investigated sev-
eral variants in the interleukin-1 beta-converting enzyme (IL-1βC ) gene – a gene
that is likely to influence plasma IL-1β levels. Cross-sectional and longitudinal
associations were observed for individual SNPs and haplotypes in 5,804 persons
aged 75 years (s.d. 3) from the PROspective Study of Pravastatin in the Elderly
at Risk (PROSPER). Some of the genetic variants in the IL-1βC gene that asso-
ciated with better performance on cognitive function also associated with lower
IL-1β plasma levels. This was particularly the case for the cognitive measure




Digit Coding Test. Cognition was assessed at six separate time-points during the
study: before randomization, at baseline, after 9, 18 and 30 months, and at the
end of the study (36–48 months). Linear regression was used in the cross-sectional
analyses with mixed effects models being used to analyse the multi-wave data.
Polymorphisms from the IL-1 genes have also been associated with systemic
levels of inflammatory markers including CRP and IL-6 (Reiner et al. 2008b) and
with central obesity and metabolic syndrome in a population with CHD (Carter
et al. 2008a).
4.6.4 Apolipoprotein ε
One further gene that was investigated during the analysis for this thesis was
Apolipoprotein ε (APOε). The APOε gene is located on chromosome nineteen
(19q13.2)7 and has three alleles - ε2, ε3, ε4. By genotyping two SNPs in the
region (rs429358 and rs7412) and generating haplotypes, allele status can be
determined (Seripa et al. 2007). In particular, the TT haplotype generates the ε2
allele, the TC haplotype generates the ε3 allele, and the CC haplotype generates
the ε4 allele. The frequency of these three alleles in the general population is
approximately 0.08, 0.78, and 0.14, respectively (Rebeck et al. 1993).
As the major lipid carrying protein of the central nervous system, APOε is
critical for the management of cholesterol transportation in the repair, growth,
and maintenance of myelin and neuronal membranes during development or after
injury (Seripa et al. 2007). There is also evidence that it is a potent scavenger
of soluble amyloid and therefore, may play a role in the deposition of amyloid
plaques, which are a characteristic of an AD brain.
APOε has been studied extensively in relation to cognitive ability and is, to
date, one of only a few genes to be consistently associated with this trait (Bertram
& Tanzi 2008). Of the various APOε alleles, carriers of the ε4 allele are at greater
risk of developing dementia.
Moreover, CRP levels have been shown to vary by APOε genotype. Several
studies have found that the high risk allele for dementia (ε4) was associated
with lower levels of CRP (Grönroos et al. 2008, Judson et al. 2004, Kahri et al.
2006, März et al. 2004). This finding is somewhat counter-intuitive given the
independent associations between both elevated CRP levels and APOε4 status
with impaired cognition. The study by März et al. also looked at the association





This chapter provided a brief introduction to the biomarkers IL-6 and TNF-
α. The cross-sectional and prospective evidence for associations with cognitive
ability and cognitive decline is mixed. Whilst the evidence for an association
is slightly stronger for IL-6, the number of well-designed, large studies has been
few. As with fibrinogen and CRP, the potential mechanisms through which IL-6
and TNF-α operate in relation to cognition are currently unclear. In addition
to the biomarker-cognition studies, one group studied a single SNP from each of
the IL-6 and TNF-α genes and found evidence for significant associations with
late-life cognition. Finally, this chapter also introduced several other genes (IL-1,
TCF-1, F13A1, and APOε) that have been related to inflammation and cognitive
ability. Brief descriptions were provided for the structure and function of these
genes before they were related to CRP levels (TCF-1 and IL-1 ), fibrinogen levels
(F13A1 ), IL-6 levels (IL-1 ), and cognitive ability (IL-1 and APOε).
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Literature summary and study
aims
Determining the relationship between individual components of the inflammatory
and rheological systems and cognitive decline is important in order to inform the
development of targeted preventive interventions. However, data from large-scale
epidemiological studies with adequate cognitive testing and reasonable length of
follow-up are scarce. Although a number of studies have explored the association
between the inflammatory marker C-reactive protein (CRP) and cognitive decline,
few have been of sufficient size and methodological rigour and even these gave
contrasting results (Alley et al. 2008, Dik et al. 2005, Schram et al. 2007, Weuve
et al. 2006). A single, relatively small study on plasma fibrinogen and cognitive
decline found an association with 5–year change in non-verbal reasoning scores
and estimated lifetime decline of memory scores, but not with decline in general
intelligence, executive function or processing speed (Rafnsson et al. 2007). A
study on the association between human cognition and blood rheology found
significant associations between plasma viscosity and haematocrit and tests of
general intelligence and decision speed. However, findings were confined to men
and did not address the issue of cognitive decline subsequent to measurement
of these rheological factors (Elwood et al. 2001). Finally, there have been very
few large-scale, long term follow-up studies to associate levels of the upstream
inflammatory markers IL-6 and TNF-α with cognitive function.
In view of these limited findings, the hypothesis that higher levels of the
inflammatory markers CRP and fibrinogen and of the rheological factors plasma
viscosity and haematocrit are associated with cognitive decline was investigated
using data from the Aspirin for Asymptomatic Atherosclerosis (AAA) Trial. This
cohort had the advantage not only of size (over 2,000 subjects cognitively tested),
availability of detailed cognitive testing within a range of cognitive domains and 5-
years of follow-up, but was also free of clinical cardiovascular disease at baseline
when inflammatory and rheological markers were measured. Given that CRP
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levels in particular may be affected by atherosclerosis (a strong risk factor for
cognitive decline), this helps to reduce the chance that any observed associations
between inflammatory marker and cognitive decline were confounded by prevalent
vascular disease at baseline.
Furthermore, a similar hypothesis was then tested using cross-sectional data
from the Edinburgh Type 2 Diabetes Study (ET2DS). Specifically, the aims were
to determine the associations between the downstream inflammatory markers
CRP and fibrinogen, the upstream inflammatory markers IL-6 and TNF-α, and
a general inflammation factor, (derived using information from the four markers)
and cognition. As persons with Type 2 diabetes are at greater risk of both
cognitive impairment and dementia, and given that they also decline at a faster
rate, this population should provide an accelerated model of cognitive decline
compared to the AAA Trial population.
To determine the mechanisms of the potential relationships, a genetic associ-
ation analysis was then performed using SNP information from the CRP, FGA,
and FGB genes in the AAA Trial, the ET2DS, and two replication cohorts, the
Edinburgh Artery Study (EAS), and the 1936 Lothian Birth Cohort (LBC1936).
Several SNPs from the genes described in Chapter 4 were also investigated in
relation to cognitive ability. The following chapters describe in detail the study
methodology of these cohorts, the statistical analysis of their data, the results
generated from the analyses, and their implications.
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Chapter 5
The Aspirin for Asymptomatic
Atherosclerosis (AAA) Trial
5.1 Introduction
This chapter describes the baseline methodology and follow-up procedures em-
ployed by the Aspirin for Asymptomatic Atherosclerosis (AAA) Trial, a ran-
domised controlled trial of aspirin on the prevention of cardiovascular disease in
an asymptomatic atherosclerotic population. Moreover, the chapter provides in-
formation on the AAA Trial study population, the procedures of recruitment at
baseline, and the layout of the baseline and follow-up clinical examinations. In
addition, the cognitive function testing that was carried out in 1999/2001 and
2003/2006 is discussed in depth. The chapter draws to a close by describing the
methods of data storage, variable manipulation and transformation in prepara-
tion for the main analyses. Much of the descriptive information presented in
this chapter is referenced from the AAA Trial grant application, in addition to
previously published papers that analysed data from the Trial (Price et al. 2006,
2008c, Stewart et al. 2006).
5.2 The AAA Trial: Baseline survey
The primary purpose of the AAA Trial was to test, using a double blind, placebo
controlled, randomised trial, the effect of low dose aspirin in the prevention of
cardiovascular events and death in subjects at high risk of cardiovascular events.
A secondary objective was to investigate the relationship between late-life inflam-
matory and rheological biomarker levels with late-life cognitive ability, late-life
cognitive change, and estimated lifetime cognitive change.
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5.2.1 Study population
The study population of the AAA Trial comprised 3,350 men and women living
in central Scotland (Lanarkshire, Edinburgh, and Glasgow), aged 50–75 years.
Recruitment to the trial began in 1998 when 165,795 invitations were sent out to
members of the general public through their general practices (83% of practices
contacted agreed to participate). Screening then took place on 29,147 subjects.
At the screening clinic, researchers recorded right and left brachial, posterior
tibial, and dorsalis pedis systolic pressures with a standard sphygmomanometer
and a Doppler probe. The ankle-brachial pressure index (ABPI) was calculated as
the ratio of the lowest pressure in either ankle to the higher of the measurements in
the left or right arm. ABPI is both an accurate (Ouriel et al. 1982, Yao et al. 1969)
and reliable (Fowkes et al. 1988) marker of generalised atherosclerosis with values
≤ 0.95 shown to be a good predictor of mortality and subsequent cardiovascular
events (Heald et al. 2006). A detailed eligibility examination was then carried
out on 4,914 subjects with an ABPI ≤ 0.95 to exclude persons for any of the
following criteria: current use of aspirin, other antiplatelet, or anticoagulant;
severe indigestion; history of myocardial infarction, stroke, angina, or peripheral
arterial disease; chronic liver or kidney disease; chemotherapy; contraindications
to treatment with aspirin; and an abnormally high or low packed cell volume.
Screening took place at over 20 different clinic sites across Lanarkshire, Glas-
gow, and Edinburgh with those eligible randomised to either low dose aspirin
(100mg enteric coated) or placebo (both preparations provided by Bayer Health-
Care). The intention was to follow-up 3,300 subjects for five years for cardio-
vascular events and death although this figure was surpassed with 3,350 subjects
available for randomisation. This population was similar, in terms of age, sex, and
level of deprivation, to the general population of Scotland (Price et al. 2008d). A
flow chart detailing the recruitment process to the trial is presented in Figure 5.1.
5.2.2 Sample size determination
As the inflammation-cognition investigation was part of a secondary analysis, this
had some bearing upon the sample size calculations, which were calculated post-
hoc. Nonetheless, the study of baseline inflammatory marker levels as predictors
of follow-up cognition was powered at 90% (α = 0.05) to detect a standardised
effect size of 0.056, assuming a follow-up sample size of 3,350. Allowing for a
combined 40% drop-out rate or missing data (n = 2,010), the study was powered
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668 refused cognitive testing 
40 impractical to test or unable to contact 
13 testing incomplete 
 
504 cognitively 
tested using a 
five test battery 
Plasma fibrinogen (n = 2,915) 
Plasma viscosity (n = 3,334) 
Plasma CRP (n = 2,699) 
Haematocrit (n = 3,349) 
2,312 cognitively 
tested at follow-up 
 
Figure 5.1: AAA Trial recruitment process.
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for every standard deviation change in marker level the cognitive score changes
by 0.072 standard deviations.
For a sub-group of 504 participants who received extensive cognitive testing
at both waves of the study, the Trial was powered at 90% (α = 0.05) to detect a
standardised effect size of 0.14. After allowing for a sample-size reduction of 20%
(n = 403), the study was powered at 90% (α = 0.05) to detect an effect of 0.16
between the baseline inflammatory marker levels and five year cognitive change.
5.2.3 Ethical approval
Ethical approval for the AAA Trial was granted by the ethical committees of
Lanarkshire, Edinburgh and Glasgow. In addition, all subjects provided written
informed consent prior to the start of the trial.
5.2.4 Baseline examination
At the baseline stage of the trial, participants were randomised to aspirin or
placebo before being asked to complete a medical history questionnaire. A ques-
tionnaire on smoking habits was also used to identify current smokers, previous
smokers, or those who had never smoked. Persons who were current or ex-smokers
were asked for the average number of cigarettes they smoked per day, and the
number of years they had smoked or the number of years since cessation. Other
measures taken at this stage included ABPI, systolic and diastolic blood pressure,
and a plasma sample for biomarker measurements. All current prescribed or reg-
ular medications were also recorded. After a three month period, participants
were asked to return for a brief compliance visit and for cognitive testing. At this
point, those with missing biomarker or questionnaire data from the baseline visit
were re-examined.
5.2.5 Inflammatory and rheological biomarker measure-
ments
Baseline venous blood samples were used to measure plasma viscosity, haemat-
ocrit, fibrinogen, and CRP. Assays were performed in the University Department
of Medicine, Glasgow Royal Infirmary. Plasma viscosity was assayed in a fresh
blood sample anticoagulated with K2EDTA in a capillary viscometer (Coulter)
at 37 ◦C (Tzoulaki et al. 2006). In the same sample, haematocrit was measured
using a microcentrifuge and optical reader (Hawksley) (Tzoulaki et al. 2006). In
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stored plasma anticoagulated with trisodium citrate, fibrinogen was assayed by
the automated Clauss assay (MDA-180 coagulometer, Organon Teknika), and
CRP using a high-sensitivity immunonephelometric assay (Tzoulaki et al. 2006).
5.3 The AAA Trial: Five-year follow-up exam-
ination
Approximately five years after the baseline clinical examination all surviving and
eligible subjects were invited to attend a follow-up clinical examination. The
procedures of this examination are detailed below.
5.3.1 Invitation to study
All subjects had been followed up annually by means of telephone contact since
the inception of the trial. Prior to the fifth year phone call, a letter was sent
to all participants to inform them about the processes involved for the follow-up
cognitive testing. Participants were then contacted to arrange a time and date
for a visit to a local research clinic for the cognitive examination. Persons who
were unable to make it to the clinic were given the option of a home visit. Those
who did not attend the clinic, missed their appointment, or failed to respond to
the invitation were re-contacted up to three times or were asked to complete a
brief telephone interview to identify a reason for withdrawal/non-participation.
In total, the number of participants who were available for follow-up cognitive
testing was 2,312. Of those lost to follow-up (n = 1,038), 160 were deceased, 157
had withdrawn, 668 refused to be cognitively assessed, 40 persons were imprac-
tical to test or unable to contact, and 13 had incomplete testing.
5.3.2 Clinical examination
In addition to the cognitive testing, a brief clinical examination was performed
on participants at follow-up to measure ABPI and (systolic and diastolic) blood
pressure.
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5.4 Methods of cognitive function testing
5.4.1 Baseline cognitive testing
Cognitive assessment of the AAA Trial was launched three months after screening
and randomisation took place. A vocabulary-based test was administered to all
willing participants of the trial with a subset of 504 persons also receiving an
extensive five test omnibus of cognitive tests. The same battery was applied to
all participants along with another vocabulary-based test at the five year follow-
up. Extensive details on the tests used in the cognitive battery are provided in
the subsection on the second round of cognitive testing.
5.4.2 Baseline subject recruitment
Of those who attended the three month clinic, 2,733 (81.6%) completed the Mill
Hill Vocabulary Scale (MHVS). A subset of this population was then selected
for extensive cognitive testing. The selection process for this subset was not ran-
domised. Briefly, research funding became available to perform extensive baseline
cognitive testing after approximately one third of subjects had been through the
three month clinic. Thereafter, participants were invited sequentially to take the
additional cognitive testing until this group totalled a target of 480 in number.
In practice, 504 persons ended up taking part in this additional cognitive exam-
ination. However, these data clearly introduce the possibility of bias through a
non-representative sample.
5.4.3 Baseline medical questionnaire
In an attempt to account for any medical conditions that may have interfered
with the subjects performances on the cognitive tests, a brief questionnaire was
administered. Subjects were asked to relate information on other relevant diseases
such as severe arthritis and vision or hearing difficulties that may have had an
affect on cognitive function or the ability to complete the tests.
5.4.4 Baseline cognitive testing
The cognitive function testing, which began in 1999 and was completed in 2001,
was carried out by two members of staff (a research nurse and a research fellow)
who were trained in the cognitive test procedures by a senior member of aca-
demic staff (Psychology consultant on the AAA Trial) from the Department of
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Psychology at the University of Edinburgh.
5.4.5 Follow-up cognitive testing
The recruitment of AAA Trial subjects to follow-up cognitive testing began in
early 2003. All subjects who were enrolled into the trial at baseline were poten-
tially eligible for participation. Testing took place between May 2003 and April
2006. The mean duration of participation in the trial was five years: 230 par-
ticipants were tested after four years; 259 after six years; two after seven years;
and the remainder at five years. Details of the cognitive test battery and quality
control measures for testing are described below.
Before the start of the cognitive function testing, training in the administra-
tion of the cognitive tests was provided. Between six and eight trained research
nurses were hired at any one point to administer the testing. All nurses were
informed about the basic cognitive test procedures by the research fellow who
conducted the testing at baseline.
At both waves of cognitive testing an informal assessment of inter-rater agree-
ment was carried out. The lack of formal comparisons between the cognitive
testers may have introduced bias into the results although all the testers at both
waves were trained by a single supervisor.
5.4.6 The cognitive test battery
The detailed cognitive test battery assessed at both waves of the AAA Trial
included five identical neuropsychological tests. A screening test for dementia
(the Mini-Mental State Examination) was administered at both baseline and
follow-up. However, persons were not removed from the study if they had a
low MMSE score. Participants were all community-dwelling and attended the
clinic under their own freewill. If they asked to discontinue with the testing at
any timepoint, or if their GP contacted the AAA Trial research team asking for
their participation to be stopped then this was granted with immediate effect.
Similarly, testing was stopped if the research nurse felt that this was causing the
participant any distress. A vocabulary-based measure of pre-morbid cognitive
ability (the National Adult Reading Test) was also assessed at the 5-year follow-
up although this test does differ slightly from the Mill Hill Vocabulary Scale used
at baseline. Nonetheless, the correlation between these two similar measures
(Crawford et al. 2001) was extremely high (r = 0.721). The test administration
time was approximately one hour. The individual components of the test battery
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are described below in the order they were presented to the participants.
List of Cognitive Tests
Mill Hill Vocabulary Scale
During the visit that occurred three months after commencement of the trial,
subjects were asked to complete a combined version of the Junior and Senior Form
A synonyms of the Mill Hill Vocabulary Scale (MHVS) (Raven et al. 1998). The
MHVS is a self-administered test that contains 44 items. Each item comprises
a word for which the subject must identify the closest synonym from a choice
of six given alternatives. The words become increasingly esoteric as the test
progresses. In common with other vocabulary-based measures of cognition, the
MHVS may be thought of as an indicator of pre-morbid or best-ever cognitive
ability. As mentioned in Section 1.3.2, vocabulary measures vary little over a
lifetime (Crawford et al. 2001, Schaie 2005). Assessment of the MHVS allowed
for a baseline comparison of the trial population and the subset, in addition to a
crude measure of the difference in cognitive ability of participants who were lost
to follow-up. The maximum possible score on the MHVS is 44 (range 0 – 44).
Mini-Mental State Examination
The Mini-Mental State Examination (MMSE) is a commonly used instrument in
the screening of cognitive function in both clinical practice and research (Folstein
et al. 1975). The test is not sensitive to subtle changes in cognition but it may
be used to indicate the presence of cognitive impairment, for example suspected
dementia (Crum et al. 1993). Furthermore, it is possible for people with low
intelligence or education to score poorly on this test in the absence of cognitive
impairment (Tombaugh & McIntyre 1992) whilst well educated people may score
well despite having cognitive impairment (Brayne & Calloway 1990). The MMSE
is a short test comprised of 20 questions and tasks across the following domains:
orientation-time, orientation-place, memory-registration, attention and calcula-
tion, memory–recall, praxis–ideational, praxis–copying and drawing, and sponta-
neous praxis–writing. As an example of a question from the memory–registration
domain, the subject is asked to recall immediately a list of three words. The ex-
aminer then informs the subject that they will be asked to recall the same three
words at a later point in the assessment, while in the praxis–copying domain, the
subject is asked to draw a copy of two interlocking pentagons. A single point is
awarded for each correct answer with 30 points being the maximum score pos-
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sible (range 0 - 30). In healthy cohorts the distribution of MMSE scores tends
to exhibit a ceiling effect with the majority of subjects answering all questions
correctly. A common cut-off used as a screening measure for dementia is a score
of less than 24 points.
Verbal Fluency Test
The Verbal Fluency Test (VFT) assesses executive function via measurement
of the number of words, orally presented by a subject within a restricted time
interval (Lezak 1995). The VFT consists of three, one-minute word-naming trials.
The examiner asks the subject to list as many words as possible beginning with a
particular letter of the alphabet within a one minute period (the letters C, F, and
L were used in the AAA Trial). An overall score is assigned after summing the
total number of acceptable words from all three of the trials. The letters selected
for the trials are chosen on the relative frequency of English language words that
beginning with these letters. For example, words beginning with the letter C are
relatively common, words beginning with F are slightly less common, and words
beginning with L are the least common of this trio. Proper nouns are not counted
and the same word with a suffix variation (e.g. make and makes) is only counted
once. Before the main test begins, the subject is asked to complete a practice
example using the letter S, or a similarly common letter for the beginning of a
word. After providing several words beginning with this letter, the subject is
asked to move onto the timed trials.
Raven’s Standard Progressive Matrices
To assess the participants’ skills in non-verbal reasoning, Raven’s Standard Pro-
gressive Matrices (RAVENS) were administered (Raven et al. 1998). This test
relies heavily on problem solving skills and requires the subject to decipher puzzles
through identification of relationships between complex structures. The RAVENS
test comprises five batches of 12 items (60 in total). Each individual item requires
the subject to solve a pattern problem that has a piece missing from it. Either
six or eight possible options are given for the missing piece with only one correct
option per item. The subject must choose one piece per item to complete the
pattern. Items increase in difficulty within each batch and from the first to the
fifth batch. A single point is assigned to each item, giving a maximum possible
score of 60 (range 0 - 60). In the AAA Trial, participants were allowed 20 minutes
to complete as many items of the test as possible after having had a brief practice
trial involving the first three test items. Participants were also allowed to change
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their answers to any question during the 20 minute test period.
Auditory Verbal Learning Test
Immediate and delayed memory was assessed by administration of the Auditory
Verbal Learning Test (AVLT) (Lezak 1995). The test involves five presentations
with recall of a list of 15 words, one presentation of an alternative list of 15 words,
and then a sixth recall trial. The test usually takes in the region of 15 minutes
to administer with retention being examined anywhere from 30 minutes, hours,
or days later. The order in which the words are recalled is irrelevant. In the
AAA Trial, the scores from the first five trials were aggregated to provide a joint
measure of immediate and delayed memory. Although not examined in the AAA
Trial, the AVLT can provide information about an individual’s learning strategies
by noting the order of recall response. As there are five trials with 15 items per
trial, the maximum possible score on the AVLT is 75 (range 0 - 75).
Trail Making Test, Parts A and B
Parts A and B of the Trail Making Test (TMT) were used to assess mental flex-
ibility via visual conception and visuo-motor tracking (Spreen & Strauss 1991).
Part A of the test requires the subject to draw connective lines between consecu-
tive numbers printed randomly on a piece of paper. The subject is not allowed to
remove the pen/pencil from the paper and must complete the task as quickly as
possible. Part B of the test is similar, except the subject must now follow a se-
quence of consecutive number-letter combinations e.g. 1-to-A-to-2-to-B-to-3-to-C
etc. Again the pen/pencil is not allowed to leave the paper with the aim being
to complete the test as quickly as possible. The time taken to completion but
not the number of errors was recorded by the examiner. In the case where the
subject got stuck, the examiner would prompt them to the next letter/number in
the sequence. For all subsequent analyses of the AAA Trial data, only the time
to completion of the TMT Part B was used.
National Adult Reading Test
A similar test to the MHVS, the National Adult Reading Test (NART) assesses
vocabulary skills – specifically, reading ability (Nelson & Willison 1991). It is
commonly used to estimate pre-morbid cognitive function. The NART requires
the subject to correctly pronounce a list of 50 words from the English language
that are irregular with respect to common rules of pronunciation. The difficulty of
the words increases sequentially throughout the test. Some examples of the words
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used in the test (in increasing order of complexity) are chord, gaoled, drachm,
and demesne. The test administrator notes a correct or incorrect answer for each
word, allowing slight variations for regional accents. The marking of the test re-
lies entirely on the ability of the examiner to interpret correctly the participant’s
responses. As a marking aid, the examiner is provided with the correct pronun-
ciation of all words in both written and audio format. The maximum possible
score on the NART is 50 (range 0 – 50).
Digit Symbol-Coding Test
The Digit Symbol-Coding Test (DST) is a subtest from the Wechsler Adult In-
telligence Scale (WAIS-IIIUK) - a clinical instrument designed for evaluating the
intellectual ability of adults 16 to 89 years of age (Wechsler 1998a). The purpose
of the DST is to measure an individual’s processing speed through the recoding
of symbols into numbers. The task is laid out with four rows of 25 paired boxes.
The top box of each pair contains a symbol and the participant has to use the
digit-symbol key at the top of the page to assign the correct number to the blank
box below each symbol. Prior to the test, the participant practices on the first
seven boxes, which do not count towards the final score. The main test requires
the examinee to fill in as many blank boxes with the corresponding symbols as
possible in 90 seconds. An overall test score is given upon summation of the
correctly completed boxes within the given time limit. The maximum score ob-
tainable is 93 (range 0 – 93). Moreover, participants must complete the test in
order from top left to bottom right i.e. they are not allowed to go through the
test systematically coding the symbols one at a time.
5.5 Genotypic data
Blood samples collected from AAA Trial participants at the three month visit
were used for genotyping. Fifty-two candidate SNPs were selected from thirty
different genes for genotyping. SNPs were chosen on the basis of previously re-
ported associations with cognitive ability or because they lay in genes strongly
associated with phenotypic variants thought to be important in cognitive pro-
cesses. A list of all SNPs typed in the study and analysed in this thesis are
presented in Table 5.1. Genomic DNA was isolated from whole blood by stan-
dard procedure at the Wellcome Trust Clinical Research Facility Genetics Core,
Western General Hospital, Edinburgh. Genotyping was carried out by KBio-
science (Herts, UK) using their in-house chemistry of Competitive Allele Specific
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PCR (KASPar). As discussed in Subsection 4.6.4, in order to generate APOε alle-
les, one must create a haplotype using information from the rs429358 and rs7412
SNPs. This was done by exporting the raw SNP information from KBioscience
into a Microsoft Excel comma–separated variable file before being read into the
computer software package SimHap (Carter et al. 2008b). For individuals with
ambiguous phase, SimHap uses biallelic SNP genotype data to impute haplotype
frequencies at the individual level. The most likely haplotypes were then selected
for each individual with the new data being transferred back into Excel prior to
statistical analysis. This haplotype information was then used to generate APOε
alleles for each individual.
Gene SNP Gene SNP










FGB rs4220 IL-6 rs2069832
rs1800788 rs2069840
rs2227412 rs1800795
Table 5.1: Genotyped SNPs from the AAA Trial
Of the 3,350 men and women recruited into the trial, 2,312 underwent cogni-
tive testing at 5 year follow-up. For the genetic analyses presented in this thesis,
the AAA Trial study population consists of 2,091 subjects who completed three
or more tests from the five test follow-up cognitive battery in addition to having
DNA available for testing. Some persons were also included in the genetic anal-
ysis if they had DNA available for testing and a plasma CRP or fibrinogen level
in the upper or lower decile of the distribution – irrespective of the availability of
cognitive data.
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5.6 Data handling and management
5.6.1 Entry of cognitive data
Data from both rounds of cognitive testing were double entered into a computer
using Microsoft Access. The cognitive packs were checked prior to data entry for
errors, such as scores beyond the range of possible values for the test, and missing
values. Under both scenarios, the original paper questionnaires were consulted
and checked with regards to whether the participant had left out individual items
(and the corresponding test scored as missing), refrained from doing the test, or
whether there had been a transcription error in the double data entry. The
participants’ unique study numbers were used to match the follow-up data with
the baseline data for the cognitive and physiological/demographic variables. The
data merging was performed by running a query in Microsoft Access. The data
were then exported into an Excel file to allow them to be read into the analysis
software packages R and SPSS.
5.6.2 Missing data and bias
At the baseline and follow-up visits there were numerous examples of missing
values in both the cognitive and demographic/physiological variables. Data im-
putation was considered for the cognitive tests where persons had three or more
scores to impute from. However, no formal analyses were conducted to investigate
the assumption of the data being missing at random. A brief analysis was con-
ducted using the Expectation-Maximization (EM) algorithm to impute missing
values although this made little difference to the study findings and interpreta-
tion. Moreover, not analysing persons with missing data is likely to lead to more
conservative estimates of any associations uncovered. The baseline MHVS scores
were lower for those who completed fewer cognitive tests (Table 5.2). This was
most noticeable when comparing the group with full follow-up cognitive data to
those with at least one missing test result (p < 0.001). However, as it was not
the primary scope of this thesis to investigate missing data, it was deemed more
appropriate to list the lack of a formal missing data and imputation analysis as
a limitation instead of conducting a crude and ill-considered analysis.
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Tests completed Mean s.d. n t d.f. p-value
≥ 1 tests 31.1 4.74 2,191 -2.16 2,731 0.031
0 tests 30.6 4.59 542
≥ 3 tests 31.1 4.72 2,154 -2.47 2,731 0.014
≤ 2 tests 30.5 4.68 579
5 tests 31.2 4.71 1,930 -4.11 2,731 <0.001
≤ 4 tests 30.4 4.69 803
Table 5.2: Comparison of mean MHVS scores by number of cognitive tests com-
pleted.
5.6.3 General intelligence factor and Principal Compo-
nents Analysis
Given the high correlation between each of the five cognitive tests (Table 5.3),
a general factor representing the variance common to all tests was created via
Principal Components Analysis. The correlations between the TMT and the
other tests are negative due to higher scores on the TMT reflecting a poorer
cognitive performance i.e. the score reported is the time to completion of the
task.
AVLT RAVENS VFT DST ln(TMT)
AVLT 1.000
RAVENS 0.421 1.000
VFT 0.362 0.400 1.000
DST 0.425 0.589 0.411 1.000
ln(TMT) -0.401 -0.591 -0.389 -0.658 1.000
Table 5.3: Pearson correlations between follow-up cognitive test scores.
It is standard practice in neuropsychological studies to use statistical tech-
niques to reduce the dimension of cognitive test data. For example, if several
tests of memory are administered in a cognitive battery then it may be desirable
to extract an overall memory component instead of dealing with multiple, highly
correlated variables. As mentioned in Subsection 1.3.1, it is recognised that there
are strong correlations between most cognitive tests. By using a process called
Principal Component Analysis (PCA) it is possible to extract a general ability
score.
Mathematically, PCA is defined as an orthogonal linear transformation that
transforms the data to a new coordinate system such that the greatest variance
by any projection of the data comes to lie on the first coordinate (called the first
84
principal component), the second greatest variance on the second coordinate, and
so on. Conceptually, PCA visualises the data in an n–dimensional space (where
n corresponds to the number of variables) before altering the perspective to find
the most informative view of the data. This ‘most informative’ view is reported
as the first principal component.
For the AAA Trial, scores from the five cognitive tests at baseline (follow-up)
were incorporated into the PCA. Both analyses provided evidence for a single,
principal component (Tables 5.4, and 5.5). At baseline (follow-up) the first com-
ponent explained 52.6% (56.9%) of the total variation of the cognitive data. By
examining the eigenvalues it is clear that there is only a single component of in-
terest at both time–points - as a general rule, one would only extract components
with λ > 1. The PCA analysis also prints the component matrix and the com-
ponent score coefficient matrix. The former matrix indicates the loading of the
individual cognitive tests onto the component. This is presented as a correlation
between the individual test and the principal component. For the AAA Trial
data it can be seen that all of the tests loaded strongly onto the first component
(baseline range 0.581 – 0.818), confirming the presence of a general ability factor.
This matrix does differ depending on which statistical package the analysis is
run in. Whilst all generate the same eigenvalues and g-scores, R and SPSS use
different scaling methods to calculate the factor loadings. SPSS tends to gen-
erate larger loadings than R although the ratios between loadings are identical.
Each of the PCA analyses reported in this thesis were performed using SPSS.
The second matrix reports the factor scores used to calculate the g score for each
trial participant. For the baseline data of the AAA Trial this gave participant i’s
g-score as
gi = (0.225 × bAVLTi) + (0.298 × bRAVENSi) + (0.221 × bVFTi) + (0.311 ×
bDSTi) - (0.308 × ln(bTMTi))
These g-scores were then standardised and added to the database. As general
intelligence is not something that can be measured directly, g is referred to as a
latent variable.
5.6.4 Adjustment variables
The following variables, based on their associations with cardiovascular disease
and/or cognition were considered as adjustment variables in the AAA Trial:
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Baseline
Principal Eigenvalue % Variance Cognitive Factor Factor
Component (λ) explained Test Loading Score
1 2.63 52.6 AVLT 0.592 0.225
2 0.81 16.1 RAVENS 0.785 0.298
3 0.73 14.5 VFT 0.581 0.221
4 0.46 9.2 DST 0.818 0.311
5 0.38 7.6 -ln(TMT) 0.810 0.308
Table 5.4: PCA baseline output for the AAA Trial.
Follow-up
Principal Eigenvalue % Variance Cognitive Factor Factor
Component (λ) explained Test Loading Score
1 2.85 56.9 AVLT 0.659 0.232
2 0.73 14.5 RAVENS 0.809 0.284
3 0.64 12.9 VFT 0.643 0.226
4 0.43 8.6 DST 0.825 0.290
5 0.36 7.1 -ln(TMT) 0.813 0.286
Table 5.5: PCA follow-up output for the AAA Trial.
• Age at the time of cognitive testing in 2003/2006.
• Sex.
• Peak prior cognitive ability, which was estimated using baseline MHVS
scores.
• Baseline levels of smoking. Pack-years of smoking were estimated by mul-
tiplying the number of 20-cigarette packs smoked per day with the number
of years as a smoker. A zero value was entered for life-long non-smokers.
• Diastolic blood pressure.
• Baseline serum levels of total cholesterol.
• ABPI.
5.7 Summary
This chapter has described the recruitment procedures and variable measurements
taken in the AAA Trial. After screening participants for an ABPI ≤ 0.95, 3,350
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persons were enrolled into either the aspirin or placebo arm of the Trial. All
participants had a blood sample taken at baseline of the Trial for biomarker
measurements and genotyping. Also at baseline, the population were cognitively
assessed using the Mill Hill Vocabulary Scale to provide an estimate of peak
cognitive ability. A subset of 504 persons was further assessed using a battery of
five cognitive tests, which were then administered to all participants at the Trial’s
five year follow-up. General intelligence (g) factors were calculated at both time
points by means of Principal Components Analyses.
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Chapter 6
The Edinburgh Type 2 Diabetes
Study (ET2DS)
6.1 Introduction
This chapter describes the baseline methodology and preparation for follow-up
for the Edinburgh Type 2 Diabetes Study, a prospective cohort study to anal-
yse the impact of inflammation, microvascular disease and dysregulation of the
hypothalamic-pituitary-adrenal axis on cognitive dysfunction. It provides infor-
mation on the ET2DS study population, the procedures of recruitment at base-
line, and the layout of the baseline clinical examination. In addition, the cog-
nitive function testing that was carried out in 2006/2007 is discussed in depth.
The chapter draws to a close by describing the methods of data storage, vari-
able manipulation and transformation in preparation for the main analyses. The
study details and descriptions presented in this chapter are all referenced from
the ET2DS protocol paper (Price et al. 2008b).
6.2 The Edinburgh Type 2 Diabetes Study: Base-
line survey
6.2.1 Study design
The relationship between diabetes and cognitive function has not been the pri-
mary focus of major longitudinal studies. Moreover, the investigation into diabetes-
related variables that are involved with cognitive function has been limited (Allen
et al. 2004, Strachan et al. 2003). The primary purpose of the ET2DS was to
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test, using a prospective cohort study of persons with Type 2 diabetes, the re-
lationship between inflammation, microvascular disease and dysregulation of the
hypothalamic-pituitary-adrenal (HPA) axis and cognitive dysfunction
6.2.2 Study population
Sampling frame and exclusion criteria
Participants for the ET2DS were selected from a population of 20,000 persons
from the Lothian Diabetes Register (LDR). The LDR is a computerised database
with details on almost all persons with diagnosed Type 2 diabetes who are living
in the Lothian region of Scotland.
Although World Health Organisation criteria need to be met before a patient
can be added to the LDR, the ET2DS study team re-validated the existence of
diabetes in all potential study subjects. For this confirmatory diagnosis, several
diagnoses were accepted as an indication of Type 2 diabetes:
• if the subject was being treated with oral anti-diabetic agents or insulin.
• if the subject was being treated via dietary intervention and they had a
DCCT-aligned HbA1c measure of > 6.5% when tested at the research clinic.
Dietary controlled diabetics who had an HbA1c reading below 6.5% had their
clinical records checked by a consultant diabetologist to confirm a correct diag-
nosis. Additional checks were carried out on persons who satisfied criteria making
it more likely for them to be wrongly classified as having Type 2 diabetes. This
included persons who had begun insulin treatment within one year of diabetes
diagnosis; or who were under 35 years old and being treated with insulin; or
who had reported evidence of pancreatic disease/surgery at the clinic. Persons in
whom it was not possible to confirm a clinical diagnosis of Type 2 diabetes were
excluded from participating in the study. Subject exclusion was also considered
under the following circumstances:
• the subject was a non-English speaker (since fluent English is required for
some of the cognitive tasks).
• the subject’s corrected visual acuity was worse than 6/36 for distance vision
or if they were unable to read large print text, as at least moderate visual
function is required to complete some of the cognitive tasks.
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• the subject was unwilling to give consent (or judged by clinical research
staff to be unable to give fully-informed consent).
• the subject was not physically able to complete the clinical and cognitive
examination.
Study population
Using the LDR as the sampling frame, elderly adults aged between 60 and 75
years (as of 1st August 2006) were used to generate the study population. Eli-
gible subjects were chosen from sex and five year age banded groups. Initially,
5,454 persons were invited to take part in the study; invitations were sent by the
custodians of the LDR over a one year period from 20th June 2006 to 1st June
2007. The response rate for these invites was 60% with 2,104 failing to reply with
an additional 64 invites being returned as a result of non-residence at the address
provided in the LDR records. Of those who did reply, 1,252 (38%) were happy
to volunteer as study participants. For those who failed to reply to the invitation
or who did not wish to participate in the study a fresh list of randomly selected
subjects was chosen from the stratified LDR records. Patient confidentiality was
maintained with names and addresses of only those willing to participate being
supplied to the ET2DS team.
Those interested in taking part in the study were sent a questionnaire for
completion via post and also an appointment time for a visit to the research clinic.
To ensure maximal turnout for the clinical examination, an offer to organise all
travel arrangements was made. All travel expenses were fully reimbursed and
a flexible appointment scheme was provided for each subject to arrange a date
when it would be convenient for them to come to the clinic.
A reminder phone call was made by a member of the team the day before
the scheduled appointment to finalise confirmation or to re-schedule the visit.
In total, 1,077 of the 1,252 volunteers attended the baseline clinic. For the 175
who did not attend: the ET2DS team were unable to re-contact 56 individuals,
111 were unable or unwilling to attend for clinical examination when invited, five
repeatedly failed to attend their research clinic appointment, and three had died
Further withdrawals were made from the study due to: an inability to com-
plete the cognitive or physical examinations (n = 4), a failure to meet the criteria
for being diagnosed as suffering from Type 2 diabetes (n = 7). Of this group
two dietary-controlled patients with an HbA1c < 6.5% could not be confirmed as
having diabetes, four subjects were believed to have Type 1 and not Type 2 dia-
betes, and one subject had a previous pancreatic neuroendocrine tumour. These
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exclusions resulted in a final population of 1,066 subjects who were both willing
and eligible to take part in the ET2DS. A flow chart detailing the recruitment
process to the ET2DS is presented in Figure 6.1.
6.2.3 Sample size determination
A priori, the targeted sample size of 1,000 was large enough to be powered at
90% (α = 0.05) to detect a Pearson correlation of 0.10 and above between the
cognitive test scores and the independent variables. At the four year follow-up
of the study, even if the sample size is reduced to 800, the ET2DS will still be
powered to detect correlations of 0.12 or greater.
In multiple linear regression analyses with four covariates and an R2 of 0.25,
the study is powered at 90% (α = 0.05) to detect a 0.01 increase in R2 upon the
addition of another covariate. The study will retain a similar power to detect a
0.01 increase in R2 at follow-up assuming sample attrition of 20% i.e. n = 800.
This implies that the study will be able to detect a variable that explains 1% or
more of the variance in the cognitive test scores.
6.2.4 Ethical approval
Ethical permission was obtained from the Lothian Medical Research Ethics Com-
mittee.
6.2.5 Baseline examination
Prior to the baseline clinic, participants had been asked to observe an overnight
fast. Upon arrival at the research facility, written informed consent was provided
for study participation. The assessment began with the collection of a urine
sample and a blood sample. Following a short break for breakfast, the participants
underwent a physical examination and cognitive assessment.
The physical examination was carried out by one of six trained nurses and
measurement technicians, using standard operating procedures. A specially de-
signed form for data collection was used with great care being taken to ensure
consistency both between and within the nurses assessments. Moreover, subjects
were asked to submit the questionnaire that had been mailed to them along with
their invitation to the clinic. This contained information on demographic charac-
teristics, educational attainment, diabetes history and treatment, cardiovascular





n = 5,454 
Replied 
n = 3,286  
 
No response (n = 2,104) 
Moved address (n = 64) 
Not interested in participation 
(n = 2,034) 
Interested in participation 
n = 1,252  
Attended baseline clinic 
n = 1,077  
ET2DS participants 
n = 1,066 
Failed to meet inclusion criteria 
(i) unable to complete cognitive/physical 
examination (n =  4) 
(ii) not Type 2 diabetes (n = 7) 
 
Did not attend baseline clinic 
(i) unable/unwilling to attend (n = 111) 
(ii) could not be contacted (n = 56) 
(iii) repeatedly failed to keep appointment (n = 5) 
(iv) deceased (n = 3) 
 
Figure 6.1: ET2DS recruitment process.
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ployment/occupation, stress, satisfaction with life, subjective social status and
personality.
6.2.6 Inflammatory and rheological biomarker measure-
ments
At baseline, a venous blood sample was taken after an overnight fast for DNA
extraction, and measurement of biomarkers. Assays to measure plasma CRP,
fibrinogen, IL-6, and TNF-α were performed in the University Department of
Medicine, Glasgow Royal Infirmary. In stored plasma anticoagulated with trisodium
citrate, fibrinogen was assayed by the automated Clauss assay (MDA-180 coag-
ulometer, Organon Teknika), and CRP using a high-sensitivity immunonephelo-
metric assay (Tzoulaki et al. 2006). TNF-α and IL-6 antigen levels were deter-
mined by high-sensitivity ELISA kits from R&D Systems, Oxon UK.
6.2.7 Assessment of cardiovascular risk factors
Questionnaire
The baseline questionnaire completed by all participants asked for details about
current and previous medical diagnoses and treatments for angina, myocardial in-
farction, stroke, and several other conditions. Both the year of diagnosis or event
and the hospital or general practice attended were requested in the form. This
enabled the study team to validate the data through comparison with Information
Services Division (ISD) Scotland and LDR data.
Several criteria were used in combination to define a myocardial infarction.
These included
• subject recall of a doctor’s diagnosis of the event.
• a positive WHO chest pain questionnaire for MI.
• ECG evidence of ischaemia (Minnesota codes 1.1 to 1.3, 4.1 to 4.2, 5.1 to
5.3 or 7.1)
• a prior hospital discharge code for MI (ICD10 codes I21-I23, I252).
A positive recording for MI was made if either two of the first three criteria were
met, or if the first and last criteria were met. The corresponding criteria for
angina included
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• subject recall of a doctor’s diagnosis of the condition or of being on regular
medication for angina
• a positive WHO chest pain questionnaire for angina
• ECG evidence of ischaemia
• a prior hospital discharge code for ischaemic heart disease (ICD10 codes
I20-I25).
A positive recording for angina was made again, it two of the first three criteria
were met, or if both the first and last criteria were met. A composite coronary
heart disease (CHD) measure was defined for persons who were coded as either
an MI or angina sufferer.
A history of stroke was assessed using data from the self-report questionnaire.
The participants had to answer ‘yes’, ‘no’, or ‘not sure’ as to whether they had
had a stroke. For the analysis, those in the ‘not sure’ category were treated as
missing data. Where a positive answer was given, the date of the stroke and the
hospital where the subject was treated were also asked for. Hospital records were
then checked to confirm the stroke diagnosis by use of ICD codes. Of the 90 self-
reported strokes, 36 were found to have no cerebrovascular code, the remainder
had a code that met criteria for ICD-stroke or ICD-other cerebrovascular disease.
These 36 persons were included in the analyses, which may have been a source
of bias. However, excluding the stroke variable as a covariate made very little
difference to the results reported.
A questionnaire of smoking history and the WHO Chest Pain (Rose et al.
1977) and Edinburgh Claudication Questionnaires (Leng & Fowkes 1992) were
also completed at baseline. For the analysis in this thesis, smoking was treated
as a categorical variable: never-smoked, current smoker, or ex-smoker.
Physical examination
The physical examination measured systolic and diastolic brachial blood pressures
in the right arm (± 2 mmHg). Subjects were assessed in the supine position with
their arm resting at the level of the mid-sternum, using a standard stethoscope
and an aneroid, 6 inch dial, desk standing sphygmomanometer (AccesonTM, AC
Cossor & Son (Surgical) Ltd, Harlow, UK).
The individual components used to derive body mass index were assessed
as follows: standing height was measured to the nearest mm, without shoes,
using a wall-mounted vertical rule; Weight was assessed to the nearest 0.1 kg
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without outdoor clothing or shoes using SECA 761 electronic weighing scales.
BMI was calculated as the fraction of weight in kg to height2 in m2. The ankle
brachial pressure index was calculated in an identical manner to the AAA Trial.
Right and left brachial, posterior tibial and dorsalis pedis systolic pressures were
recorded with the subject in the supine position and after at least 5 minutes rest,
using the aneroid sphygmomanometer and a doppler probe (Dopplex R© advanced
pocket Doppler, Huntleigh Healthcare Ltd., Cardiff, UK). An ABPI measure was
derived for each subject by dividing the lowest of the ankle pressures by the higher
of the two arm pressures. To assess inter-observer variation in ABPI, a total of
20 subjects had repeat measurements performed independently in a single day by
all six of the clinic staff.
6.3 Methods of cognitive function testing
6.3.1 Baseline cognitive testing
At baseline, a battery of psychometric tests providing a comprehensive and val-
idated assessment of cognitive function and mood state was administered. Indi-
vidual testers were trained and then observed for validation by one of the ET2DS
investigators. A detailed discussion on the cognitive test battery that was used
is provided below.
6.3.2 The cognitive test battery
In the ET2DS an omnibus of seven cognitive tests was completed by all will-
ing participants: Logical Memory test, Faces and Families Recognition Subtest,
Letter-Number Sequencing, Matrix Reasoning, Verbal Fluency Test, Digit Sym-
bol Test, and Trail Making Test, Part B. A full description of the latter three
tests is provided in Subsection 5.4.6 with details on the first four presented below.
In addition to the battery of tests, measures of vocabulary (MHVS - see Subsec-
tion 5.4.6 for details), anxiety and depression, and general function (MMSE - see
Subsection 5.4.6 for details) were also obtained.
Logical Memory
The Logical Memory test (LM) is a measure of immediate and delayed verbal
declarative memory from the Wechsler Memory Scale (WMS-IIIUK) (Wechsler
1998b). The test administrator reads two short stories, stopping after each one
to allow for recall from the test participant. Both stories contain 25 elements with
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the second story being administered twice. Participants are informed that they
will be asked to recall details from the stories again later (a delay of around 25–35
minutes). In the ET2DS, only the first story of the Logical Memory Test was
completed i.e. immediate and delayed recall was measured for Story A, which
contained 25 elements. The two individual scores were summed to create an
overall memory component, which had a scoring range 0 – 50.
Faces and Families Recognition Subtest
To test the participants’ abilities in immediate and delayed non-verbal mem-
ory, the Faces and Families Recognition Subtest from the WMS-IIIUK was ad-
ministered (Wechsler 1998b). Participants are initially shown a sequence of 24
photographs of faces. Each photograph is presented for two seconds with the
participant being told to try and remember all 24. Immediately after, a second
batch of 48 photographs is shown to the participant. All 24 of the faces to be
remembered were contained in the batch and the examinee has to tell the exam-
iner whether or not they had seen each of the 48 faces previously. The maximum
score for the immediate recall is 48 (range 0 – 48). Around 25 minutes later, after
completing some other cognitive tests, the examiner shows the participant a new
set of 48 faces. The aim is again to identify the 24 initial faces although this time
some of the false faces from the immediate recall test are re-used in addition to
some new faces. The scoring range is identical to the immediate memory recall
and no time restriction is placed on the response to either of the tasks. In the
ET2DS, scores from both tasks were combined to create an overall non-verbal
memory component (FACES). The scoring range for this variable was 0 – 96.
Matrix Reasoning
To assess the participants’ non-verbal reasoning skills, the Matrix Reasoning
(MR) subtest from the WAIS-IIIUK was administered (Wechsler 1998a). This
test is similar to the Raven’s Progressive Matrices used in the AAA Trial in that
the participant must examine a pattern arrayed in a matrix with one missing
piece. The elements of the matrix follow a particular pattern or rule. The task is
to work out the rules and to apply them to find out what the missing piece should
be. For each item (there are 26 in total) the subject must correctly select the
missing piece from the six possible answer options (five possible pieces or ‘don’t
know’). The range of scores possible is from 0 to 26. Three practice items are
administered prior to the start of the test although these do not count towards
the total score. Moreover, if a subject incorrectly answers either question 4 or
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5 then the examiner takes them back to questions 1–3 (in reverse order) and re-
tests them until they obtain two correct answers consecutively before returning
to the question that had been incorrectly answered. The test terminates under
three possible scenarios: four consecutive scores of zero, four scores of zero on
five consecutive items, or completion of all 26 items.
Letter-Number Sequencing
Another subtest from the WAIS-IIIUK , Letter-Number Sequencing (LNS) was
used to assess working memory (Wechsler 1998a). Participants listen while the
tester reads mixed strings of numbers and letters. The aim is for the participant
to repeat the list to the tester, starting with the numbers in numerical order, and
then the letters in alphabetical order. The test is split into seven sections of three
items. Section one contains three sets of single letter, single number combinations.
The sections become increasingly more complex with section seven containing
eight pieces of information - four numbers and four letters. Participants score a
point for each item within a section for which they give the correct response i.e.
the maximum possible score is 21 (range 0 – 21). The test is stopped at the end
of the seventh trial or when the participant fails to correctly answer any of the
items within one of the seven sections.
Hospital Anxiety Depression Scale
The Hospital Anxiety Depression Scale (HADS) assesses recent mood states (Zig-
mond & Snaith 1983). It contains seven items for anxiety and seven for depres-
sion. The items are presented in alternate order beginning with an anxiety ques-
tion. There are four possible responses for each ranging from very negative to
very positive options. For example, the first anxiety item asks the participant to
respond to the statement “I feel tense or wound up” by selecting one of:
• Most of the time,
• A lot of the time,
• From time to time, occasionally,
• Not at all.
Three points are allocated if the most negative option is selected, two for the
second most negative, one for the third most, and zero for a positive response. The
maximum possible score on each scale is 21, with probable anxiety or depression




Baseline blood samples collected from ET2DS participants were used for geno-
typing. Sixteen candidate SNPs were selected from twelve different genes for
genotyping. SNPs were again chosen on the basis of previously reported associa-
tions with cognitive ability or because they lay in genes strongly associated with
phenotypic variants thought to be important in cognitive processes. A list of
the SNPs analyzed in this thesis are presented in Table 6.1. Genomic DNA was
isolated from whole blood by standard procedure at the Wellcome Trust Clinical
Research Facility Genetics Core, Western General Hospital, Edinburgh. Geno-
typing was carried out by KBioscience (Herts, UK) using their in-house chemistry
of Competitive Allele Specific PCR (KASPar).
Gene SNP Gene SNP
CRP rs1130864 IL-1 rs554344
rs1205 rs580253
rs1800947 IL-6 rs8192284
FGA rs2070016 TNF-α rs1800630
FGB rs4220 TCF-1 rs2464196
rs2227412
Table 6.1: Genotyped SNPs from the ET2DS.
6.5 Data handling and management
6.5.1 Entry of cognitive data
Data from the baseline questionnaire and data collection forms were coded and
entered into a Microsoft Access database. The results of plasma assays were en-
tered onto the same master database, either from paper records (biochemistry and
haematology) or from electronic files provided by the participating laboratories.
The majority of data from paper records were double entered with discrepancies
resolved by reference to the original paper documentation; for the remaining data,
a random sample of records was double-checked. A small amount of baseline data
that was found to be missing was collected at the one year clinic (primarily clarifi-
cation of incomplete or inconsistent personal and clinical details) and entered onto
the master database. Questionnaire data and plasma assays collected at the one
year clinic visit were entered initially onto a separate Microsoft Access database
and checked for inconsistencies prior to transfer onto the master database. All
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data, including the master database, were stored securely on dedicated university
computers and backed up on a dedicated university server.
6.5.2 General intelligence factor and Principal Compo-
nents Analysis
As with the AAA Trial, given the high correlation between each of the seven
cognitive tests in the battery, a general cognitive factor representing the variance
common to all the cognitive tests was created via Principal Components Analysis.
The results of the PCA showed the first component to explain 44% of the
total variation of the dataset. By examining the component eigenvalues it was
clear that there was only a single component of interest. It is also apparent from
Table 6.2 that all of the tests loaded strongly onto this component (range 0.454
– 0.794). The g score attributed to each individual was derived from the factor
scores, and were calculated using the formula below. These scores were then
standardised and added to the database.
gi = (0.216 × MRi) + (0.230 × LNSi) + (0.217 × VFTi) + (0.245 × DSTi) -
(0.258 × ln(TMTi)) + (0.147 × FACESi) + (0.172 × LMi)
Principal Eigenvalue % Variance Cognitive Factor Factor
Component (λ) explained Test Loading Score
1 3.08 44.0 MR 0.666 0.216
2 0.91 13.0 LNS 0.710 0.230
3 0.78 11.2 VFT 0.670 0.217
4 0.69 9.8 DST 0.755 0.245
5 0.65 9.3 -ln(TMT) 0.794 0.258
6 0.54 7.8 FACES 0.454 0.147
7 0.34 4.9 LM 0.529 0.172
Table 6.2: PCA output for the ET2DS.
6.5.3 Adjustment variables
The following variables, based on their associations with cardiovascular disease
and/or cognitive outcomes, were used as covariates in the ET2DS:
• Age in years at the time of cognitive testing in 2006.
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• Sex.
• Peak prior cognitive ability, which was estimated using the MHVS.
• Smoking status – measured as current smoker, ex-smoker, or never smoked.
All of cigars, pipes, and cigarettes were considered as smoking. In addition,
persons who were listed as non-smokers but who had given up in the past
6 months were recoded as current smokers.
• Diastolic blood pressure.
• Serum levels of total cholesterol.
• Glycated haemoglobin – HbA1c.
• ABPI.
• Coronary Heart Disease – defined as history of angina or MI.
• Stroke – defined using the self-report questionnaire data.
• Depression, which was measured using the HADS.
• Duration of diabetes, which was measured in years from the self-reported
date of onset to the date of visit to the clinic.
• Daily alcohol consumption per normal drinking day in the past 12 months,
which was categorised as: 0 drinks; 1 – 2 drinks; 3 – 4 drinks; 5 – 6 drinks;
7 – 9 drinks; or ≥ 10 drinks
• Self-reported highest educational attainment, which was categorised as:
University/college degree course; Other professional/technical qualification
after leaving school; Secondary school; or Primary school.
• BMI.
6.6 Summary
Chapter 6 has introduced the Edinburgh Type 2 Diabetes Study, its study design
and recruitment policy. In total, 1066 persons were enrolled in the study. These
persons were assessed at the study baseline for cognitive ability (using a seven
test battery), pre-morbid cognitive ability (using the Mill Hill Vocabulary Scale),
and four inflammatory biomarker measurements (CRP, fibrinogen, TNF-α, and
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IL-6). Extensive demographic, physiological, and genetic information was also




Edinburgh Artery Study (EAS)
and The 1936 Lothian Birth
Cohort (LBC1936)
7.1 Introduction
In addition to the AAA Trial and the ET2DS, two other elderly Scottish cohorts
were considered for the genetic analysis of CRP and fibrinogen SNPs with late-
life cognitive ability. These studies were the Edinburgh Artery Study and the
1936 Lothian Birth Cohort. A brief description of both studies, including sub-
ject selection and cognitive test details are provided below. Many of the details
described in this chapter can be attributed to the PhD thesis of Dr. Snorri Björn
Rafnsson1, and the 1936 Lothian Birth Cohort protocol paper (Deary et al. 2007),
both of which provide an extensive guide to the respective studies.
7.2 The Edinburgh Artery Study
The principal objective of the Edinburgh Artery Study (EAS) was to examine
the relationship between clinical cardiovascular disease, vascular risk factors, and
cognitive function in older people.
1Cardiovascular diseases, risk factors and cognitive decline in the general population, PhD
thesis, Dr. S.B. Rafnsson, Centre for Population Health Sciences, University of Edinburgh, 2006
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7.2.1 Study population
The EAS population constituted residents of the City of Edinburgh who were be-
tween 55–74 years in age. Participants were randomly selected from age–sex regis-
ters of eleven Edinburgh general practices, which represented the whole spectrum
of socioeconomic strata in all parts of the city. A priori sample size calculations
indicated a target of 272 subjects to be randomly selected from each general
practice, using four age-sex specific bands to stratify equal numbers into each
group (34 males and females in each five year age band). General practitioners
were then asked to review a list of 2,720 patient names, which had been obtained
from the practices, to exclude persons they considered unable to participate in
the study. For example, persons with advanced mental or physical illness, those
who had changed general practice, or those who had died. In total, 353 (13%)
subjects were excluded and replaced by other randomly selected participants.
All subjects eligible for the study were invited to attend a University of Ed-
inburgh clinic for medical examination (n = 2,709). A media campaign was
undertaken, after which, potential participants were sent a letter inviting them
to take part in the study. Those who responded positively were sent by post an
appointment date, a map of the University area, and detailed description of the
clinical examination. Where letters of invitation were returned by the post office,
those persons were replaced by alternative randomly selected subjects (n = 163).
Non-repliers to the first invitation were sent a second invitation letter, and those
who had confirmed participation but were unable to attend the examination were
offered a new appointment at a subsequent date. Persons who were unable to
attend the clinic at the University were given the option of a home visit. Full
refunds were provided to all participants for any travel expenses incurred.
The enrolment stage of the EAS began in 1987 and ended in 1988, after a
total of 809 men and 783 women were successfully invited to participate (total n
= 1,592). Several follow-up visits were subsequently organised with the first wave
of cognitive testing occurring in 1998/1999, by which point the available sample
size was 1,209. The second wave of cognitive testing was administered between
2002/2003 when the available sample size had shrunk to 601 participants. Given
the reduced numbers at follow-up, in addition to the lack of complete cognitive
data, information was only used from the first wave of cognitive testing. Moreover,
after accounting for non-participation, this left a sample of 534 persons with both
cognitive scores and genotyping data for the analysis.
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7.2.2 Sample size determination
Given that the SNP-cognition associations did not form part of the primary anal-
ysis for the EAS, post hoc calculations were conducted to identify the statistical
power of the study. Using the sample size of 534 subjects, the EAS had 80%
power to detect a standardised effect size of 0.12 (α = 0.05) for the relationship
between baseline biomarker levels and follow-up cognition.
7.2.3 Ethical approval
Ethical approval for the EAS was granted by the Lothian Health Board Ethics
of Medical Research Sub-Committee for Medicine and Clinical Oncology. As
with the AAA Trial and ET2DS, written informed consent was provided by each
participant prior to the clinical examination.
7.2.4 Baseline examination
All eligible subjects were invited to a baseline examination which involved a de-
tailed collection of sociodemographic information, medical history, and clinical
data. Plasma CRP was measured at baseline in 384 of the 534 (71.9%) par-
ticipants using a high-sensitivity assay in a BN ProSpec nephelometer (Dade
Behring, Milton Keynes, UK). Of the other variables measured in the EAS, age
and sex were included in the analysis as covariates, whilst the descriptive statis-
tics for cholesterol, smoking status, and blood pressure were recorded to allow for
population comparisons between the various cohorts.
7.2.5 The cognitive test battery
Eleven years after the baseline visit in 1987/1988 to the clinic, participants were
asked to take part in a cognitive test examination. The battery of tests used
included:
• Raven’s Standard Progressive Matrices – RAVENS.
• Verbal Fluency Test – VFT.
• Digit Symbol Test – DST.
• Logical Memory – LM.
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Whilst these tests have been described in detail previously, there was a slight
variation with the assessment of Logical Memory. For the EAS two stories were
read (instead of one, as in the ET2DS) with delayed but not immediate memory
assessed. Information from the four test battery was aggregated for the deriva-
tion of a general intelligence g-factor. The methodology used for this was PCA,
which has been described in detail previously. Briefly, the results yielded a single
principal component of relevance (Table 7.1), the scores of which were standard-
ised and saved as a g-factor. Each of the tests loaded strongly onto g and the
individual scores were calculated using the formula below.
gi = (0.364 × RAVENSi) + (0.318 × VFTi) + (0.377 × DSTi) + (0.288 × LMi)
Principal Eigenvalue % Variance Cognitive Factor Factor
Component (λ) explained Test Loading Score
1 2.18 54.5 RAVENS 0.793 0.364
2 0.80 20.1 VFT 0.693 0.318
3 0.59 14.6 DST 0.822 0.377
4 0.43 10.8 LM 0.628 0.288
Table 7.1: PCA output for the EAS.
An estimate of pre-morbid cognitive ability was also assessed at the first wave of
cognitive testing in the EAS using the National Adult Reading Test (NART).
7.2.6 Genotypic data
Blood samples from the baseline examination were used for the genetic analysis.
Genotyping was carried out using a 5’–nuclease assay (TaqMan) by Helen Ireland
in the laboratories of Professor Steve Humphries and Dr. Aroon Hingorani at
University College London.
7.3 The 1936 Lothian Birth Cohort
A unique epidemiological study, the 1936 Lothian Birth Cohort (LBC1936) com-
prises survivors of the 1947 Scottish Mental Survey now living in Lothian, Scot-
land. The survey tested nearly all (70,085 of a possible 75,211 (93.2%)) Scottish
school children born in 1936 when they were mostly age 11 (on June 4th 1947)
using the Moray House Test, Number 12 – a validated test of general cognitive
105
function. Survivors from the initial survey who were living in the Lothian area
were recruited for cognitive testing when they were aged around 70 years. Hav-
ing measures of cognition at age 11 and again nearly 60 years later provides a
rare and extremely exciting opportunity to assess change in cognitive ability over
what is nearly a lifetime’s duration.
7.3.1 Study Population
Subject Identification
To identify potential participants from the 1947 survey, the Lothian Health Board
investigated Community Health Indices (CHI) on behalf of the LBC team. CHI
numbers provide a unique identifier for persons living in a specific area who are
registered with a general practice. Using this resource, the Lothian Health Board
were requested to identify all persons on the Lothian CHI who were born in 1936.
Unfortunately, CHI details may not be fully correct due to a time lag between
updating the system after deaths and migration to or from a region. The number
of subjects identified by the Health Board who may have taken part in the 1947
survey was 3,810.
Given that researchers are not allowed to make direct contact with people
identified from their CHI data, initial contact was made via the Lothian Health
Board on behalf of the LBC team. This constituted a letter from the Health
Board, an invitation letter – written and signed by the LBC Study Director,
Professor Ian Deary, a letter explaining the motivation behind the LBC study,
and a reply slip with a pre-paid reply envelope addressed to the LBC study team
at the University of Edinburgh. Persons were asked for their contact details
in addition to their date of birth, country of schooling, and schools attended.
Moreover, persons were given an option as to whether they were interested in
receiving more details about the LBC study. Invitations were posted in batches
of between 200–300 at a time to aid a swift response from the LBC team.
Subject Recruitment
Of the initial 3,810 persons identified from the CHI, 3,686 were contacted about
potential study participation. This began in June 2004 and ran until Novem-
ber 2006. The loss of numbers can be explained by the flaws in using the CHI
that were identified previously. Nonetheless, of this group, a response was ob-
tained from 1,703 (46.2%) persons, 286 of whom requested no further contact
regarding the study. An analysis was performed to try and identify reasons for
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non-compliance: 46 were ineligible, 9 refused on medical grounds, 22 failed to
provide sufficient information to determine their eligibility, and 66 failed to state
whether they were willing to take part or not. All 66 persons in this final cate-
gory ended up being excluded from the study for other reasons including: medical
grounds (n = 5), schooled in another country (n = 59), and not born in 1936
(n = 2). This left 209 persons who were seemingly eligible but unwilling to take
part in the study. After these exclusions a total of 1,132 persons were eligible to
partake in the LBC1936 study.
The non-responders from the initial invitation were re-contacted in an attempt
to increase participation and the response rate. However, given the confidential
nature of the CHI, this meant that everyone in the sample had to be sent a
second letter. After updates to the CHI, this resulted in letters being sent to
1,741 persons. A lower response rate (n = 615, 35.3%) was observed for this
repeat procedure but a further 94 eligible and willing persons were identified.
In a final recruitment drive, a media campaign was launched to identify addi-
tional participants who had been missed from the CHI-based approach. In Febru-
ary 2007 an advert for volunteers was placed in a freely-distributed Edinburgh
newspaper with a further advert being placed in an Edinburgh-based evening
newspaper in March 2007. Response to the adverts was low with less than 100
replies received. The eligibility details of these replies have been incorporated
into the figures presented above.
Study Population
Taking the positive respondents from the two mailing campaigns and the media
promotion left 1,226 persons eligible and interested to take part in the study.
Prior to being cognitively tested at the research clinic, 85 persons withdrew from
the study. An inability to contact or arrange a clinical appointment before the
end of testing in May 2007 resulted in a loss of a further 50 individuals. This
left a 1936 Lothian Birth Cohort study population of 1,091 who had complete
cognitive data and questionnaire data.
7.3.2 Sample size determination
The LBC1936 sample size of 1,091 provided 90% power (α = 0.05) to detect
a standardised effect size of 0.098 for the cross-sectional association between
biomarker levels and cognition at age-70. Power calculations for the secondary,
genetic analysis are discussed in the results section.
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7.3.3 Ethical approval
Ethical permission for the LBC1936 was granted by the Multi-Centre Research
Ethics Committee for Scotland and the Lothian Research Ethics Committee. All
subjects were required to give written, informed consent prior to study partici-
pation.
7.3.4 Baseline examination
Cognitive and clinical testing along with a general health interview were con-
ducted on all subjects at the Wellcome Trust Clinical Research Facility at the
Western General Hospital, Edinburgh. Testing was carried out by a trained psy-
chologist and a research nurse. Upon arrival, the participants were introduced to
the psychologist and reminded about the study and the measures that were going
to be assessed. An opportunity to ask any questions was given before the com-
pletion of written, informed consent for study participation. The measurements
assessed at the visit are summarised below in the chronological order in which
they were administered. Depending on the availability of staff, the position of
the physical examination varied in the sequence of events. All individuals were
allowed a break of no less than 15 minutes for refreshments during their visit to
the clinic.
Social and medical history and medications
The first interview given required the subjects to provide current contact details,
educational history (school leaving age, further and higher education, and their
highest qualification obtained), main occupation (and that of their spouse for
women), and age at retirement. Additional questions ascertained each partici-
pant’s smoking history and current alcohol consumption. A structured interview
was then given to assess history of disease and a list of current medications.
Moray House Test No. 12
Initially administered when most of the cohort were aged 11 in 1947 (Scottish
Council for Research in Education 1949), the Moray House Test Number 12
(MHT) was re-administered nearly 60 years later when the cohort were aged about
70. The same test was used on both occasions with the same instructions and
time limits. Two small changes were made for items where the content was now
archaic (Deary et al. 2000). Despite often being referenced as a measure of ‘verbal
reasoning’ ability, the MHT also includes items of a variety of types: following
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directions (14 items), same-opposites (11), word classification (10), analogies (8),
practical items (6), reasoning (5), proverbs (4), arithmetic (4), spatial items (4),
mixed sentences (3), cypher decoding (2), and other items (4). The maximum
possible score on the MHT is 76 (range 0 – 76). The scores from the original 1947
MHT were obtained through the Scottish Council for Research in Education’s
office in Glasgow, to enable an accurate and comprehensive electronic index of
all persons who completed the MHT.
Physical examination and interview
The LBC cohort was heavily phenotyped at the physical examination and inter-
view stage. However, as only age and sex were adjusted for in the analyses, details
of the characteristics measured were not discussed extensively. Nonetheless, to
provide a general comparison between the LBC1936 and the other cohorts, some
measures were presented. Briefly, sitting and standing systolic and diastolic blood
pressure were assessed using an Omron 705IT monitor. Smoking status was de-
termined from the interview with each subject being asked to state whether they
were a current or ex-smoker, or if they had never smoked.
7.3.5 Inflammatory and rheological biomarker measure-
ments
Blood samples were taken to allow for measurement of the acute-phase inflam-
matory proteins C-reactive protein and fibrinogen. CRP was assessed using a dry
slide immuno-rate method on the OrthoFusion 5.1 F.S analysers. Fibrinogen was
measured using an automated Clauss assay (TOPS coagulometer, Instrumenta-
tion Laboratory) (Hart et al. 2005).
7.3.6 The cognitive test battery
Whilst an extensive battery of cognitive tests were administered to the LBC1936
population, only tests in common with those from the AAA Trial and ET2DS
were considered for the analysis in this thesis. Briefly, these included
• Matrix Reasoning – MR.
• Letter Number Sequencing – LNS.
• Verbal Fluency Test – VFT.
• Digit Symbol Test – DST.
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• Logical Memory – LM
Measurement of LM differed from the ET2DS and the EAS with both stories being
read and recalled immediately and also after a delay. A general intelligence, g-
factor, was derived using the information from the five cognitive tests. As with
the other studies, PCA indicated the presence of a single principal component
(Table 7.2). Each of the individual tests loaded strongly onto the general factor
(range 0.640 – 0.775), which accounted for 48.4% of the variance of the entire data.
The g-scores were calculated using the formula below before being standardized
and saved onto the database.
gi = (0.290 × MRi) + (0.320 × LNSi) + (0.292 × VFTi) + (0.264 × DSTi) +
(0.267 × LMi)
Principal Eigenvalue % Variance Cognitive Factor Factor
Component (λ) explained Test Loading Score
1 2.42 48.4 MR 0.702 0.290
2 0.78 15.5 LNS 0.775 0.320
3 0.66 13.3 VFT 0.707 0.292
4 0.62 12.3 DST 0.640 0.264
5 0.52 10.5 LM 0.645 0.267
Table 7.2: PCA output for the LBC1936.
7.3.7 Genotypic data
Blood samples were taken for DNA extraction from white blood cells. Genomic
DNA was isolated from whole blood by standard procedure at the Wellcome Trust
Clinical Research Facility Genetics Core, Western General Hospital, Edinburgh.
Genotyping was carried out by KBioscience (Herts, UK) using their in-house
chemistry of Competitive Allele Specific PCR (KASPar).
7.4 Summary
This chapter provided a brief summary of the Edinburgh Artery Study and
the 1936 Lothian Birth Cohort, which were used as replication cohorts for the
inflammation-cognition genetic analyses. Both studies were set in central Scot-
land. The EAS contained 534 persons who were cognitively tested, using a four
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test battery, at the study’s eleven year follow-up in addition to having genotyping
data available. Biomarker measures of plasma CRP were made at the baseline
stage of the study. The 1936 Lothian Birth Cohort contained 1,091 persons from
the Lothian region of Scotland who undertook cognitive testing at age-11 and
again at age-70. Biomarker measurements, genotyping details, and other physio-
logical variables were also assessed age-70.
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Chapter 8
Regression analysis of biomarker
levels and cognition.
8.1 AAA Trial Results
8.1.1 Introduction
This section begins by describing the general characteristics of the AAA Trial
population. This includes a comparison between those in the subset who were
cognitively tested at baseline and the remainder of the population. Bivariate
correlations are then presented showing the raw, unadjusted associations between
the biomarker levels and cognitive test scores. Multivariate linear regression is
then used to assess in more detail the relationships between the late-life biomarker
levels and cognition. The first set of models adjust for age and sex, before the
addition of covariates to control for cardiovascular risk factors, estimated pre-
morbid cognitive ability, and in a subset model, baseline cognitive ability. Finally,
a section is devoted to the APOε gene and its association with cognition and CRP.
8.1.2 Descriptive statistics and variable summaries
A summary of the predictor and adjustment variables are presented in Table 8.1
with the follow-up cognitive test scores summarised in Table 8.2. Categorical
variables were described with regard to the frequency at each level of the vari-
able. The distribution of continuous variables was explored using basic descriptive
statistics, Q-Q Plots, and formal tests for normality. Where visually obvious out-
liers were present they were removed. Where dependent or independent variables
were found not to follow the normal distribution (CRP and TMT - both of which
were right-skewed), natural logarithm transformations were conducted. Conse-
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quently, the median and inter-quartile range are reported for the raw values of
these variables. Histograms and Q-Q Plots of the raw and transformed CRP




















































































































































































































































































































































































































































































Test n Subset n Population
(n = 504) (n = 2,312)
AVLT 389 68.5 (15.53) 2,182 63.0 (16.81)
RAVENS 387 38.0 (8.84) 2,101 34.7 (9.32)
VFT 403 41.3 (11.54) 2,228 37.4 (12.78)
DST 405 42.4 (11.34) 2,285 40.0 (11.67)
TMT 401 85 (70–115) 2,252 97 (76–129)
g 378 0.36 (0.92) 1,998 0.00 (1.00)
MHVS 501 32.7 (4.58) 2,191 31.1 (4.74)
Table 8.2: AAA Trial follow-up cognitive test scores (baseline MHVS scores).
Compared to the entire AAA Trial population, there was little difference in
the demographics of the group of subjects who went on to be cognitively tested
at follow-up. The mean age of the trial participants was just under 70 years
with women accounting for almost three quarters of the population. The ABPI
was low with a mean value of 0.86 (s.d. 0.09). The mean blood pressure (sys-
tolic/diastolic) was 148/84, and the mean cholesterol reading was ∼6.2mmol/l.
The final adjustment variable listed in the table was smoking, which had an
approximate equal distribution of persons across all states (current smoker, ex-
smoker, and never smoked).
The descriptive statistics for the biomarkers all fall within a normal, healthy
range. The median CRP was 2.00 mg/l which is within healthy bounds in terms
of risk of developing cardiovascular disease. A similar interpretation can be made
from the fibrinogen output where the mean value was elevated, but not substan-
tially so, from a healthy reading. Haematocrit, which is the proportion of blood
volume occupied by red blood cells, was raised in females with a mean value
of 41.4% compared to a healthy reference estimate of 38% (Purves et al. 2004).
By contrast, the mean haematocrit for men was 44.8%, which is well within the
normal range for a healthy adult (Purves et al. 2004). Finally, the plasma vis-
cosity readings had identical mean values of 1.27mPa.s across the three groups
presented.
Comparing the cognitively tested subset and the cognitively tested popula-
tion, there are few demographic differences between the two groups. The subset
was a little over a year older on average and in slightly better health with lower
blood pressure and cholesterol measurements. Their biomarker measurements
were elevated for CRP and fibrinogen. Although not significantly different, the
latter association may be due to a greater proportion of the subset being cur-
rent smokers. Nonetheless, these descriptives reflect a seemingly healthy, ageing
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Contrasting the mean cognitive scores of the subset with the cognitively tested
population showed substantial differences in both baseline MHVS and follow-up
cognitive scores. The subset consistently and significantly outperformed the main
population on all of the tests, scoring a mean of 0.36 standard deviations above
the whole sample for general intelligence.
8.1.3 Correlations between biomarker levels and cognitive
test scores
To assess the relationship between the cognitive test scores and biomarker levels,
a series of bivariate Pearson correlations were calculated. In addition to the four
markers, plasma viscosity was re-analyzed after adjusting for fibrinogen in order to
explore the properties of its residual component. The only assumption that needs
to be met when calculating Pearson correlations is that of a normal distribution
for each of the variables. However, in addition to providing the statistical power
to detect small correlations, the large sample size of the study dominates any
problems regarding lack of normality of the variables.
The raw correlations between the cognitive test scores and biomarker levels
(Table 8.3) were all quite small (maximum r = 0.113 for the plasma viscosity-TMT
correlation, p < 0.001) and in the direction of increased marker levels associating
with decreased cognitive test scores. Significant correlations were found between
all of the markers and the majority of the cognitive tests. One exception was
the VFT, which only correlated significantly with CRP (p < 0.05). Furthermore,
CRP was the only biomarker to correlate significantly with MHVS scores.
After adjustment for age and sex, the correlations decreased in magnitude
although most remained statistically significant (Table 8.4). Small but strongly
significant correlations were found for both fibrinogen and CRP with RAVENS,
DST, TMT, and g (p < 0.01). Plasma viscosity associated significantly with
scores on the DST, TMT, and with g (p < 0.01). These associations became non-
significant after adjustment for fibrinogen levels with the exception of the TMT
correlation. CRP again correlated significantly with the baseline MHVS scores (p
< 0.001). Inverse correlations for all tests except the TMT, in which high scores
reflect lower cognitive ability, indicated that higher levels of the biomarkers were
associated with poorer cognitive performance. No significant correlations were
found between haematocrit levels and any of the cognitive tests.
The age and sex-adjusted correlations are equivalent to standardised beta
weights from a linear regression and provide an indication of how much variation
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in the cognitive test scores can be explained by the biomarkers. Explicitly, a
correlation of 0.10 suggests that 1% of the variation in cognitive ability is being
explained by the biomarkers.
Finally, there were no large correlations (r > 0.30) between the covariates.
The solitary exception was the correlation between systolic and diastolic blood
pressure (r = 0.675, p < 0.001). Subsequent modelling therefore adjusted for all
of the covariates except systolic blood pressure, which was excluded in an attempt











































































































































































































































































































































































































































































































































































































































8.1.4 Linear regression analysis of baseline marker levels
and follow-up cognitive test scores
The associations identified by the correlations were analyzed further via a series
of linear regressions that modelled the biomarker levels against follow-up cog-
nition, actual five year cognitive change across individual tests, and estimated
cognitive change. In each of the models, age and sex were entered as covariates
with further adjustments being made when modelling five year change (baseline
cognitive scores) and estimated change (MHVS). The use of prior scores as co-
variates is better than modelling with the actual change in cognitive ability, as
this reduces the spurious correlation between the baseline and follow-up cognitive
scores (Campbell & Kenny 1999). For the estimated cognitive decline models, the
use of a robust and validated approximation of peak cognitive ability (MHVS)
enabled the assessment of decline from best ever cognitive function (Deary et al.
2004). Analyses were repeated to account for the role of cardiovascular risk fac-
tors by adjusting all models for ABPI, diastolic blood pressure, cholesterol level,
and smoking (measured in pack years). Plasma viscosity calculations were also
repeated after adjusting for its main constituent, fibrinogen, to enable an in-
vestigation of its residual component. Finally, all biomarkers were trimmed for
outliers, points beyond ± 3.5 standard deviations from the mean, prior to the
analysis. Full results for all of the models described are shown in Tables 8.5,
and 8.6 with the significant output discussed in the text.
CRP regression results
After age and sex-adjustment, raised plasma CRP levels were significantly asso-
ciated with poorer functioning on:
• RAVENS (standardised β = -0.085, p < 0.001),
• VFT (standardised β = -0.054, p < 0.05),
• DST (standardised β = -0.095, p < 0.001),
• TMT (standardised β = 0.093, p < 0.001),
• g (standardised β = -0.095, p < 0.001).
Additional adjustment for the MHVS weakened the associations slightly, with the
VFT result becoming non-significant:
• RAVENS (standardised β = -0.045, p < 0.05),
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• DST (standardised β = -0.069, p < 0.001),
• TMT (standardised β = 0.063, p < 0.01),
• g (standardised β = -0.048, p < 0.05).
In the fully saturated models only two of the associations remained significant at
the p = 0.05 threshold:
• DST (standardised β = -0.047, p < 0.05),
• TMT (standardised β = 0.045, p < 0.05).
Fibrinogen regression results
After age and sex-adjustment, raised plasma fibrinogen levels were significantly
associated with poorer functioning on:
• AVLT (standardised β = -0.045, p < 0.05),
• RAVENS (standardised β = -0.066, p < 0.01),
• DST (standardised β = -0.083, p < 0.001),
• TMT (standardised β = 0.090, p < 0.001),
• g (standardised β = -0.081, p < 0.01).
Additional adjustment for the MHVS to attain an estimate of lifetime cogni-
tive decline weakened the associations slightly, although all remained statistically
significant apart from the AVLT:
• RAVENS (standardised β = -0.052, p < 0.01),
• DST (standardised β = -0.080, p < 0.001),
• TMT (standardised β = 0.082, p < 0.001),
• g (standardised β = -0.069, p < 0.001).
In the fully saturated models including the four cardiovascular risk factors, the
associations were again weakened but still statistically significant. The only ex-
ception was the β weight for the RAVENS test, which showed a trend association:
• RAVENS (standardised β = -0.045, p < 0.10),
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• DST (standardised β = -0.060, p < 0.01),
• TMT (standardised β = 0.067, p < 0.01),
• g (standardised β = -0.057, p < 0.01).
Plasma viscosity regression results (unadjusted)
Not surprisingly, the plasma viscosity regression results showed a similar pattern
to the fibrinogen output. Upon age and sex-adjustment, elevated plasma viscosity
associated significantly with decreased cognitive function on:
• DST (standardised β = -0.068, p < 0.001),
• TMT (standardised β = 0.089, p < 0.001),
• g (standardised β = -0.065, p < 0.01).
However, this marker did seem to be less sensitive to adjustment for MHVS scores
with neither magnitude nor significance of the associations being overly affected:
• DST (standardised β = -0.061, p < 0.001),
• TMT (standardised β = 0.082, p < 0.001),
• g (standardised β = -0.063, p < 0.001).
Even upon full adjustment for the cardiovascular covariates, the weight of the
standardised βs diminished only slightly:
• DST (standardised β = -0.049, p < 0.01),
• TMT (standardised β = 0.069, p < 0.001),
• g (standardised β = -0.048, p < 0.05).
Haematocrit regression results
The regression models for haematocrit yielded a solitary significant association
with the cognitive scores. Consistent with the findings for the other biomarkers,
this was with the TMT but only in the estimated lifetime change model after
additional adjustment for MHVS.
• TMT (standardised β = 0.044, p < 0.05).
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Plasma viscosity regression results (adjusted for fibrinogen)
The model estimating the residual, or non-fibrinogen component, of plasma vis-
cosity yielded significant associations with only the TMT. Again, increased marker
levels were associated with cognitive dysfunction.
• TMT (standardised β = 0.066, p < 0.01),
Interestingly, adjustment for MHVS scores resulted in an increase to the absolute
weight for the general intelligence factor, which jumped from a non-significant
-0.036 (p = 0.15) in the age and sex-adjusted model to -0.048. As with the
unadjusted plasma viscosity model, the association with the TMT was significant.
• TMT (standardised β = 0.069, p < 0.01).
• g (standardised β = -0.048, p < 0.05).
In the fully saturated models, the TMT results still held whilst the associations
with g weakened slightly showing a statistical trend:
• TMT (standardised β = 0.062, p < 0.01),
• g (standardised β = -0.039, p < 0.10).
Throughout the modelling process, strongly significant associations persisted
between all of the markers and the TMT scores (the mental flexibility domain).
Consistent associations also persisted for the DST and the general intelligence
factor, g.
Baseline biomarker levels and actual 5-year cognitive change.
When cognitive decline was measured in the subset of study participants who
undertook detailed cognitive testing at both baseline and follow-up (Table 8.6),
several associations were found to be statistically significant. Raised plasma CRP
showed weak associations with an improvement in performance on the AVLT
(standardised β = 0.078, p < 0.05), and decreased performance on RAVENS
(standardised β = -0.066, p < 0.05) and the VFT (standardised β = -0.052,
p < 0.10). These associations were retained upon covariate adjustment in the
saturated models. Plasma fibrinogen showed an inverse trend association with
change in VFT scores (standardised β = -0.053, p < 0.10), whilst plasma viscosity
and haematocrit showed some sign of increased levels being related to decline on
the TMT (standardised β = 0.079, p < 0.05, and 0.071, p < 0.10, respectively).
These associations remained as statistical trends in the fully adjusted models.
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Removal of persons with acute inflammation
To discount the possibility of acute inflammation biasing the findings between
CRP and cognition, the analyses were repeated after the exclusion of subjects
with a CRP measurement greater than 10 mg/l. CRP values above this thresh-
old are regarded as being indicative of acute inflammation (Ockene et al. 2001).
However, the number of subjects with CRP levels > 10 mg/l was only 112 (4.8%
of the original population of 2,312) and after exclusion of these subjects from
the dataset, the results remained similar (Table 8.7). Nonetheless, in addition
to a small decrease in the already small effect sizes, the previously significant









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































There are several assumptions that need to be satisfied in order to carry out a
linear regression analysis. These include:
• a linear relationship between dependent and independent variables,
• independence of the errors (no serial correlation),
• homoscedasticity (constant variance) of the errors,
• normality of the error distribution.
If any of the above assumptions are violated then the predictions and confidence
intervals generated from the regression model may be inefficient or biased. These
four assumptions were checked and satisfied for all models presented. A detailed
description of the output generated is given for the age and sex-adjusted model
of CRP against DST.
8.1.6 Regression diagnostics.
Test for linearity
In linear regression with a single independent variable, a scatter plot of the de-
pendent versus independent variable provides an indication of the linearity of
the relationship. When regression is extended to models with more than one
independent variable, partial residual plots, which account for the impact of the
competing independent variables, may be plotted for each variable. These partial
residual plots take the form
(Residuals + βixi) versus xi
where
• Residuals = residuals from the full model,
• βi = regression coefficient from the ith independent variable in the full
model,
• xi = the ith independent variable.
Figure 8.2 shows the plots from the CRP-DST model. Given the extremely large




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 8.2: Partial residual plots for the CRP-DST model.
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or otherwise. Nonetheless, it does not seem unreasonable that the assumption
was satisfied for the model.
Test for independence of the errors
To test for autocorrelation amongst the residuals a Durbin-Watson statistic can
be calculated. As this statistic is meaningful when the data form a time-series,
there was no need to calculate it for any of the models presented in this thesis.
Test for homoscedasticity
Linear regression makes an assumption of constant variance for the error terms
in the model. A plot of the studentized residuals against the fitted values of the
model indicates any change in variance by predicted values. For example, a funnel
shaped plot shows that the model provides less accurate estimates as the values
of the dependent variable increase. Other errors possible from this plot include
a bow-shaped distribution that would suggest the addition of a quadratic term
into the model. However, as can be seen from Figure 8.3, there was no evidence
to suggest non-constant variance in the CRP-DST model.
Test for normality
The final of the four assumptions is that the model residuals follow a normal
distribution. Violations of normality compromise the estimation of coefficients
and the calculation of confidence intervals. To test this assumption it is standard
practice to graph a Q-Q Plot of the residuals. Formal tests of normality may
also be conducted using, for example, the Shapiro-Wilk test. In addition to
identifying outlying data points from the Q-Q Plot, Cook’s distance may also
be plotted to show points with large influence on the regression analysis. It can
often be informative to drop such points before repeating the analysis to see how
this impacts upon the coefficients and confidence intervals generated. Figure 8.4
shows the Q-Q Plot of the residuals for the CRP-DST model. As the residuals
followed the 45◦ line quite closely it was reasonable to assume that they were
approximately normally distributed.
8.2 APOε analyses
As described in Subsection 4.6.4, APOε is one of the few genetic markers to be
consistently associated with cognitive ability (Bertram & Tanzi 2008). Specifi-
cally, carriers of the ε4 allele (as opposed to ε2 or ε3 carriers) are found to be at









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 8.4: Normal Q-Q Plot for the residuals from the CRP-DST model.
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associated with lower values of circulating CRP (März et al. 2004). Using the
data from the AAA Trial, a series of analyses were conducted to answer three
questions:
• Is APOε allele status associated with cognitive ability?
• Do plasma CRP levels vary by APOε status?
• Are APOε4 stratified CRP levels associated with cognitive ability?
APOε and cognitive ability
From the study population of 2,091 the distribution of APOε alleles is presented
in Table 8.8. The overall proportions of ε2, ε3, and ε4 carriers were 0.097, 0.766,
and 0.137, which is in accordance with population-level figures reported in the
literature (Rebeck et al. 1993). Whilst the majority of persons had at least one
copy of the ε3 allele, 30 were found to have two copies of the high risk ε4 allele
with 47 having two copies of the low risk ε2 allele. The number of persons with
data missing for APOε status was 396.
ε2 ε3 ε4
ε2 47 196 39
ε3 1,019 364
ε4 30
Table 8.8: Distribution of APOε alleles in the AAA Trial population.
To test for differences between APOε and cognition, age and sex-adjusted
ANCOVA was used to compare the mean cognitive scores of the ε4 carriers versus
non-ε4 carriers. The ANCOVA models were built using the ‘lm’ function in R.
The results from these analyses showed non-significant associations between ε4
status and each of the individual cognitive tests (p-range 0.09 – 0.34), g (p =
0.08), and the MHVS (p = 0.73). Nonetheless, the age and sex-adjusted means
were all in the direction of poorer cognitive performance for APOε4 carriers.
Despite the lack of an APOε-cognition association, age and sex-adjusted AN-
COVA was used to try and identify the high risk and low risk genotypes for de-
creased cognitive ability. These analyses again showed non-significant results for
APOε status (Appendix A). Examining the APOε genotypes, it was found that
the ε4ε4 carriers had poorer cognitive scores relative to all other genotypes, and
in particular with the protective ε2ε2 genotype. There were also consistent trends
for impaired performance with carriers of the ε2ε4 and ε3ε4 genotypes. Nonethe-
less, the relationship between the VFT scores and APOε actually pointed towards
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better cognitive performance for those in the ε4ε4 group. The overall ability of
the models to explain variation in cognition tended to range between 8.9% and
16.2% although the model for VFT only explained 0.09% of the variance. This
may help explain the unusual findings between this test and the ε4 allele. Overall,
the main explanatory power lay with the age and sex covariates; the APOε gene
explained a maximum of 0.6% of the variance (for the TMT model).
The assumptions for ANCOVA surround the normal distribution of the re-
sponse variable within each group and equal variances between the groups. Box-
plots of g by APOε genotype were used to check for equality of variance between
groups. This was formally assessed using Bartlett’s test, which yielded a K2
value of 5.79 on 5 degrees of freedom, p = 0.33. The assumption of normality
was assessed for all groups by visually inspecting Q-Q Plots and histograms for
deviation from the normal distribution.
Plasma CRP levels by APOε
To test for differences between mean CRP levels by APOε status, an age and
sex-adjusted ANCOVA model was used. The fit of the model was tested using
the methods described previously. Using the ε2ε2 group as the reference category,
significantly lower CRP levels were found for those in the ε3ε4 and ε4ε4 groups.
lm(formula = log(bCRP) ~ Age + Sex + APOE, data = AAA)
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.702440 0.338317 2.076 0.0380 *
Age 0.002198 0.004466 0.492 0.6227
SexM -0.017980 0.064327 -0.280 0.7799
APOEe2e3 -0.030113 0.191653 -0.157 0.8752
APOEe2e4 -0.324447 0.248730 -1.304 0.1923
APOEe3e3 -0.169827 0.176586 -0.962 0.3364
APOEe3e4 -0.432215 0.183494 -2.355 0.0186 *
APOEe4e4 -0.703580 0.281490 -2.499 0.0125 *
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
These analyses were repeated to investigate the relationship between APOε and
fibrinogen levels, plasma viscosity, and haematocrit but with null findings (overall
ANCOVA p = 0.14, 0.81, 0.97, respectively).
APOε stratified CRP by cognition
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To mirror the analysis performed by Schram et al., which showed no evidence
for an APOε:CRP interaction with cognition (Schram et al. 2007), a series of
linear regression analyses were undertaken. An APOε term (ε4 versus non-ε4)
and an APOε–CRP interaction term were added to the age and sex-adjusted
models described previously. For each model, both the interaction term and the




This section provides a summary of the ET2DS data and the methods that were
used to analyse the associations between the inflammatory biomarker levels and
cognitive ability. Descriptive statistics are used to summarise each of the inde-
pendent biomarker variables, dependent cognitive test variables, and adjustment
variables. Correlations are then presented between the biomarkers and the cogni-
tive test scores. This is followed by the main analysis, which used linear regression
methods to investigate the contemporaneous associations between inflammation
and cognition, and estimated cognitive decline.
8.3.2 Descriptive statistics and variable summaries
Tables 8.9 and 8.10 give the baseline characteristics of the ET2DS population.
The mean age of the population was 67.9 years (s.d. 4.20), and approximately
half of the sample (n = 547, 51.3%) was male. The mean blood pressure and
cholesterol measurements were low, which is most likely a consequence of the
medication being taken to control for cardiovascular risk factors. The mean BMI
of the sample was 31.4, which places the majority of participants as being over-
weight or obese. Finally, whilst the mean duration of Type 2 diabetes was 8 years
(s.d. 6.46), the range of reported values was large, varying between 6 months and
43 years.
All cognitive and inflammatory biomarker data were approximately normally
distributed with the exception of the TMT scores, CRP, IL-6, and TNF-α levels,
which were positively skewed and therefore, transformed using natural logarithms.
A general inflammation factor (Inflam) was derived from the four inflammatory
biomarkers by means of an unrotated principal components analysis. All four
markers loaded strongly onto the first principal component (0.439-0.805), which
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Test n mean (s.d.)
MR 1,052 12.8 (5.28)
LNS 1,048 9.7 (2.75)
VFT 1,060 36.9 (12.83)
DST 1,057 49.2 (14.77)
TMT 1,052 104 (81–139)
FACES 1,059 65.8 (7.88)
LM 1,050 25.2 (8.17)
g 1,021 0.00 (1.00)
MHVS 1,049 30.9 (5.23)
Table 8.9: ET2DS cognitive test scores.
accounted for 49.7% of the total variance (Table 8.11). The four markers and the
inflammatory factor were all trimmed for outliers, points exceeding 3.5 standard
deviations from the mean, prior to the correlation and regression analyses.
8.3.3 Correlations between biomarker levels and cognitive
test scores
To investigate the relationship between the cognitive test scores and the biomarker
levels a series of bivariate Pearson correlations were calculated. As with the AAA
Trial, the correlations between the covariates were minimal with none exceeding
± 0.30 except between systolic and diastolic blood pressure (r = 0.39, p < 0.001).
Further analyses of the covariate associations with the inflammatory marker lev-
els and the general inflammatory factor found age, sex, ABPI, CHD, duration
of diabetes, HADS-D, stroke, and BMI to be consistently significant predictors.
In combination, the covariates explained 4.4% (adjusted R2) of the variation in
ln(TNF-α) levels, between 10.2% and 13.7% of the other inflammatory markers,
and 17.6% of the general inflammatory factor. The predictive power of the covari-
ates increased when assessing the cognitive test scores, explaining between 6.6%
and 16.1% of the variation in the individual tests and 22.5% of the variation in
g.
The raw associations between the biomarkers and cognition are presented in
Table 8.12. The magnitude of the CRP and fibrinogen correlations were fairly
small, never exceeding ± 0.1. Significant associations were noted between both
markers and MR (p < 0.01), and between fibrinogen and TMT (p < 0.01), and
g (p < 0.05)
Compared to the downstream markers, the correlations for the upstream
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ET2DS Population (n = 1066)
Variable Mean (s.d.) Variable Mean (s.d.)
Age (years) 67.9 (4.20) Daily alcohol - n (%)
Male - n (%) 547 (51.3) 0 drinks 309 (29.0)
ABPI 0.98 (0.21) 1-2 drinks 471 (44.1)
Systolic BP (mmHg) 133.3 (16.44) 3-4 drinks 178 (16.7)
Diastolic BP (mmHg) 69.1 (9.01) 5-6 drinks 56 (5.3)
Cholesterol (mmol/L) 4.31 (0.90) 7-9 drinks 21 (2.0.)
HbA1c (%) 7.40 (1.12) 10 + drinks 7 (0.7)
BMI (kg/m2) 31.4 (5.69) Education - n (%)
Smoker - n (%) Primary School 171 (16.0)
Current 153 (14.4) Secondary School 307 (28.8)
Ex-smoker 499 (46.8) Professional Qualification 581 (54.5)
Never smoked 414 (38.8) University/College 7 (0.7)
Duration of diabetes 8.1 (6.46) Fibrinogen (g/l) 3.65 (0.74)
CHD (Yes) - n (%) 330 (31.0) CRP (mg/l) 1.86 (0.87–4.37)
Stroke (Yes) – n (%) 90 (8.4) IL-6 (pg/ml) 2.87 (1.97–4.46)
HADS-D score 3.9 (2.89) TNF-α (pg/ml) 1.07 (0.69–1.62)
Table 8.10: ET2DS descriptive statistics (mean (s.d.) or median (IQR) unless
otherwise stated).
Principal Eigenvalue % Variance Biomarker Factor Factor
Component (λ) explained Loading Score
1 1.97 49.3 ln(CRP) 0.803 0.407
2 0.99 24.6 Fibrinogen 0.755 0.383
3 0.60 15.0 ln(IL-6) 0.753 0.382
4 0.45 11.1 ln(TNF-α) 0.434 0.220
Table 8.11: PCA output for the ET2DS general inflammation factor.
markers and the general inflammation factor were around twice the size. Signifi-
cant results were found for all three markers on all of the cognitive tests excluding
LM, DST (TNF-α), and VFT (Inflam). All of the markers apart from fibrinogen
correlated significantly with the MHVS estimate of pre-morbid cognitive ability
(p < 0.05 or p < 0.01). The inverse nature of the associations again support
the hypothesis that raised biomarker levels relate to decreased cognitive ability.
After adjustment for age and sex, the correlations became smaller but retained












































































































































































































































































































































































































































































































































































































































8.3.4 Linear regression analysis of cross-sectional biomarker–
cognition associations
Analogous to the AAA Trial analysis, linear regression was used to assess the
association between the markers and age and sex-adjusted cognitive test scores.
Further adjustments were made for MHVS scores to enable an estimate of lifetime
cognitive change, and for additional covariates to control for depressed mood; to-
tal plasma cholesterol; BMI; ABPI; diastolic brachial blood pressure; smoking;
self-reported duration of diabetes; coronary heart disease – myocardial infarc-
tion or angina; typical daily alcohol consumption per drinking day in the last
year; highest level of self-reported education; stroke; and glycated haemoglobin
(HbA1c).
Age and sex-adjusted regression results of the biomarker levels against the
cognitive test scores are shown in Table 8.14. The results for the downstream
markers fibrinogen and CRP tended to be weakly significant or non-significant
with the exception of the fibrinogen-TMT association (standardised β = 0.088,
p < 0.01). By contrast, the standardised βs for the upstream markers, IL-6 and
TNF-α, were of a greater magnitude (significantly greater for IL-6 with DST and
g, and for both IL-6 and TNF-α with TMT (p < 0.05)). The standardised βs for
the upstream markers were also significantly different from zero for the majority
of the tests.
IL-6
• MR (standardised β -0.113, p < 0.001)
• LNS (standardised β -0.075, p < 0.05)
• VFT (standardised β -0.077, p < 0.05)
• DST (standardised β -0.152, p < 0.001)
• TMT (standardised β 0.173, p < 0.001)
• FACES (standardised β -0.084, p < 0.01)
• g (standardised β -0.161, p < 0.001)
TNF-α
• MR (standardised β -0.120, p < 0.001)
• TMT (standardised β 0.091, p < 0.01)
141
• FACES (standardised β -0.074, p < 0.05)
• g (standardised β -0.106, p < 0.001)
A similar pattern to the upstream markers was found for the overall marker of
inflammation with five of the eight βs being significant at the p = 0.05 threshold.
General Inflammation Factor
• MR (standardised β -0.122, p < 0.001)
• DST (standardised β -0.095, p < 0.01)
• TMT (standardised β 0.140, p < 0.001)
• FACES (standardised β -0.075, p < 0.05)
• g (standardised β -0.133, p < 0.001)
All inflammatory measures, with the exception of fibrinogen, associated sig-
nificantly with the MHVS, which was again used as an indicator of peak prior
cognitive ability (standardised β range -0.065 to -0.085, p < 0.01).
Results of the regression models investigating marker levels and estimated life-
time change in cognition are also shown in Table 8.14. After age, sex, and MHVS-
adjustment, only the fibrinogen-TMT association remained for the downstream
markers. However, this association persisted after further covariate adjustment
in the saturated model (standardised β = 0.067, p < 0.05).
For the upstream markers, adjustment for MHVS scores weakened both the
magnitude and statistical significance of the associations. Nonetheless, the strongest
associations from the age and sex-adjusted models were retained after accounting
for both MHVS and the other covariates, particularly when using IL-6 as the
marker of inflammation.
IL-6
• MR (standardised β -0.077, p < 0.05),
• DST (standardised β -0.083, p < 0.01),
• TMT (standardised β 0.117, p < 0.001),
• FACES (standardised β -0.056, p < 0.10),
• g (standardised β -0.087, p < 0.001).
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TNF-α
• MR (standardised β -0.088, p < 0.01),
• TMT (standardised β 0.049, p < 0.10),
• g (standardised β -0.052, p < 0.05 – MHVS-adjusted model only).
General Inflammation Factor
The general inflammatory factor retained significant associations after adjustment
for MHVS (DST and g: p < 0.05) and also in the fully adjusted models with:
• MR (standardised β -0.066, p < 0.05),
• TMT (standardised β 0.093, p < 0.01),































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This chapter presented a summary of the AAA Trial and ET2DS variables. Cor-
relations were used to provide raw estimates of the associations between the
biomarkers and cognition. The main analyses for both studies modelled the
biomarker levels against late-life cognitive ability, late-life cognitive change, and
estimated lifetime cognitive change. Small but significant associations were found
in both studies: between CRP, fibrinogen, plasma viscosity and measures of pro-
cessing speed, mental flexibility, and g in the AAA Trial; and between IL-6, TNF-
α, a general inflammation factor and processing speed, and g in the ET2DS. These
prospective and cross-sectional associations tended to persist after adjustments
were made for potential confounding variables and also for the vocabulary-based
estimate of peak cognitive ability.
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Chapter 9
Genetic association analysis and
causal inference.
9.1 Introduction
One of the ultimate aims of epidemiological research is to uncover causal path-
ways of disease and to identify interventions that will delay or even ameliorate
the progression of disease. In the situation where disease mechanisms are un-
derstood, randomised controlled trials are among the most powerful ways to test
treatment effects. However, the working mechanisms of many diseases are unclear
and until such knowledge is available, treatments and cures are likely to remain
elusive. When analysing data from prospective cohort studies, one of the most
difficult things to control for is whether an identified association between pheno-
type/exposure and outcome is spurious and actually the result of confounding.
In recent times, the advancement of genome wide association studies has led to
large sections of the genome being typed at relatively low cost. With a price reduc-
tion also occurring for candidate gene analyses, a genetic epidemiology approach
is becoming increasingly common in the quest to identify causal associations.
To apply this approach to the inflammation, rheology and cognition data re-
quires the identification of genetic variants (SNPs) that affect synthesis of the
inflammatory/rheological markers. The relationship between these SNPs and
cognitive outcomes can then be tested. Given that genotypic information is de-
termined at conception, it cannot be subjected to the influence of confounding
variables. Therefore, if significant associations can be shown between genotype,
phenotype, and outcome then this would provide evidence for a causal role of
inflammation/rheology in cognition. Unfortunately, these types of analyses are
unable to identify the mechanisms through which the associations are involved.
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However, determining the evidence for causal or non-causal relationships will bet-
ter inform the design of future studies and help unravel the complex processes
that drive cognitive decline.
One approach that relates a phenotype variable to an outcome variable via
a genetic predictor of the phenotype is Mendelian randomisation (Davey Smith
& Ebrahim 2003). This method may be thought of as a ‘natural’ randomised
controlled trial that assigns subjects to groups based on their genetic profile. Ex-
plicitly, Mendelian randomisation models the phenotype variable against genetic
predictors before considering its association with the outcome variable. As poten-
tial confounder variables are not likely to be associated with the genetic variants,
they should be distributed equally across the genotypes.
The primary aim of this chapter is to use genetic information to assess the
evidence for a causal association between elevated levels of CRP and fibrinogen
and decreased cognitive ability.
9.2 Classical Two-Stage Least-Squares (2SLS)
Regression
The classical statistical methodology that runs in parallel with Mendelian ran-
domisation is two-stage least-squares regression (2SLS). In order to run a suc-
cessful 2SLS regression the genetic variants must be strong predictors of the
intermediate variable. The strength of the genetic ‘instrument’ is measured using
the F statistic from the regression of SNP on marker level (Lawlor et al. 2008).
If the F statistic exceeds 10 then the SNP is said to be a strong instrument and
good predictor of the plasma biomarker level. The second stage of the regression
then models the SNP-stratified biomarker levels against the cognitive outcome
variable. Using the SNP and biomarker data for CRP and fibrinogen, a classical
Mendelian randomisation analysis was conducted on the AAA Trial data.
9.2.1 Fibrinogen SNPs
In addition to measuring plasma levels of fibrinogen, eight fibrinogen SNPs were
genotyped in the AAA Trial. Five of the SNPs were located in the fibrinogen alpha
(FGA) gene with the other three in the fibrinogen beta (FGB) gene. A summary
of each of the SNPs is printed in Table 9.1. To compare the representativeness
of the AAA Trial sample with the general population, the minor allele frequency
(MAF) for the CEU (European) HapMap population are also printed in this table.
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A quick comparison suggests little difference between the genotype distributions
of the two groups.
Gene SNP n Major Minor MAF MAF HWE
allele allele CEU p-value
FGA rs2070022 2,038 C T 0.20 0.14 0.17
rs6050 2,014 A G 0.25 0.24 0.59
rs2070016 2,044 T C 0.15 0.16 0.93
rs2070018 2,042 T C 0.13 0.13 0.43
rs2070011 2,030 G A 0.38 0.37 0.89
FGB rs4220 2,029 G A 0.17 0.19 0.94
rs1800788 2,024 C T 0.19 0.23 0.57
rs2227412 2,030 A G 0.19 0.12 0.56
Table 9.1: AAA Trial fibrinogen SNP descriptives
Prior to conducting the 2SLS regression, the SNPs were checked for Hardy-
Weinberg Equilibrium and for pairwise LD. Hardy-Weinberg Equilibrium was
tested for using the HWE.exact command in the genetics library of R. This test is
equivalent to a Chi-square test of independence with the null hypothesis implying
random mating within the population. Deviation from the null may be caused by
violations such as inbreeding, assortative mating (mating between persons with
similar phenotypes), a small population sample (genetic drift), or by population
structure and genotyping error. The HWE p-value for each of the fibrinogen SNPs
is presented in Table 9.1 with none being below the 0.05 significance threshold.
To test for LD between the fibrinogen SNPs, the LD function in the genetics
library of R was used. This tests for pairwise LD between SNPs using three
distinct measures:
D: The raw difference in frequency between the observed number of ‘AB’ pairs
and the expected number.
D = p(AB) - (p(A) × p(B))





where, if D > 0:
Dmax = min (p(A)p(b), p(a)p(B))
or if D < 0:
Dmax = max(–p(A)p(B), –p(a)p(b))
r: The correlation coefficient between the markers
r =
–D√
(p(A)× p(a)× p(B)× p(b))
where
• p(A) is defined as the observed probability of allele ‘A’ for marker 1,
• p(a) = 1 – p(A) is defined as the observed probability of allele ‘a’ for marker
1,
• p(B) is defined as the observed probability of allele ‘B’ for marker 2,
• p(b) = 1 – p(B) is defined as the observed probability of allele ‘b’ for marker
2,
• and p(AB) is defined as the probability of the marker allele pair ‘AB’.
Two measures (D’ and r) were monitored to assess both the independence of
the SNPs and also their predictive power of one another. It is useful to consider
both measures when determining LD status, but particularly the r value. For ex-
ample, two SNPs where one has a very small MAF may have a high D’ but a very
low r. In general, two SNPs are said to be in high LD if the squared correlation
(r2) exceeds 0.80. For the eight fibrinogen SNPs, rs2070022 and rs2227412 were
in high LD (D’ = 0.94, r = 0.89, r2 = 0.80). Of the other SNPs, most showed




In the AAA Trial, four SNPs were typed from the CRP gene: rs1205, rs1800947,
rs1130864, and rs1417938. The SNP descriptives again showed little deviation
from the CEU population in terms of MAFs (Table 9.2). Moreover, there was
no departure from Hardy-Weinberg Equilibrium with a minimum p-value of 0.11.
The LD mapping found strong dependence relations between all four of the SNPs
with rs1417938 and rs1130864 also sharing a high r2 of 0.992.
Gene SNP n Major Minor MAF MAF HWE
allele allele CEU p-value
CRP rs1205 2,025 C T 0.33 0.34 0.11
rs1800947 2,026 G C 0.06 0.07 0.20
rs1130864 2,011 C T 0.30 0.30 0.59
rs1417938 2,022 T A 0.30 0.33 0.83
Table 9.2: AAA Trial CRP SNP descriptives
9.2.3 Strong ‘instruments’
To identify strong instruments for the 2SLS analysis, age and sex-adjusted AN-
COVA was used to model the SNPs against the biomarker levels. The F statistics
from the analyses are presented in Table 9.3 and show that none of the fibrinogen
SNPs satisfy the assumption for the 2SLS model. One of the CRP SNPs, rs1205,
had a large F statistic of 12.46, which enabled its usage for further calculations.
Gene SNP F-statistic p-value





FGB rs4220 9.42 8.4e−05
rs1800788 1.90 0.15
rs2227412 1.91 0.15




Table 9.3: Strong ‘instruments’ in the AAA Trial
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9.2.4 Ordinary 2SLS analysis in the AAA Trial
To conduct the main 2SLS regression analysis, the tsls command from the sem
library in R was used. The code and results for the 2SLS model with rs1205 as the
instrument and g as the dependent variable is presented verbatim in the output
below. The outcome of importance is the regression coefficient and p-value for
log(bCRP). In this instance the data yielded a non-significant p-value of 0.62. The
p-values for CRP from the models examining the individual cognitive test scores
were also found to be non-significant: AVLT (p = 0.32); RAVENS (p = 0.66);
VFT (p = 0.63); DST (p = 0.26); and ln(TMT) (p = 0.51). Adjustment for age
and sex made no difference to the lack of significant findings. A positive β weight
for the log(bCRP) term also implies that after stratification for rs1205, age, and
sex, that increased CRP is associated with increased cognitive performance.
> library(sem)
> summary(tsls(follow.g~log(bCRP), ~rs1205, data=data))
2SLS Estimates
Model Formula: follow.g ~ log(bCRP)
Instruments: ~rs1205
Residuals:
Min. 1st Qu. Median Mean 3rd Qu. Max.
-3.15e+00 -6.70e-01 6.57e-02 1.61e-17 7.33e-01 3.24e+00
Estimate Std. Error t value Pr(>|t|)
(Intercept) -0.06841 0.1282 -0.5337 0.5936
log(bCRP) 0.09936 0.1981 0.5015 0.6161
Residual standard error: 1.0174 on 1499 degrees of freedom
9.2.5 Ordinary 2SLS analysis in the ET2DS
Taking an identical approach to the AAA Trial analysis, a classical 2SLS was run
on the ET2DS data for both fibrinogen and CRP. In this study, three fibrinogen
and three CRP SNPs were typed. Their descriptives are presented in Table 9.4.
Comparison with the HapMap output shows similar minor allele frequencies. The
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HWE and LD structure of the SNPs were also analysed. Once more, the SNPs
were all found to be in HWE and despite highly dependent associations being
found, there was no evidence to suggest any pairwise LD.
Gene SNP n Major Minor MAF MAF HWE
allele allele CEU p-value
FGA rs2070016 1,008 T C 0.15 0.16 0.90
FGB rs4220 1,007 G A 0.17 0.19 0.91
rs2227412 1,028 A G 0.17 0.12 0.58
CRP rs1205 1,012 C T 0.33 0.34 0.26
rs1800947 1,017 G C 0.05 0.07 0.18
rs1130864 1,016 C T 0.30 0.30 0.16
Table 9.4: ET2DS fibrinogen and CRP SNP descriptives
Modelling the SNPs against their respective biomarker levels showed no ev-
idence for strong instruments. The largest F-statistics for fibrinogen and CRP
were 3.47 (rs4220) and 8.48 (rs1800947), respectively. Given these findings it was
deemed inappropriate to continue to the main 2SLS analysis for the ET2DS data.
9.2.6 Discussion on classical 2SLS
The Mendelian randomisation approach to test for causal associations between
the biomarkers CRP and fibrinogen and cognitive ability gave null findings. These
are consistent with findings for CRP with several other outcomes such as insulin
resistance, Type 2 diabetes (Brunner et al. 2008), metabolic syndrome (Timpson
et al. 2005), carotid intima-media thickness (Kivimäki et al. 2008), and coronary
heart disease (Davey Smith et al. 2004).
In addition, classical modelling of Mendelian randomisation problems is lim-
ited by several factors. These include its inability to account for measurement
errors and intra-individual variation in the phenotype. Moreover, the nature
of classical testing requires caution and great care when interpreting output.
Whereas a Bayesian approach will give the strength of evidence for or against
a hypothesis, the classical approach is designed towards a dichotomous outcome
i.e. rejecting or failing to reject the null hypothesis. In the situation where there
is insufficient power to detect a significant association – which is likely to be the
case for the AAA Trial and ET2DS analyses – a Bayesian approach will output a
Bayes Factor close to 1 implying a lack of evidence to make a decision either way.
By contrast, the classical approach will always allow a conclusion to be drawn
with the usual cut-off p-value for rejecting H0 being set to 0.05.
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9.3 Introduction to Bayesian Statistics
In classical statistical methodology, parameters are treated as fixed variables.
By contrast, a Bayesian approach models these parameters as random variables
with probability distributions. To illustrate this point, Crawford and Garthwaite
present a simple example (Crawford & Garthwaite 2007):
“suppose m is the (unknown) mean IQ in a specified population. Then a
Bayesian might say ‘the probability that m is less than 90 is .95’ while classical
statistics does not permit a probabilistic statement about m. With the classical
approach, m is either less than 90 or it is not, and there is no random uncertainty,
so the probability that m is less than 90 is either 1 or 0 and nothing in between.”
To explain Bayesian methods mathematically, from probability theory if we let
• θ = unobservable population parameters of interest
• y = the observed sample data drawn from the population
• p(.|.) = conditional probability distribution





gives the marginal density of the data. By extension using Bayes Theorem we
can write




∝ p(y | θ)p(θ)
which provides the posterior density of θ given the observed data y.
A Bayesian approach requires the modeller to specify a set of priors, p(θ), be-
fore conducting an analysis. A prior is a probability statement surrounding prior
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knowledge of a parameter before any data have been collected. Prior distribu-
tions may be selected from results of past experiments, or from expert knowledge.
This prior information is then combined with the likelihood to generate a poste-
rior distribution for the random variable.
9.4 Bayesian hypothesis testing
Assume that the hypothesis to be tested is
H0 : θ ∈ Θ0 versus HA : θ ∈ ΘA
and that the prior probabilities on each of the hypotheses are
π0 = Pr(H0) = Pr(θ ∈ Θ0)
πA = Pr(HA) = Pr(θ ∈ ΘA)
Taking πA/π0 gives the prior odds on HA against H0. After collecting experimental




















To interpret Bayes Factors, a value > 1 provides support for HA as opposed to
H0 and vice-versa. Computationally, it is often easier to work with log10 BF.
The weight of evidence presented by Bayes Factors is nicely summarised by Jef-
freys (Jeffreys 1961)(Table 9.5). Unfortunately, the choice of prior distribution in
combination with the likelihood function often results in non-trivial joint poste-
rior distributions that require numerical techniques such as Markov-Chain Monte
Carlo to solve.
9.5 Introduction to Markov-Chain Monte Carlo
Markov chain Monte Carlo (MCMC) is a computational tool that is used to
generate samples from a probability distribution. After a large number of steps,
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Bayes Factor Evidence against H0
1 to 3.2 Not worth more than a bare mention
3.2 to 10 Substantial
10 to 100 Strong
> 100 Decisive
Table 9.5: Strength of evidence for Bayes Factors.
and when the chain approaches convergence, it can be used as a sample for the
sought after distribution. Most chains require a burn-in phase with the quality
of the sample improving as the number of steps increases.
9.5.1 Markov Chain
A (First-order) Markov chain is a stochastic process, which possesses the Markov
property that its current value, Xn+1 is conditional on value Xn but not the values
of X0, , Xn−1. Formally, this can be presented as
Pr(Xn+1 = x | Xn = xn, . . . , X1 = x1) = Pr(Xn+1 = x | Xn = xn).
9.5.2 Monte Carlo
The Monte Carlo part of MCMC refers to the computational algorithm that is
used to aggregate the results of the individual Markov chain output. By taking
random draws from the Markov chain-derived distribution they can generate a
distribution for the random variable of interest. Classic Monte Carlo techniques
used in Bayesian statistics include the Metropolis Hastings algorithm and Gibbs
sampling.
9.6 Bayesian 2SLS analysis in the AAA Trial
The Bayesian model used for the analysis was based on a model created by Profes-
sor Paul McKeigue. In the initial application McKeigue et al. tested the associa-
tion of Uric acid with metabolic syndrome through the Uric acid transporter SNP
rs13129671. The differences between that model and the inflammation-cognition
model defined here include a continuous instead of dichotomous outcome, and




Firstly, consider the model of CRP levels (xi) against CRP SNPs (gi):
xi = α0 + αggi + εi
Where i runs from 1 to 2,091, and εi ∼ N(0, σ2i ). Now let the model of the
outcome variable, follow-up g scores (yi) against the SNP stratified CRP levels
be written as:
yi = β0 + βxxi + βεεi
To speed up the mixing of the MCMC sampler and to provide more interpretable
output, the second model was re-parameterized as:
yi = β0 + βx(α0 + αggi + εi) + βεεi = β0 + γx(θ〈xi | gi〉+ εi)
Where
• γx = βx + βε
• θ = βx
γx
• and 〈xi | gi〉 = α0 + αggi
In this model, θ is the ratio of causal to crude effect of plasma CRP on g. By
setting θ equal to 0 and 1 we obtain the models for a causal and a confounded
relationship respectively. Testing the null hypothesis that θ = 1 vs. θ = 0, we
obtain a Bayes Factor for the evidence in favour of a causal or non-causal asso-
ciation between CRP and g. The model was extended to include age and sex as
covariates and also to incorporate multiple SNPs in unison. All 2,091 subjects
were included in the model with missing values for CRP, genotype, and g being
sampled from their joint posterior distribution.
The model was run using the JAGS2 (Just Another Gibbs Sampler) software
interfaced with R version 2.8.1. Prior to running the model, the variables were
defined and prepared in R. The file describing this preparation and the running
of the model is presented in Appendix B.
2http://www-ice.iarc.fr/∼martyn/software/jags/
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9.6.2 Bayesian 2SLS results for CRP
The most important output of the model is the log-likelihood function for θ
(Figure 9.1). The critical point on the graph is when the ratio of causal to crude
effect is equal to 1. At this point the log-likelihood is approximately -0.5. The
negative sign implies that the evidence is in favour of a non-causal association
with the magnitude of 0.5 corresponding to a likelihood ratio of around 3 to
1 (e0.5 to 1). This corresponds to weak to non-existent evidence. However, the
direction of the association when taken in tandem with the results from the
classical 2SLS approach does suggest that the association is more likely to be
built on confounding than causal evidence.
Ratio causal / crude effect of 



















Figure 9.1: Log-likelihood plot of the causal effect of CRP on cognition.
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9.6.3 Model diagnostics
To check the reliability and fit of the model, several diagnostic criteria were
monitored. Traceplots display the parameter values against the iteration number
(Figures 9.2 and 9.3). Model convergence should result in the plot values deviating
around the mode of the posterior distribution. In the CRP model, there do not
appear to be any visible trends in the traceplots suggesting non-convergence.
Nonetheless, it is possible that the chain may have converged at a local region
instead of covering the whole posterior distribution space.
Autocorrelation was examined for both of the chains generated (Figures 9.4
and 9.5). If sequential draws from a chain are highly correlated, this can result
in the sampler taking a long time to explore the complete posterior distribution.
When the autocorrelations are high for the parameter of interest, the traceplot
becomes a poor diagnostic for convergence. The autocorrelation structure for θ in
the CRP model shows dampening as the number of lags in both chains increases.
This suggests that the model has been parameterized suitably.
Finally, Gelman-Rubin plots were produced to calculate the potential scale
reduction factor. This factor is computed by sampling from each of the two chains
that were initialised. After discarding the first 50 draws, the within and between
chain variances are calculated. The estimated variance of the parameter can then
be derived as a weighted sum of the within and between chain variance. When
this factor has a large value (> 1.2) then we should consider running the chains
out longer to improve convergence to the stationary distribution. Whilst the
97.5 percentile for θ is raised slightly, the median value is close to 1, suggesting
convergence of the chain.
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N = 1000   Bandwidth = 0.01249
Density of beta.gx[1]














N = 1000   Bandwidth = 0.00876
Density of beta.gx[2]












N = 1000   Bandwidth = 0.007668
Density of beta.gx[3]


















N = 1000   Bandwidth = 21.17
Density of tau.x
Figure 9.2: Traceplots for the causal CRP-cognition model (1).
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N = 1000   Bandwidth = 0.005667
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N = 1000   Bandwidth = 0.009309
Density of tau.y















N = 1000   Bandwidth = 0.3941
Density of theta
Figure 9.3: Traceplots for the causal CRP-cognition model (2).
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Figure 9.4: Autocorrelation plots for the causal CRP-cognition model (1).
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Figure 9.5: Autocorrelation plots for the causal CRP-cognition model (2).
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Figure 9.6: Gelman diagnostics for the causal CRP-cognition model.
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9.6.4 Bayesian 2SLS results for fibrinogen
An identical approach was taken to analyse the fibrinogen data and g from the
AAA Trial. The likelihood function for θ is presented in Figure 9.7 and shows
an extremely flat profile. The point estimate is fractionally above zero, which
suggests evidence in favour of a causal association. However, the magnitude of
the estimate is so small that it translates into no strength whatsoever to favour
the causal over the crude model. All of the diagnostic plots for the model were
satisfactory.
Ratio causal / crude effect of 



















Figure 9.7: Log-likelihood plot of the causal effect of fibrinogen on cognition.
9.6.5 Limitations of the 2SLS approach
There are several commonly reported limitations of a Mendelian randomisation
approach for genetic analyses (Davey Smith & Ebrahim 2003). These include:
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• pleiotropy and the multi-function of genes. It is possible that the SNP(s)
under investigation affect the outcome through pathways not involving the
intermediate phenotype.
• canalization. This describes the situation where the possible negative im-
pact of gene variation on normal development is softened by developmental
compensation.
• the genetic variant being tested could be in high LD with the causal SNP.
If the true causal SNP lies in the same gene then the casual region will still
have been identified. However, if the causal variant is located in a different
gene then this could have a major impact upon potential therapies and
hypothesised mechanisms.
One further potential problem of Mendelian randomisation for both Bayesian
and classical methods is the inability to directly assess SNP-outcome associations.
This may be an issue when investigating late-life biomarker levels, especially CRP,
due to the dynamic nature of their levels. For example, CRP is involved in many
different physiological processes and is affected by multiple factors, especially in
later life. Furthermore, the mediating factors which cause elevated CRP may
result in CRP-cognition associations that are not causally related to CRP. It is
certainly plausible that late-life CRP measurements are a confounded measure
of lifetime exposure to CRP. Whilst the Mendelian randomisation process should
distribute this confounded variation equally across groups, the use of genetic
variants that are involved in CRP synthesis may be a better measure of CRP
level than the marker itself. Such an approach will be particularly beneficial
when the number of persons homozygous for the minor allele is small, due to
small amounts of confounding on CRP levels having a potentially great influence
on any analyses performed.
In the absence of serial biomarker measurements across an individual’s life-
time, it is debatable whether a single, late-life measure gives a true reflection
of lifetime exposure to circulating marker levels. It was subsequently chosen to
examine the direct associations between SNPs and cognitive outcomes, believing
them to be a better indicator of the biomarker levels than the actual biomarker
measures.
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9.7 Direct SNP–cognition associations
9.7.1 Aims
To test the hypothesis of there being a direct association between inflammatory
marker SNPs and cognitive ability, data from the two main studies (AAA Trial
and ET2DS) and the replication cohorts (EAS and LBC1936) were analysed.
The combined sample size from these populations was 4,776 (AAA Trial: n =
2,091, ET2DS: n = 1,060, EAS: n = 534, LBC1936: n = 1,091). Furthermore,
the additional inflammatory SNPs typed in the AAA Trial and ET2DS were also
analysed in relation to late-life cognitive ability and estimated lifetime decline.
9.7.2 Statistical methods and results
As discussed previously, several SNPs from the CRP, FGA, and FGB genes were
genotyped in the four cohorts. A recap of these are presented in Table 9.6. The
study descriptives are presented in Table 9.7.
Comparing the cognitive scores across cohorts (Table 9.8), the ET2DS group
scores significantly lower than the other three cohorts (p < 0.05). The only
exception was the VFT scores in the AAA Trial and ET2DS, which were similar.
A substantial difference is seen between DST scores in the AAA Trial and EAS
compared to the other two cohorts due to a 90 second time allowance in the
former studies with a 120 second time limit in the ET2DS and LBC1936. It was
not possible to compare LM scores across the ET2DS, EAS, and LBC1936 due
to only delayed recall being assessed in the EAS, and with the ET2DS subjects
only being assessed for immediate and delayed recall on one of the two stories.
The AAA Trial had substantially fewer men and a greater proportion of cur-
rent smokers than the ET2DS and LBC1936 (Table 9.7). The EAS also contained
a high proportion (∼40%) of current smokers. The only other noticeable differ-
ence across cohorts was the low blood pressure and cholesterol measurements of
the ET2DS participants. This is likely to be a consequence of the increased med-
ication this group were taking to control their cardiovascular risk factors. Prior
to the analysis, CRP and fibrinogen levels were trimmed for outliers by excluding
values exceeding 3.5 standard deviations in either direction from the mean.
The first stage of the modelling used age and sex-adjusted linear regression to
assess the association between CRP and fibrinogen levels and cognitive ability.
Additional adjustment was also made for estimated or actual pre-morbid ability
(MHVS scores in the AAA Trial and ET2DS, NART scores in the EAS, and
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age-11 MHT scores in the LBC1936) to examine the association between late-life
marker levels and estimated (AAA Trial, ET2DS, EAS) or actual (LBC1936)
lifetime cognitive change. The AAA Trial, and ET2DS results have already been
presented and described in detail. However, slightly different figures are presented
here as a result of the prior AAA Trial and ET2DS calculations being based on
the larger, cognitively assessed samples of 2,312 and 1,066, irrespective of the
availability of genotypic data. The AAA Trial, ET2DS, and LBC1936 analyses
were powered at over 90% for a two-sided significance test (α = 0.05) to detect a
standardised β coefficient of 0.10. The EAS was powered at 80% for a two-sided
significance test (α = 0.05) to detect a standardised β coefficient of 0.15.
Age and sex-adjusted ANCOVA was used to test for differences in CRP (fib-
rinogen) level by CRP (fibrinogen) SNP genotype. Prior to the analysis, SNPs in
the EAS and LBC1936 were assessed for deviation from Hardy-Weinberg equilib-
rium and also for patterns of LD. Age and sex-adjusted ANCOVA was used to test
for associations between genotype and cognitive ability. Assuming a minor allele
frequency (MAF) of 0.26 (0.2), which is the mean MAF of the CRP (fibrinogen)
SNPs in the HapMap CEU population, the AAA Trial, ET2DS, and LBC1936
cohorts were able to detect a genetic contribution of 1% of the variance in the
cognitive phenotype with over 90% power (α = 0.05) with the EAS powered at
over 80% to detect 1.5% of the variance in the cognitive phenotype (α = 0.05).
9.8 CRP results
9.8.1 Plasma CRP–cognition regression
The regression results showed strong associations between CRP levels and cog-
nition for all of the AAA Trial tests (p < 0.05) except the measure of memory
(Table 9.8). For the other studies, sporadic associations were detected: ET2DS
- MR (p < 0.05); EAS - VFT and DST (p < 0.01); LBC1936 - DST (p < 0.05).
The only consistent result across all studies was between CRP level and the
vocabulary-based estimate of prior cognitive ability, and the age-11 MHT score
in the LBC1936 (p < 0.05). After adjusting the models for estimated or actual
prior intelligence, the significant associations disappeared in the ET2DS, EAS
and LBC1936.
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9.8.2 Plasma CRP–CRP SNP associations
The second stage of the analysis looked at the relationship between the CRP
SNPs and plasma CRP levels. All SNPs passed Hardy-Weinberg equilibrium
(p > 0.05) although rs1130864 and rs1417938 in the AAA Trial (and rs3093068
and rs3093077 in the LBC1936) were found to be in high LD (D’ = 0.99 (0.98),
r2 = 0.99 (0.94)). The -log10 p-values of the SNPs modelled against age and
sex-adjusted CRP levels are shown in Figure 9.8.
All four SNP-biomarker associations from the AAA Trial reached Bonferroni-
adjusted significance (p range 4.2e−06 - 7.0e−04). Similarly, rs1205 and rs1800947
were significant in the ET2DS (p = 4.8e−05 and 2.2e−04). However, just one of the
SNPs in the LBC1936 was associated with CRP level (p = 0.0068 for rs1130864)
and two of the three EAS SNPs showed borderline significant relationships (p =
0.041 for rs1205 and p = 0.056 for rs3093077).
9.8.3 CRP SNP–cognition associations
The main analysis used ANCOVA to model age and sex-adjusted cognitive scores
by CRP SNP genotypes. Applying a Bonferroni correction alters the nominal p-
value from 0.05 to 0.002, 0.002, 0.003, and 0.001 in the AAA Trial, ET2DS, EAS,
and LBC1936 groups, respectively. Using these criteria, no significant difference
in cognitive score by genotype was found for any of the tests in any of the four
studies (Table 9.9). Considering a nominal significance threshold of p = 0.05,
three significant results were found in the AAA Trial: rs1417938 with RAVENS
and VFT (p = 0.034 and 0.017); and its LD partner rs1130864 with VFT (p =
0.016). Three significant results were also found in the ET2DS: rs1130864 with
DST, TMT, and FACES (p = 0.012, 0.030, and 0.017).
Further adjustment for the estimates/measure of pre-morbid IQ resulted in
a general decreased significance in the findings (Table 9.10). However, the VFT
associations with rs1130864 and rs1417938 in the AAA Trial remained significant
(at a nominal p = 0.05 threshold) along with the ET2DS rs1130864–FACES
association, which was significant even after considering a Bonferroni correction
to the p-value (p = 0.0010).
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9.9 Fibrinogen results
9.9.1 Plasma fibrinogen–cognition regression
The standardised βs and standard errors from the regression of plasma fibrinogen
levels against cognitive ability are presented in Table 9.11. The AAA Trial results
showed strongly significant associations between fibrinogen levels and scores on
the RAVENS, DST, TMT, and g (p< 0.001) These relationships became stronger,
with the exception of the RAVENS test, after further adjustments for MHVS.
There was no evidence of an association between fibrinogen levels and MHVS (p
= 0.20).
For the ET2DS, fibrinogen associated significantly with the MR (p < 0.10),
TMT (p < 0.01) and g (p < 0.05). As with the AAA Trial results, adjustment
for MHVS made little difference to the strength of these associations (p < 0.10,
0.01, and 0.10, respectively).
In the LBC1936 cohort, significant associations were found between fibrinogen
levels and the MHT-11 scores (p < 0.01). Weakly significant results were observed
for LNS, DST, LM, and g (p range 0.037 - 0.087). These associations were
attenuated after adjustment for MHT-11 scores.
9.9.2 Plasma fibrinogen–fibrinogen SNP associations
The second stage of the analysis looked at the relationship between the fibrino-
gen SNPs and plasma fibrinogen levels. All SNPs typed passed Hardy-Weinberg
equilibrium (p > 0.05) although rs2070022 and rs2227412 in the AAA Trial were
found to be in high LD (D’ = 0.94, r2 = 0.80). The –log10 p-values of the SNPs
modelled against age and sex-adjusted fibrinogen levels are shown in Figure 9.9.
Three SNPs from the AAA Trial were significant after a Bonferroni correction for
multiple testing: rs6050, rs2070016, and rs4220 (p = 0.0039, 2.5e−06, and 1.2e−05,
respectively). In the ET2DS, rs4220 associated significantly with plasma fibrino-
gen levels whilst rs2070016 and rs2227412 were borderline significant (Bonferroni
p-value and nominal p-value, respectively). The associations for the LBC1936
SNPs were all non-significant.
9.9.3 Fibrinogen SNP–cognition associations
In the main stage of the analysis, fibrinogen SNPs were modelled against the
cognitive outcomes. The ANCOVA p-values for the models testing age and sex-
adjusted cognitive scores by genotype groups are reported in Table 9.12. Applying
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a Bonferroni correction alters the nominal p-value from 0.05 to 0.0009, 0.0019,
and 0.0024 in the AAA Trial, ET2DS, and LBC1936 groups, respectively. Using
these criteria, a significant difference in cognitive score by genotype was found for
the VFT, DST, and g scores by rs2227412 in the ET2DS (p = 1.6e−03, 8.0e−05,
and 3.3e−04, respectively) but not for any of the results in the AAA Trial or
LBC1936.
Using the nominal significance threshold of p = 0.05, significant results were
found between rs2227412 and six of the eight ET2DS cognitive tests (maximum
p = 0.024); between rs2070022, which is in high LD with rs2227412, and VFT
in the AAA Trial; and between rs2070016 and LNS in the LBC1936. Trends (p
< 0.10) were also observed between rs2070022 and AVLT and between rs4220
and VFT in the AAA Trial. None of the SNPs associated significantly with the
MHVS or MHT measures.
Further adjustment for the estimates/measure of pre-morbid IQ resulted in a
general decreased significance in the findings (Table 9.13). Again the results indi-
cated an association between cognition and rs2227412 in the ET2DS and between
rs2070016 and LNS scores in the LBC1936. Furthermore, a new association ap-
peared between rs2227412 and DST scores (p = 0.039) and between rs4220 and
VFT scores (p = 0.023) in the AAA Trial cohort.
In light of these findings, standardised residuals from regression models of age
and sex on cognitive test scores were compared across SNPs showing significant
or borderline significant ANCOVA results (Appendices C.1, C.2, C.3). This was
done to try and identify a cognitive risk genotype for each SNP. The standardised
differences between high and low risk genotypes are presented in Figure 9.10. A
similar procedure was undertaken to obtain standardised age and sex-adjusted
fibrinogen levels by fibrinogen genotype (Table 9.14).
Contrasting results were found for the rs2070016 genotypes. The CC genotype
associated with decreased performance in the AAA Trial and ET2DS cohorts but
with increased performance in the LBC1936. However, the CC group in the
AAA Trial was much larger than the corresponding ET2DS or LBC1936 group
(40 versus 21 versus 17 persons, respectively). The association between rs2070016
and plasma fibrinogen showed significantly higher levels in individuals with a CC
genotype in the AAA Trial cohort (p = 3.1e−05), higher levels in the LBC1936,
but lower levels in the ET2DS.
For rs4220 the AA genotype was consistently implicated with poorer cognitive
scores in the AAA Trial and ET2DS cohorts. Again, a slight increase in perfor-
mance was noted in the LBC1936. The AA genotype was associated with higher
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fibrinogen levels compared to G allele carriers in the AAA Trial (p = 0.008).
There was no evidence for a significant difference in fibrinogen level by AA versus
other genotype in the ET2DS or LBC1936.
The heterozygous GA genotype of the rs2227412 SNP associated with poorer
cognition in all of the ET2DS tests. A similar pattern was also observed for the
AAA Trial and LBC1936 cohorts, albeit with much smaller and non-significant
differences. The VFT differences in both of these cohorts were in the opposite
direction, suggesting a possible protective effect. The GA genotype was linked
to slightly higher plasma fibrinogen levels than the combined homozygote level
in the AAA Trial and ET2DS and with higher levels than the GG genotype in
the LBC1936. Finally, the rs2070022 SNP in the FGA gene, which is in high LD
with rs2227412 showed decreased memory performance but increased executive
function performance for those with a TT genotype.
9.10 SNP-cognition associations for other genes.
In addition to the CRP, FGA, and FGB genes, SNP-cognition associations were
investigated in the AAA Trial and the ET2DS using variants from the TCF-1,
IL-6, F13A1, IL-1α, IL-1β, and TNF-α genes.
A list of the SNPs, complete with MAFs and Hardy-Weinberg Equilibrium
descriptives, are presented in Table 9.15. All SNPs were found to be in HWE (p
> 0.05). The three TCF-1 SNPs and the IL-6 pair rs2069832 and rs1800795 in
the AAA Trial, and the two IL-1 SNPs in the ET2DS were found to be in LD
(r2’s all > 0.80).
Age and sex-adjusted ANCOVA was used to assess the association between
each of the SNPs and the cognitive test scores in the respective studies (Ta-
ble 9.16). This resulted in only a few significant findings:
• rs2856838 (IL-1α) and TMT scores in the AAA Trial (p < 0.05),
• rs8192284 (IL-6 ) and DST scores in the ET2DS (p < 0.05),
• rs1800630 (TNF-α) and TMT scores in the ET2DS (p < 0.10),
• rs1800630 (TNF-α) and LM scores in the ET2DS (p < 0.01).
All of these associations persisted upon adjustment for MHVS scores with the
exception of the trend association between rs1800630 and the TMT.
• rs2856838 (IL-1α) and TMT scores in the AAA Trial (p < 0.10).
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• rs8192284 (IL-6 ) and DST scores in the ET2DS (p < 0.05).
• rs1800630 (TNF-α) and LM scores in the ET2DS (p < 0.05).
9.11 Summary
The aim of this chapter was to present the genetic evidence for an association
between inflammation and age-related cognitive decline. Three methodologies
were used for the analysis including both a classical and Bayesian approach to
Mendelian randomisation. These methods were then rejected in favour of a direct
analysis of biomarker SNPs against cognitive ability.
The results of the direct SNP-cognition associations showed strongly signif-
icant results for the fibrinogen beta rs2227412 SNP with the majority of the
cognitive tests in the ET2DS. The findings for this SNP were not replicated
across the other cohorts although other fibrinogen SNP-cognition associations
were found. Despite one or two weakly significant associations between cognitive
ability and SNPs in the CRP gene, the overall suggestion is for a non-causal
relationship. Similar null findings were made for the other inflammatory genes
investigated. However, the coverage of variants from these genes was not nearly
as comprehensive as for CRP and fibrinogen.
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Study
Gene SNP AAA Trial ET2DS EAS LBC1936
CRP rs1205 • • • •
rs1800947 • • •






rs2070016 • • •
rs2070018 •
rs2070011 •
FGB rs4220 • • •
rs1800788 •
rs2227412 • • •











































































































































































































































































































































































































































Cognitive Test Mean (s.d.) n β s.e. p Adjusted-p∗
AVLT 63.6 (16.44) 1675 -0.13 0.35 0.72 0.32
RAVENS 34.9 (9.27) 1635 -0.77 0.2 1.0e−04 0.0097
VFT 37.5 (12.69) 1715 -0.57 0.28 0.043 0.46
DST 40.4 (11.52) 1743 -1.02 0.23 7.80e−06 1.60e−04
ln(TMT) 4.6 (0.41) 1723 0.035 0.01 3.50e−05 0.001
g 0.007 (1.01) 1551 -0.09 0.02 3.00e−05 0.0067
MHVS 31.2 (4.71) 1680 -0.39 0.1 1.70e−04 -
ET2DS
Cognitive Test Mean (s.d.) n β s.e. p Adjusted-p∗
MR 12.8 (5.25) 1028 -0.28 0.14 0.045 0.19
LNS 9.7 (2.75) 1024 -0.018 0.074 0.81 0.55
VFT 37.0 (12.82) 1036 -0.22 0.35 0.53 0.79
DST 49.3 (14.83) 1033 -0.59 0.39 0.13 0.41
ln(TMT) 4.7 (0.42) 1028 0.019 0.011 0.094 0.23
FACES 65.8 (7.88) 1035 -0.13 0.21 0.52 0.94
LM 25.3 (8.17) 1026 0.19 0.22 0.39 0.091
g 0.006 (1.00) 997 -0.046 0.027 0.088 0.57
MHVS 31.0 (5.24) 1025 -0.3 0.14 0.038 -
EAS
Cognitive Test Mean (s.d.) n β s.e. p Adjusted-p∗
RAVENS 33.3 (9.73) 361 -0.35 0.47 0.46 0.43
VFT 38.7 (12.92) 370 -1.81 0.66 0.0065 0.23
DST 40.1 (11.51) 323 -1.7 0.6 0.0047 0.18
LM 35.2 (13.65) 364 0.35 0.69 0.62 0.046
g 0.014 (1.01) 318 -0.091 0.054 0.097 0.99
NART 31.6 (9.73) 369 -1.74 0.5 5.60e−04 -
LBC1936
Cognitive Test Mean (s.d.) n β s.e. p Adjusted-p∗
MR 13.5 (5.10) 1047 -0.35 0.18 0.058 0.55
LNS 10.9 (3.17) 1040 -0.12 0.11 0.30 0.94
VFT 42.5 (12.50) 1047 -0.14 0.45 0.76 0.38
DST 56.7 (12.94) 1046 -1.16 0.46 0.012 0.25
LM 71.5 (17.97) 1049 -0.69 0.64 0.28 0.77
g 0.006 (1.00) 1032 -0.068 0.035 0.054 0.84
MHT-11 49.0 (11.79) 990 -1.44 0.44 0.0011 -
Table 9.8: Age and sex (∗ and vocabulary)-adjusted regression of plasma CRP
levels against cognitive test scores in the four study cohorts (Unstandardised βs
































































































































































































































































Cognitive Test rs1205 rs1800947 rs1130864 rs1417938
AVLT 0.67 0.27 0.57 0.64
RAVENS 0.73 0.14 0.082 0.034
VFT 0.56 0.22 0.016 0.017
DST 0.38 0.22 0.69 0.65
ln(TMT) 0.88 0.61 0.46 0.57
g 0.78 0.43 0.47 0.49
MHVS 0.38 0.45 0.14 0.085
ET2DS
Cognitive Test rs1205 rs1800947 rs1130864
MR 0.58 0.36 0.52
LNS 0.59 0.70 0.32
VFT 0.95 0.76 0.38
DST 0.31 0.38 0.012
ln(TMT) 0.28 0.96 0.030
FACES 0.98 0.26 0.017
LM 0.87 0.68 0.28
g 0.69 0.41 0.092
MHVS 0.33 0.25 0.072
EAS
Cognitive Test rs1205 rs1130864 rs3093077
RAVENS 0.11 0.40 0.96
VFT 0.79 0.36 0.41
DST 0.24 0.60 0.95
LM 0.43 0.29 0.67
g 0.13 0.74 0.97
NART 0.75 0.78 0.78
LBC1936
Cognitive Test rs1205 rs1800947 rs1130864 rs3093077 rs3093068
MR 0.53 0.88 0.12 0.61 0.52
LNS 0.33 0.088 0.96 0.094 0.21
VFT 0.33 0.76 0.92 0.26 0.60
DST 0.58 0.41 0.70 0.90 0.77
LM 0.21 0.22 0.35 0.78 0.83
g 0.22 0.73 0.70 0.24 0.28
MHT-11 0.086 0.46 0.44 0.81 0.70
Table 9.9: ANCOVA p-values for the age and sex-adjusted associations between
CRP SNPs and cognitive ability (p-values less than 0.05 highlighted in bold).
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AAA Trial
Cognitive Test rs1205 rs1800947 rs1130864 rs1417938
AVLT 0.41 0.31 0.29 0.26
RAVENS 0.88 0.17 0.42 0.24
VFT 0.64 0.13 0.017 0.014
DST 0.57 0.15 0.92 0.95
ln(TMT) 0.60 0.49 0.17 0.20
g 0.83 0.27 0.44 0.48
ET2DS
Cognitive Test rs1205 rs1800947 rs1130864
MR 0.80 0.25 0.17
LNS 0.91 0.70 0.84
VFT 0.68 0.88 0.42
DST 0.13 0.44 0.083
ln(TMT) 0.26 0.59 0.17
FACES 0.82 0.41 0.0010
LM 0.87 0.70 0.76
g 0.42 0.41 0.38
EAS
Cognitive Test rs1205 rs1130864 rs3093077
RAVENS 0.085 0.37 0.85
VFT 0.65 0.14 0.73
DST 0.18 0.59 0.82
LM 0.51 0.21 0.78
g 0.12 0.51 0.87
LBC1936
Cognitive Test rs1205 rs1800947 rs1130864 rs3093077 rs3093068
MR 0.80 0.017 0.96 0.10 0.18
LNS 0.073 0.49 0.076 0.94 0.53
VFT 0.73 0.93 0.96 0.32 0.63
DST 0.92 0.52 0.56 0.29 0.46
LM 0.39 0.061 0.31 0.77 0.70
g 0.47 0.21 0.61 0.25 0.20
Table 9.10: ANCOVA p-values for the age, sex, and vocabulary-adjusted as-
sociations between CRP SNPs and estimated/actual lifetime cognitive change
(p-values less than 0.05 highlighted in bold).
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AAA Trial
Cognitive Test Mean (s.d.) n β s.e. p Adjusted-p∗
AVLT 63.4 (16.52) 1793 -1.04 0.57 0.068 0.13
RAVENS 34.9 (9.28) 1745 -1.14 0.33 4.7e−04 7.00e−04
VFT 37.5 (12.73) 1837 -0.40 0.45 0.38 0.57
DST 40.3 (11.58) 1863 -1.57 0.37 2.60e−05 7.30e−06
ln(TMT) 4.6 (0.41) 1842 0.07 0.01 1.70e−06 1.00e−06
g 0.0004 (1.01) 1659 -0.14 0.04 1.60e−04 7.90e−05
MHVS 31.2 (4.70) 1795 -0.22 0.17 0.20 -
ET2DS
Cognitive Test Mean (s.d.) n β s.e. p Adjusted-p∗
MR 12.8 (5.27) 1036 -0.41 0.23 0.075 0.053
LNS 9.7 (2.76) 1032 -0.03 0.12 0.79 0.87
VFT 37.0 (12.85) 1044 -0.07 0.58 0.91 0.99
DST 49.3 (14.80) 1041 -0.58 0.64 0.37 0.39
ln(TMT) 4.7 (0.41) 1036 0.05 0.02 0.006 0.004
FACES 65.8 (7.88) 1043 -0.29 0.34 0.40 0.44
LM 25.2 (8.20) 1034 -0.04 0.37 0.91 0.96
g 0.006 (1.00) 1005 -0.09 0.04 0.048 0.053
MHVS 30.9 (5.25) 1033 -0.08 0.24 0.73 -
LBC1936
Cognitive Test Mean (s.d.) n β s.e. p Adjusted-p∗
MR 13.5 (5.11) 1044 -0.17 0.25 0.51 0.43
LNS 11.0 (3.15) 1037 -0.27 0.16 0.087 0.66
VFT 42.5 (12.57) 1042 -0.57 0.62 0.36 0.82
DST 56.7 (12.92) 1043 -1.22 0.63 0.052 0.38
LM 71.6 (17.92) 1046 -1.71 0.87 0.051 0.63
g 0.01 (1.00) 1029 -0.10 0.05 0.037 0.73
MHT-11 49.0 (11.79) 989 -1.87 0.60 0.0018 -
Table 9.11: Age and sex (∗ and vocabulary)-adjusted regression of plasma fibrino-
gen levels against cognitive test scores in the three study cohorts (Unstandardised





















































































































































































































































































rs2070022 rs6050 rs2070016 rs2070018 rs2070011 rs4220 rs1800788 rs2227412
AVLT 0.07 0.85 0.47 0.76 0.77 0.70 0.81 0.32
RAVENS 0.43 0.96 0.53 0.75 0.85 0.31 0.90 0.30
VFT 0.036 0.24 0.72 0.52 0.20 0.083 0.66 0.11
DST 0.34 0.79 0.16 0.96 0.38 0.17 0.63 0.18
ln(TMT) 0.53 0.95 0.29 0.78 0.83 0.25 0.76 0.63
g 0.74 0.77 0.59 0.72 0.74 0.31 0.97 0.58





rs2070022 rs6050 rs2070016 rs2070018 rs2070011 rs4220 rs1800788 rs2227412
MR 0.46 0.66 0.024
LNS 0.59 0.43 0.022
VFT 0.55 0.25 0.0016
DST 0.92 0.86 8.00e−05
ln(TMT) 0.43 0.33 0.016
FACES 0.39 0.81 0.12
LM 0.85 0.46 0.38
g 0.89 0.45 3.30e−04





rs2070022 rs6050 rs2070016 rs2070018 rs2070011 rs4220 rs1800788 rs2227412
MR 0.37 0.20 0.49
LNS 0.020 0.45 0.93
VFT 0.87 0.74 0.29
DST 0.78 0.27 0.97
LM 0.31 0.095 0.29
g 0.22 0.075 0.84
MHT-11 0.53 0.16 0.55
Table 9.12: ANCOVA p-values for the age and sex-adjusted associations between







rs2070022 rs6050 rs2070016 rs2070018 rs2070011 rs4220 rs1800788 rs2227412
AVLT 0.13 0.68 0.16 0.82 0.83 0.22 0.79 0.73
RAVENS 0.17 0.53 0.85 0.74 0.94 0.28 0.87 0.066
VFT 0.065 0.065 0.59 0.54 0.13 0.023 0.52 0.17
DST 0.18 0.45 0.30 0.95 0.39 0.13 0.58 0.039
ln(TMT) 0.22 0.84 0.50 0.94 0.88 0.19 0.54 0.20





rs2070022 rs6050 rs2070016 rs2070018 rs2070011 rs4220 rs1800788 rs2227412
MR 0.75 0.70 0.61
LNS 0.50 0.35 0.0027
VFT 0.66 0.69 1.6e−04
DST 0.39 0.54 0.062
ln(TMT) 0.30 0.74 0.055
FACES 0.91 0.41 0.45
LM 0.39 0.79 0.23





rs2070022 rs6050 rs2070016 rs2070018 rs2070011 rs4220 rs1800788 rs2227412
MR 0.50 0.27 0.61
LNS 0.92 0.79 0.13
VFT 0.81 0.51 0.96
DST 0.016 0.49 0.88
LM 0.65 0.12 0.49
g 0.22 0.14 0.92
Table 9.13: ANCOVA p-values for the age, sex, and vocabulary-adjusted asso-
ciations between FGA and FGB SNPs and estimated/actual lifetime cognitive




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Gene SNP n Minor Major MAF CEU HWE
allele allele MAF
TCF-1 rs1169292 2,009 T C 0.31 NA 1.00
rs1169301 2,026 T C 0.29 NA 0.52
rs2464196 2,017 T C 0.29 0.30 0.33
IL-6 rs2069832 2,019 G A 0.41 0.46 0.61
rs2069840 2,006 C G 0.37 0.29 0.89
rs1800795 2,001 G C 0.41 0.46 0.96
IL-1α rs2856836 2,031 T C 0.30 0.25 0.07
rs3783546 2,024 G C 0.31 0.29 0.08
rs2856838 2,029 C T 0.39 0.40 0.85
IL-1β rs1143643 2,014 G A 0.36 0.39 0.77
rs1143634 2,021 C T 0.23 0.21 0.85
F13A1 rs5985 2,017 G T 0.27 0.21 0.26
ET2DS
Gene SNP n Minor Major MAF CEU HWE
allele allele MAF
IL-1βC rs554344 996 G C 0.17 0.19 0.44
rs580253 1,014 C T 0.17 0.19 0.91
IL-6 rs8192284 1,017 A C 0.40 0.35 0.95
TNF-α rs1800630 1,014 C A 0.15 0.15 0.06
TCF-1 rs2464196 1,018 G A 0.31 0.30 0.24





























































































































































































































































































































































































































































































































In this chapter the study findings are discussed. Firstly, a commentary on the
biomarker level-cognition associations are presented for both the AAA Trial and
the ET2DS. Following this, the genetic analyses between the biomarker SNPs
and cognition from the AAA Trial, the ET2DS and the replication cohorts are
reviewed. Where possible, the results are compared to those from the literature.
Furthermore, a critical evaluation of the pros and cons of the study methodology
and statistical analyses are also provided. The chapter concludes with a summary
of the importance and novelty of the work of this thesis in addition to giving
suggestions for further work.
10.1 Association between plasma biomarker lev-
els and cognitive ability
10.1.1 Markers of inflammation
AAA Trial
After five years of follow-up and following adjustment for age and sex, raised
levels of plasma fibrinogen and CRP were associated with poorer general cognitive
ability, non-verbal reasoning, executive function (CRP only), processing speed,
and mental flexibility. All but one of these associations remained significant after
adjustment for MHVS scores, suggesting an association with estimated lifetime
cognitive decline. Further adjustment for covariates (smoking, cholesterol, di-
astolic blood pressure, and ABPI) made little difference to the results with the
significant associations persisting in both the prospective and the estimated life-
time change models.
Contrasting the findings from the AAA Trial to those from the literature is
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difficult due to the heterogeneity of the study populations, the different cognitive
test batteries employed, and the varied methodological and analytical approaches
taken. These differences are apparent in both the longitudinal and cross-sectional
analyses.
Methodologically, the four key CRP papers reviewed in Section 2.8 varied as
follows. The paper by Dik et al. was similar to the AAA Trial in that baseline
inflammatory marker levels were modelled against cognitive change in four broad
cognitive domains - including a g factor - over a three year period (Dik et al.
2005). In their analyses, change in cognition was measured as the raw difference
between baseline and follow-up scores, and biomarker levels were split into tertiles
for the main logistic regression analysis.
The paper by Schram et al. that investigated the Rotterdam and Leiden stud-
ies was relatively analogous to the AAA Trial in terms of study design (Schram
et al. 2007). After measuring biomarker levels at baseline, a five year follow-
up took place with cognitive assessment (in three domains) at both time-points.
Cross-sectional and longitudinal analyses were performed with annual cognitive
change being calculated by means of raw differences divided by time, in years,
between the waves. Standardised effect sizes for the biomarkers were small and
statistically significant only at the cross-sectional level for CRP. A longitudinal
association was found between IL-6 and change in memory but only in the smaller
Leiden group.
The third study by Weuve et al. focussed exclusively on a CRP-cognition
relationship in women (Weuve et al. 2006). A comprehensive five test battery
was administered five years after biomarker measures were taken. For the anal-
ysis, CRP was split into quintiles with mean cognitive scores being compared
across groups. This yielded small but non-significant associations for raised CRP
(highest versus lowest quintile) to associate with poorer cognition.
The final of the key studies, by Alley et al. differed substantially from the
other three papers and also the AAA Trial in terms of its methodology and
analysis (Alley et al. 2008). Growth curve modelling was used to analyse the
CRP-cognition association using three waves of cognitive test data and baseline
CRP levels. As with Weuve, there was no evidence to link CRP with cognitive
ability or cognitive change. Moreover, the study may well have suffered from a
practice effect with the three waves of cognitive testing all occurring within a
seven year period.
The solitary key paper analysing plasma fibrinogen and cognition was by
Rafnsson et al (Rafnsson et al. 2007). This paper analysed data from the Ed-
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inburgh Artery Study (EAS), the background details of which were described in
detail in Chapter 7. Given the crossover between the EAS and AAA Trial research
groups, the methodology and analysis of the two studies were very similar. Simi-
lar to the key papers looking at CRP, the EAS showed small associations between
biomarkers and cognition. The largest of these associations were for fibrinogen
and IL-6 with the former associating with measures of processing speed and gen-
eral ability, with five year decline in non-verbal reasoning, and with estimated
lifetime decline of memory.
Given the methodological and analytical heterogeneity, it is difficult to com-
pare these papers with the findings from the AAA Trial. However, the one main
finding that can be drawn from all of the studies is that if associations do exist
between inflammatory biomarkers and cognition then they are almost certainly
going to be small. In the studies where null findings were reported, the point es-
timates of the associations were in the same direction as those from the positive
reports i.e. increased biomarker levels associate with decreased cognitive ability.
Overall, the positive findings for both CRP and fibrinogen were most pro-
nounced for tests associated with processing speed and mental flexibility. This
possibly reflects the increased sensitivity of these tests to age-related cognitive
decline compared with tests for alternative domains such as memory (Salthouse
2000). However, the Rafnsson paper did find plasma fibrinogen to associate with
estimated lifetime decline in memory.
Why so many large studies are failing to replicate each others findings is
unclear. In addition to study design differences, choice of potential confounders
and time of CRP measurement may also be highly influential. Nevertheless, the
genetic analyses of inflammatory biomarkers and cognition helped eliminate some
of the need to worry about these factors.
In addition to the CRP-cognition associations, the potential interactive effect
of APOε on the relationship was investigated. Despite no significant associations
being found between APOε and cognition, the point estimates for the ε4 allele
carriers were in the direction of poorer cognitive ability. Both this and the as-
sociation between the ε4 allele and decreased CRP levels are consistent with the
findings reported in the literature (März et al. 2004). The latter association is of
particular interest in that it seems a counter-intuitive argument. That is, those
with the worst risk profile for cognitive decline by APOε status have the lowest
levels of CRP, which are linked to the lowest risk profile group for cognitive de-
cline. There was no evidence to suggest a relationship between APOε status and
fibrinogen level.
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The reason for the association between APOε allele status and circulating
levels of CRP is unclear. The association could be related to inflammation,
although a lack of associations with other biomarkers, such as fibrinogen, both in
the AAA Trial and in the study by März et al. make this less likely.
Another possibility is that CRP production is affected by the mevalonate
pathway in the liver. Those who possess the APOε4 allele absorb cholesterol more
effectively than those without the allele (Kesäniemi et al. 1987). Subsequently,
there is a down-regulation of liver-based cholesterol synthesis and LDL receptors,
which increases the circulating levels of LDL. Moreover, this may also result
in a lower production of plasma CRP. Support for this hypothesis comes from
studies that have found statins that affect the rate-limiting step of the mevalonate
pathway and the production of cholesterol also lower the synthesis of CRP (Rontu
et al. 2006).
In the final stage of the APOε analysis a model was built to investigate the
evidence for a CRP–APOε interaction with cognition. However, this failed to
show any significant relationship between the interaction term and cognitive per-
formance.
ET2DS
In the ET2DS, raised levels of plasma IL-6 and TNF-α, as well as a gen-
eral inflammation factor were associated with poorer general cognitive ability.
Domain specific associations were most notable for measures of non-verbal rea-
soning, processing speed, non-verbal memory, and mental flexibility. A significant
association was also found between plasma fibrinogen levels and mental flexibility
with trends or weakly significant associations for fibrinogen and CRP with non-
verbal reasoning, and with g. After adjustment for vocabulary scores - which
were used to estimate prior cognitive ability - and for cardiovascular and other
health risk factors, significant associations persisted between IL-6, TNF-α, and
the general inflammatory factor, and non-verbal reasoning, mental flexibility (ex-
cluding TNF-α but including fibrinogen), and g (excluding TNF-α and a trend
observation for the general inflammatory factor). Furthermore, apart from fib-
rinogen, each of the markers associated significantly with the MHVS estimate of
pre-morbid IQ.
These findings suggest a strong relationship between cognition and the up-
stream markers of inflammation, TNF-α and IL-6. IL-6 in particular showed
consistent effects over the majority of the cognitive tests. There is also strong
evidence for a general inflammation-cognition association with the two compos-
ite factors associating significantly in the MHVS-adjusted model with a trend
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association in the fully adjusted model. However, despite all four markers load-
ing strongly onto the general inflammation component it is possible that these
results are being driven by the influence of the upstream markers.
Comparing the results of the ET2DS downstream markers (CRP and fibrino-
gen) with the findings from the AAA Trial yields a degree of similarity. Whilst
the ET2DS associations were slightly smaller and less statistically significant, the
overall pattern of results remains alike. That is, the greatest associations are
presented for the measures of processing speed. Plainly, the design and subse-
quent analysis of the ET2DS data will improve upon collection of the four year
follow-up cognitive data. It will be of great interest to see if the magnitude and
significance of the associations match in what are two homogenous populations.
As with the attempted comparison of AAA Trial results with those from the
literature, the evaluation of the upstream inflammatory markers is hampered
by study heterogeneity. Of the key papers that assessed either or both of IL-
6 and TNF-α the studies by Dik, Schram, Alley, and Rafnsson have already
been summarised as part of the CRP and fibrinogen analysis. The remainder of
the work identified was from papers where the study design did not match the
criteria specified for the literature review. For example, the longitudinal studies
by Yaffe et al. and Jordanova et al. suffered from using a single cognitive test and
assessing a very small sample from an ethnic community, respectively (Jordanova
et al. 2007, Yaffe et al. 2003). As with the downstream marker literature, these
studies failed to apply a common analytical technique to their data. Both papers
used odds ratios as their main outcome result with Yaffe et al. splitting the
biomarker levels into tertiles and Jordanova et al. using a dichotomous split.
There is a modicum of statistically significant evidence to relate the marker levels
to cognitive dysfunction with the majority of evidence pointing towards small but
consistently inverse associations.
Comparing the results of both the AAA Trial and the ET2DS with the litera-
ture it is clear that there are major inconsistencies in study methodology between
different study groups. Whilst there are restrictions on when biomarker measure-
ments are made and how long the cohort may be followed up for, there are some
changes that could make a huge impact on generalising study results. For exam-
ple, it is rare to find two studies that use the same battery of cognitive tests -
there were no instances of this in the literature reviewed. It is understandable
that different researchers will favour a different set of cognitive tests to measure
the same underlying cognitive domain. However, such an approach severely ham-
pers the possibilities for meta-analytic studies, which are sorely needed in this
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field. The only instance where consistency was present was when the cognitive
outcome assessed was the MMSE, which unfortunately, is too insensitive a test
to measure age-related cognitive decline. In addition, a g-factor which has been
derived from a large battery of different cognitive tests should provide a fairly
reliable measure of cognition.
A second improvement, which is simple to implement, would be a consis-
tent approach to the statistical handling of inflammatory biomarker variables.
For variables such as CRP, where the plasma levels can be categorised into low,
medium, and high risk of developing cardiovascular disease, it doesn’t seem unrea-
sonable that the same categories couldn’t be used in the main statistical analysis.
Alternatively, it would also be viable to treat CRP as a continuous variable (as
in this thesis) and use a regression-type approach to relate actual differences or
changes in CRP level to differences or changes in cognition. It is also critical for
studies to translate the small effect sizes in to something that is manageable and
meaningful to the reader. A common criticism for many of the published studies
reviewed in this work is the presentation of statistically significant statistics minus
a practical interpretation. If there is a causal association between inflammation
and cognition then it is essential to have an understanding of the magnitude of
elevation in biomarker level that results in increased risk of cognitive decline (the
effect sizes uncovered in this thesis are discussed in the section directly following
this). Whether such elevations are then clinically treatable is a question beyond
the scope of this thesis but nonetheless, the identification of any potentially causal
pathway widens the scope for possible upstream or downstream therapies.
Whilst several of the marker-cognition associations remained significant in
the estimated lifetime change (MHVS-adjusted) models, a weakening of both
the magnitude and significance of the findings was observed. This coupled with
the association between the markers and the MHVS scores cannot rule out the
possibility of some contribution from reverse causation.
Explicitly, vocabulary IQ may predict late-life inflammation and attenuate the
inflammation-cognition associations. A similar finding was made by Luciano et
al. who investigated CRP and fibrinogen levels with late-life cognitive ability and
lifetime cognitive decline (Luciano et al. 2009). In their study (which used the
full cognitive data from the LBC1936), IQ from age 11 rendered contemporaneous
correlations between cognition and CRP and fibrinogen at age 70 non-significant.
The association of pre-morbid IQ with late-life inflammatory risk factors might
occur via reverse causation or through both cognitive ability test scores and
levels of inflammatory markers being indicators of some more basic bodily system
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integrity i.e. confounding. Some alternative mechanisms that may explain the
association include: a direct effect for CRP, with increased levels being found in
neuritic plaques and neurofibrillary tangles in the brains of Alzheimer’s patients
(Schmidt et al. 2002); mediation through vascular disease (Ravaglia et al. 2005);
and an association with fibrinogen independent of its inflammatory properties
(van Oijen et al. 2005).
Another possible reverse causation pathway can be annotated through socioe-
conomic status. Lower socioeconomic status in adult life is a strong predictor of
raised inflammatory marker levels, including CRP and fibrinogen (Pollitt et al.
2007, Tabassum et al. 2008). These associations weaken when comparing the
biomarker levels with childhood socioeconomic status (Gimeno et al. 2007). Ad-
justment for adult cardiovascular disease risk factors also strongly attenuate the
associations between CRP and early life SES.
Effect sizes
In the AAA Trial the maximum standardised effect size found was –0.095 for
CRP using the DST to assess age and sex-adjusted cognition. This implies that for
every standard deviation change in CRP levels the DST scores change by –0.095
standard deviations. As the standard deviation on the DST was approximately
11 (Table 8.2) the effect size can be roughly interpreted as a 1.0 point decrease
on DST performance for a three-fold increase in CRP level. The magnitude of
the increase in CRP level was calculated by taking the anti-log of the standard
deviation (e1.1) of the transformed CRP levels.
Compared to the AAA Trial results and other studies of inflammation and
cognition, the magnitudes of the associations found in the ET2DS are similarly
modest. the lack of significant findings between CRP and cognition is in disagree-
ment with some, but not all, of the evidence presented in large, prospective studies
(Alley et al. 2008, Dik et al. 2005, Schram et al. 2007, Weuve et al. 2006, Yaffe
et al. 2003). Given the lack of studies investigating inflammation and cognition
in persons with Type 2 diabetes, it is possible that the inflammation-cognition
interaction differs in such populations.
Although these effect sizes are small, if inflammation does lie on the causal
pathway of cognitive decline then small changes in the levels of these proteins
may be greatly magnified through downstream processes in cognitive ageing.
10.1.2 Markers of rheology
AAA Trial
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Of the rheological factors tested, baseline plasma viscosity was associated
with: late-life general cognitive ability, processing speed, and mental flexibil-
ity; estimated lifetime general cognitive decline; and five year decline in mental
flexibility. These results are consistent with findings in men participating in
the Caerphilly Study (Elwood et al. 2001). Since plasma fibrinogen is a major
determinant of plasma viscosity it is not surprising that the findings for both
biomarkers were similar (the correlation between the marker levels was 0.454).
After adjusting for fibrinogen, plasma viscosity remained significantly associated
with scores on the TMT. This could mean that altered rheology, over and above
any effect of fibrinogen molecules themselves, accounts for the association be-
tween plasma viscosity and cognitive ability. Contrary to the Caerphilly Study,
no associations were observed between haematocrit and cognitive ability. While
further large prospective studies of haematocrit and cognitive function and de-
cline are required, it is possible that our findings reflect a more important role
for plasma viscosity than for haematocrit or whole blood viscosity in determining
blood flow in the cerebral microcirculation (Lowe 2001). The magnitude of the
plasma viscosity associations are in line with those for CRP and fibrinogen – the
maximum standardised β observed was 0.089.
10.1.3 Study strengths
AAA Trial
The main strengths of the AAA Trial included the application of a compre-
hensive cognitive battery; cognitive change measurements being taken over a five
year period (which is at least as long as the follow-up period from previous studies
by Schram et al. and Rafnsson et al.); and the assessment of four inter-related
measures of inflammation and rheology in a large population-based sample of over
2,000 persons. The AAA Trial is also one of the first studies to analyse plasma
viscosity and haematocrit with cognition in a mixed gender population. There-
fore, the positive findings for plasma viscosity (including the estimated lifetime
change models) are extremely encouraging and warrant further investigation.
Moreover, assessing participants with no history of and no prevalent cardiovas-
cular disease at baseline enabled the measurement of biomarker-cognition associ-
ations in a section of the population with minimal evidence of vascular disease.
The dampening of the potential confounding affect of CVD on both biomarker
levels and cognitive function makes this a unique cohort. Nevertheless, despite
these measures to stratify the cohort, there was still large variability in some of
the biomarker measurements, most notably CRP. This resulted in genetic markers
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of the biomarkers being used in place of the plasma levels as markers of lifetime
exposure to inflammation.
ET2DS
The strengths of the ET2DS were the application of a seven test cognitive
battery and the assessment of four inter-related measures of inflammation in a
large population-based sample of over 1,000 persons. The novel approach of cal-
culating a general inflammation factor enabled a test of the importance of overall
systemic inflammation. In conjunction with the analyses of the specific upstream
and downstream markers of inflammation, this helped in identifying if and where
inflammation is associating with cognitive function. To account for the possi-
bility of the inflammation-cognition relationship being mediated or confounded,
comprehensive adjustments were made for cardiovascular risk factors, lifestyle
factors, depression, and duration of diabetes. These analyses were amongst the
most thorough of those reviewed in the literature for covariate assessment and
adjustment.
Furthermore, this was one of the first studies to assess an inflammation-
cognition association in persons with Type 2 diabetes. Given that diabetics are
at greater risk of developing cognitive decline and that they decline at a faster
rate than the normal population, such models provide a somewhat accelerated
analysis of cognitive change. This may well become visible in the models of four




One of the main limitations of the AAA Trial was the potential affect of as-
pirin on the inflammation-cognition results. However, a recent analysis of the
unblinded Trial data found no evidence for an association between aspirin and
cognitive ability (Price et al. 2008c). Other limitations of the Trial included the
small number of persons in the cognitive subset. Whilst the study was well pow-
ered to detect small associations between the baseline marker levels and follow-up
cognitive scores, this was not the case in the subset, which was under one quarter
of the total population. Limited power in the subset may help to explain differ-
ences between the subset analysis and the estimated cognitive decline analysis.
Furthermore, a five year follow-up in a relatively young and healthy cohort is
going to increase the chance of error and bias due to a practice effect on the
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cognitive tests. As already commented, this may have been the underlying cause
of the observed association between increased CRP levels and increased memory
performance over five years. Other potential flaws of the AAA Trial methodol-
ogy include the use of single, peripheral measurements of biomarkers. In the-
ory, this may have resulted in regression bias, diluting the associations observed
(Schram et al. 2007). Although the AAA Trial cohort was population-based
and community-dwelling, bias may have resulted from selective non-response and
withdrawal from the trial. However, it is likely that persons with poorer cogni-
tive function were less likely to participate. Indeed, those with missing values at
follow-up tended to have worse scores at baseline testing. In totality, the limita-
tions of the study suggest that, if anything, the observed associations are likely
to be underestimating the true relationship between the markers and cognitive
ability or decline.
ET2DS
The main limitation of the ET2DS is its cross-sectional design. This was
partially accounted for by adjusting for a vocabulary measure (MHVS) to gain
an insight into the estimated lifetime cognitive change. Clearly, it would be ideal
to have an actual pre-morbid measure of cognition, as in the LBC1936. However,
the MHVS is a well-validated and robust estimate of peak cognitive ability with
vocabulary-based skills varying little across a lifetime.
An actual measure of cognitive change will be possible after participants at-
tend the 4 year follow-up clinic where they will be cognitively tested using the
same seven test battery. In parallel with the AAA Trial analysis, the use of a sin-
gle, peripheral measurement of the biomarkers may again have caused regression
dilution bias and an underestimation of the associations found (Emberson et al.
2004). Furthermore, as markers of inflammation are sensitive to acute illness
and are influenced by several factors prevalent in old age, it may be question-
able whether a single, late-life measurement accurately reflects the lifetime risk
of exposure to inflammation.
Whilst the novelty of examining the inflammation-cognition association in
persons with Type 2 diabetes was a study strength, it also limited the possibilities




The results from both the AAA Trial and the ET2DS provide a degree of evi-
dence for a relationship between inflammation, rheology and cognitive ability in
old age. Although effect sizes for the associations were small, they were consistent
with results from previous studies (Dik et al. 2005, Rafnsson et al. 2007, Schram
et al. 2007, Weuve et al. 2006). It is possible that the associations are not causal
but the result of other conditions that underlie both cognition and inflamma-
tion/rheology. One potential confounding, or mediating factor is cardiovascular
disease, which has been shown to be associated with both inflammation (Libby
et al. 2002) and cognitive ability (Breteler et al. 1994). However, when both sets
of modelling were repeated with cardiovascular risk factors as covariates most
of the significant associations remained. Together with the asymptomatic study
population in the AAA Trial, this suggests that the relationship between inflam-
mation and cognition is at least partially independent of cardiovascular disease.
In addition, as the fibrinogen and CRP levels correlated negatively and strongly
with the MHVS scores, there is also a possibility of reverse causation affecting
the interpretation of the results. It may be that poorer cognitive ability in earlier
life is linked to conditions affecting inflammation in later life, whether directly or
through associations with lifestyle and socio-economic status.
To help explain the physiological relationship between inflammation, rheology,
and cognitive decline and to determine whether they are causal, it would be useful
to consider the associations between cognitive ability and genetic polymorphisms
affecting biomarker levels. Indeed such an approach was taken and discussed
in detail in Chapter 9. A causal role for inflammatory markers in cognition is
certainly plausible, either with or without vascular pathology as an intermediary.
Increased plasma viscosity may also have a direct effect on cognitive function by
decreasing cerebral blood flow (Elwood et al. 2001, Lowe 2001). If blood viscosity
within the low-normal range and maintained brain performance by rehydration is
beneficial to the acutely challenged, hypo-perfused brain in older patients, then
it may be possible to extend the potential link between blood viscosity and brain
function to chronic cognitive decline in the general population (Lowe 2001).
In conclusion, it has been shown that raised circulating inflammatory and
rheological biomarker levels are contemporaneously and prospectively associated
with poorer late-life cognitive ability even after adjustment for pre-morbid IQ.
These findings are particularly notable for the upstream inflammatory marker IL-
6, the downstream inflammatory/rheological marker fibrinogen, and the rheolog-
ical marker plasma viscosity. Future longitudinal and genetic studies examining
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these markers are required to indicate the reliability of the findings and whether
the associations being observed are causal.
10.2 Genetic associations
10.2.1 CRP
Combining data from four large-scale population-based studies it appears unlikely
that CRP has a direct and causal effect on cognitive ability. However, significant
associations were observed between CRP SNPs and plasma CRP levels. More-
over, plasma CRP levels also associated with some of the measures of late-life
cognition and consistently across all four cohorts with estimated or actual prior
cognitive ability. Upon adjusting the plasma CRP-cognition models for vocab-
ulary scores, the previously significant associations were attenuated in three of
the studies and considerably weakened in the AAA Trial. The strength of the
LBC1936 study design with cognition assessed at both age 11 and age 70 adds
substantial weight to the reverse causation hypothesis proposed. It is entirely
possible that decreased cognitive ability in early life leads to an increased risk
of late-life inflammation via its association with health knowledge, lifestyle, and
socio-economic status (Beier & Ackerman 2003).
The null findings from the main analysis of the cognitive test scores by CRP
SNP genotypes are not altogether surprising. Previous Mendelian randomisa-
tion studies of the CRP gene have failed to directly implicate it in a variety of
conditions (Brunner et al. 2008, Davey Smith et al. 2004, Kivimäki et al. 2008,
Timpson et al. 2005). It is possible, but unlikely, that a direct CRP SNP cogni-
tion association does exist and that our results can be explained by a failure to
genotype the causal SNP or a SNP in high LD with the causal variant. Analysing
some of the strongest SNP predictors of CRP levels (Verzilli et al. 2008) enables
us to place a reasonable degree of confidence in our results. In all likelihood,
these data point towards CRP being a clinical correlate but not a causal factor
for determining cognitive ability and in the development of cognitive decline.
10.2.2 Fibrinogen
Combining data from three large-scale population-based studies, significant as-
sociations were shown between plasma fibrinogen levels and cognition, between
fibrinogen SNPs and plasma fibrinogen levels, and between fibrinogen SNPs and
cognition. To my knowledge, this is the first study to have examined the relation-
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ship between fibrinogen genes and cognition. Whilst no single result replicated
across the three studies, the findings do suggest a potentially causal role for fib-
rinogen in cognitive ageing.
The initial set of analyses showed elevated plasma fibrinogen levels to asso-
ciate with poorer cognitive function. Adjustments for an estimate or measure
of pre-morbid cognitive ability made little difference to these results, implying
a relationship between raised fibrinogen levels and estimated or actual lifetime
cognitive decline. However, the weakly significant associations in the LBC1936
did disappear after adjustment for age-11 scores on the MHT.
Modelling SNPs from the FGA and FGB genes against age and sex-adjusted
plasma fibrinogen levels showed rs4220 and rs2070016 to be the best predictors
of plasma fibrinogen levels. However, given that only three SNPs were typed on
more than one occasion, this conclusion is based largely upon the associations in
the AAA Trial. By contrast, a previous study found no association of rs4220 and
rs2070016 with fibrinogen levels, but a significant finding for rs2070011 after a
correction for multiple testing (Jacquemin et al. 2008).
After rejecting a Mendelian randomisation approach due to the potentially
large confounding effects on late-life fibrinogen levels, the main analysis modelled
directly the association between fibrinogen SNPs and cognitive ability. Taking
this approach, very strong evidence was found for associations between rs2227412
and cognition, even after the most stringent correction for multiple testing (Bon-
ferroni adjustment). These associations were strongest for the general intelligence
and mental flexibility/processing speed domains. For the rs2227412 SNP, carriers
of the heterozygous GA alleles were found to be at greatest risk of poorer cogni-
tive ability and greater lifetime cognitive decline. Weakly significant associations
were also found between cognition and rs2070016, rs2070022 and rs4220.
Furthermore, the genotypes that were found to be linked to impaired cognition
also tended to be associated with higher levels of fibrinogen. Of the significant
SNPs, rs2227412 (an intronic SNP) and rs4220 (a non-synonymous coding SNP)
lie in the FGB gene, which is involved in fibrinogen synthesis, whilst rs2070016
(an intronic SNP) is in the FGA gene, which helps determine clot structure (Lim
et al. 2003).
10.2.3 Other Genes
Despite a few weakly significant results, the predominant evidence was for no
association between the TCF-1, IL-1α, IL-1β, F13A1, and TNF-α genes and
cognition. A single association was significant at the p < 0.01 level: rs1800630
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(TNF-α) and verbal declarative memory in the ET2DS. This association was
retained at the p < 0.05 threshold in the estimated lifetime decline model.
10.2.4 Study strengths
The strengths of these analyses include their incorporation of four large-scale, el-
derly population-based cohorts. All studies were based in Scotland and were eth-
nically homogenous. In addition to the estimates of pre-morbid IQ, the LBC1936
had an age-11 IQ score, which was adjusted for to gain an insight into actual
lifetime cognitive decline. The four cohorts provided the opportunity for a large
and comprehensive analysis of the association between late-life CRP and fibrino-
gen levels and cognitive ability. To my knowledge, this is the first study to have
looked at variants in the genes that encode CRP and fibrinogen and cognitive
ability. For both markers it was decided to model the SNP-cognition associations
directly as opposed to taking a Mendelian randomisation-type approach. The
latter randomises the CRP (fibrinogen) levels to CRP (fibrinogen) SNP geno-
types before modelling against cognition. However, as CRP (fibrinogen) levels
are extremely sensitive to acute illness and influenced by several factors prevalent
in old age, the approach taken centred around the CRP (fibrinogen) SNPs being
better indicators of lifetime exposure to plasma CRP (fibrinogen) than late-life
plasma CRP (fibrinogen) levels. Despite slightly different cognitive batteries be-
ing administered in each of the cohorts, there was considerable overlap among
the tests, which allowed for close comparisons to be made with regard to specific
cognitive domains.
10.2.5 Study limitations
Some of the study weaknesses include the cross-sectional nature of the ET2DS
data although this should have no effect upon the SNP-cognition associations.
In addition, future studies would ideally take an early-midlife measure of the
biomarkers, instead of relying upon SNPs as being proxy measures of lifetime
exposure to CRP. Such data were available in the Honolulu-Asia Aging Study,
which showed midlife CRP levels to predict dementia 25 years later (Schmidt
et al. 2002). The similarity in age and location of our cohorts means that caution
should be taken over whether the results could be generalised to other elderly
populations, though that expectation seems reasonable. Finally, the AAA Trial,
the EAS, and the LBC1936 were all far healthier cohorts than the ET2DS. As
mentioned previously, persons with Type 2 diabetes are at greater risk of develop-
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ing cognitive decline and also decline at a faster rate. Whether the associations
seen between rs2227412 and cognition are exclusive to diabetics or if they are
only seen after a certain degree of cognitive ageing is unclear.
10.2.6 Summary
Fibrinogen
The genetic analyses showed associations between both fibrinogen levels and
fibrinogen genes with cognitive ability. Despite a lack of consistent evidence
across all three studies, the results provide a degree of support for a causal as-
sociation. Notably, the strongest SNP-cognition associations were found in the
cross-sectional, diabetic cohort. Although similar in age to the other cohorts,
this group’s cognitive scores were significantly lower. It is thus possible that the
relationship of fibrinogen genotypes with cognition only becomes apparent after a
certain degree of cognitive decline. Clearly, replication and further study are re-
quired to confirm or refute this claim and also to determine the pathways through
which fibrinogen may operate.
CRP
By contrast to the fibrinogen analyses, there was no evidence for an associa-
tion between CRP SNPs and cognitive ability. However, a consistent finding of
associations between plasma CRP and a prior intelligence estimate or measure
does suggest a possible reverse causation mechanism with poorer cognition in
early life resulting in both raised CRP and independently, poorer cognition in
later life.
Other genes
Similar to the findings for the CRP SNPs, null results were also observed for
the other genetic markers investigated. Perhaps there is further scope for inves-
tigating the TNF-α gene and the rs1800630 SNP although a thorough literature
review of the variants in this and the other genes assessed is required before pro-
ceeding. The SNPs typed in the AAA Trial and the ET2DS have provided at
best, a brief snapshot of these genes’ variation. Although the results favoured
null associations, it would be a somewhat bold move to exclude them completely
as causal factors on the cognitive decline pathway.
Causal pathways and mechanisms
The results of these genetic analyses support the evidence for an association
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between elevated fibrinogen levels and cognitive dysfunction and decline (Elwood
et al. 2001, Lowe 2001, Rafnsson et al. 2007). Raised fibrinogen levels have
also been associated with risk of both vascular dementia and Alzheimer’s disease
(van Oijen et al. 2005), and cross-sectionally with ischemic stroke and vascular
dementia (Stott et al. 2001). However, other studies have failed to replicate these
findings (Mari et al. 1996, Sevush et al. 1998). Additionally, associations have
been observed between fibrinogen haplotypes but not plasma levels and cerebral
small vessel disease (van Oijen et al. 2008), which is a risk factor for stroke and
dementia (Vermeer et al. 2003). The potential role of fibrinogen in cognitive
dysfunction is uncertain although current opinion leans towards its haemostatic
and rheological, as opposed to inflammatory properties (Lowe 2001, Rafnsson
et al. 2007, van Oijen et al. 2005).
The study by van Oijen et al. investigating the relationship between the mark-
ers CRP and fibrinogen with dementia found only the latter to be a significant
predictor. Similarly, the results of this thesis showed significant associations be-
tween fibrinogen SNPs and cognitive ability using data from the AAA Trial,
ET2DS, and LBC1936 cohorts. Combining this information with the null CRP
SNP–cognition associations suggests that more focus should be placed on the
haemostatic and rheological characteristics of fibrinogen as opposed to its in-
flammatory properties and its inflammatory correlates. Indeed, the correlation
between fibrinogen and CRP levels is typically quite strong (0.40 in the study
by van Oijen et al., 0.44–0.58 in the four studies analysed here) so perhaps the
previously reported CRP-cognition associations are merely using CRP as a proxy
marker for fibrinogen. To elaborate on its non-inflammatory properties, elevated
levels of fibrinogen increase blood clotting, which may subsequently reduce cere-
bral blood flow, causing brain damage (Lowe 2001).
10.3 Conclusions and future directions
The primary aim of this thesis was to identify the evidence for associations be-
tween biomarkers of inflammation and cognitive ability and decline in old age.
These aims were addressed using a two-fold approach. Firstly, plasma levels of the
biomarkers (CRP, fibrinogen, plasma viscosity, haematocrit, TNF-α, and IL-6)
were modelled against late-life cognitive ability and estimated lifetime cognitive
decline in two large-scale, community-dwelling cohorts – the AAA Trial and the
ET2DS. The second step of the analysis took a genetic approach, using SNP in-
formation from the genes that encode the biomarkers to determine the evidence
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for a causal association between inflammation and impaired cognitive ability and
cognitive decline.
The initial biomarker cognition analyses showed strongly significant prospec-
tive associations between late-life CRP, fibrinogen, and plasma viscosity levels
and cognitive ability after five years of follow-up. These associations were most
pronounced for the cognitive tests that measured processing speed and also the
general intelligence factor. In addition, the associations persisted after adjust-
ment for vocabulary scores, which implies a relationship between inflammation
and lifetime cognitive decline as well as with late-life cognitive ability. Despite
being cross-sectional in design, the ET2DS data showed evidence for associations
between fibrinogen, TNF-α, and most strongly with IL-6 and cognition. Again,
the significant results were retained after adjustment for the vocabulary-based
estimate of pre-morbid IQ. Whilst most studies in the literature had not used a
pre-morbid measure of IQ to estimate lifetime cognitive change, the small mag-
nitudes of the late-life cross-sectional and prospective associations were in line
with those previously presented.
The genetic analysis used data from two replication cohorts, the EAS and the
LBC1936 in addition to the AAA Trial and the ET2DS. The ET2DS analysis
showed significant associations between the rs2227412 FGB SNP and cognitive
ability. These findings were not replicated across the other cohorts. Whether this
is a false positive finding, a diabetes-specific association, or a result that is more
pronounced as cognitive performance decreases is unclear. Whilst the cohorts
were very well matched for age, the ET2DS scored consistently and significantly
lower on the cognitive tests. For the other marker gene SNPs (CRP, TCF-1,
IL-1α, IL-1β, F13A1, and TNF-α) null or weakly significant associations were
found.
The biggest strength of this thesis is that it is one of the first times inflamma-
tory biomarker SNPs have been assessed in relation to cognitive ability. Whilst
this limits the ability to compare the results with other studies, the novel research
has generated some exciting results and laid the foundations for further work in
this field.
Other novelties of this thesis include: the analysis of the inflammation cog-
nition associations in persons with Type 2 diabetes; the derivation of an over-
all inflammatory factor that was modelled against the cognitive scores in the
ET2DS; the study of the rheological variable, plasma viscosity, with cognition in
a community-dwelling population of both men and women; the assessment of late-
life inflammatory biomarkers with 59-year cognitive decline in the LBC1936 repli-
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cation cohort; and the use of a Bayesian regression model to perform a Mendelian
randomisation analysis.
In terms of recommendations for future studies, it would be ideal for studies
to have serial and longitudinal measures of both inflammatory biomarkers and
cognitive ability across the human lifespan. Clearly, this would be an expensive
and time-consuming exercise. In the meantime, I would recommend future studies
to include a crystallised measure of intelligence – such as the MHVS or NART –
as part of their cognitive assessment. Not only would this allow for an estimate of
lifetime cognitive decline but it would also add to the body of growing evidence
to suggest a reverse causation mechanism between late-life biomarker–cognition
associations through early life cognitive ability. The results of the analysis in this
thesis also point towards the importance of rheological and haemostatic factors
in addition to inflammation in predicting late-life cognitive ability. In particular,
the associations between plasma viscosity, plasma fibrinogen, and the FGA and
FGB genes with cognition and cognitive decline warrant replication and further
investigation.
Closing remark
The results of this thesis have identified a potentially causal risk factor in the
process of cognitive ageing. Whilst, replication of the associations between the
fibrinogen SNPs and cognition were not consistent over three studies, the com-
bination of evidence indicates something over and above a false positive finding.
Notably, the heterozygous genotype for the rs2227412 FGB SNP associated with
increased fibrinogen levels, poorer cognitive performance, and increased cognitive
decline in a cohort of 1,066 persons with Type 2 diabetes. To date, the majority
of inflammation-cognition associations have focussed on the acute-phase protein
CRP. The main outcomes from this thesis suggest that its close correlate, fib-
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Koenig, W., Sund, M., Fröhlich, M., Löwel, H., Hutchinson, W. L. & Pepys, M. B.
(2003), ‘Refinement of the association of serum C-reactive protein concentra-
tion and coronary heart disease risk by correction for within-subject variation
over time: the MONICA Augsburg studies, 1984 and 1987’, Am. J. Epidemiol.
158, 357–364.
Komulainen, P., Lakka, T. A., Kivipelto, M., Hassinen, M., Penttilä, I. M., Hel-
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Pulanić, D. & Rudan, I. (2005), ‘The past decade: fibrinogen’, Coll Antropol
29, 341–349.
Purves, W. K., Sadava, D., Orians, G. H. & Heller, H. C. (2004), Life: The
Science of Biology, seventh edn, Sunderland, Mass: Sinauer Associates.
222
Rafnsson, S. B., Deary, I. J., Smith, F. B., Whiteman, M. C., Rumley, A., Lowe,
G. D. & Fowkes, F. G. (2007), ‘Cognitive decline and markers of inflammation
and hemostasis: the Edinburgh Artery Study’, J Am Geriatr Soc 55, 700–707.
Rasmussen, T., Schliemann, T., Sørensen, J. C., Zimmer, J. & West, M. J. (1996),
‘Memory impaired aged rats: no loss of principal hippocampal and subicular
neurons’, Neurobiol. Aging 17, 143–147.
Rattazzi, M., Puato, M., Faggin, E., Bertipaglia, B., Zambon, A. & Pauletto,
P. (2003), ‘C-reactive protein and interleukin-6 in vascular disease: culprits or
passive bystanders?’, J. Hypertens. 21, 1787–1803.
Ravaglia, G., Forti, P., Maioli, F., Brunetti, N., Martelli, M., Servadei, L.,
Bastagli, L., Bianchin, M. & Mariani, E. (2005), ‘Serum C-reactive protein and
cognitive function in healthy elderly Italian community dwellers’, J. Gerontol.
A Biol. Sci. Med. Sci. 60, 1017–1021.
Raven, J., Raven, J. C. & Court, J. H. (1998), Manual for Ravens progressive
matrices and vocabulary scales, Oxford Psychologists Press: Oxford.
Rebeck, G. W., Reiter, J. S., Strickland, D. K. & Hyman, B. T. (1993),
‘Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and re-
ceptor interactions’, Neuron 11, 575–580.
Reiner, A. P., Barber, M. J., Guan, Y., Ridker, P. M., Lange, L. A., Chasman,
D. I., Walston, J. D., Cooper, G. M., Jenny, N. S., Rieder, M. J., Durda, J. P.,
Smith, J. D., Novembre, J., Tracy, R. P., Rotter, J. I., Stephens, M., Nickerson,
D. A. & Krauss, R. M. (2008a), ‘Polymorphisms of the HNF1A gene encoding
hepatocyte nuclear factor-1 alpha are associated with C-reactive protein’, Am.
J. Hum. Genet. 82, 1193–1201.
Reiner, A. P., Carty, C. L., Carlson, C. S., Wan, J. Y., Rieder, M. J., Smith, J. D.,
Rice, K., Fornage, M., Jaquish, C. E., Williams, O. D., Tracy, R. P., Lewis,
C. E., Siscovick, D. S., Boerwinkle, E. & Nickerson, D. A. (2006), ‘Association
between patterns of nucleotide variation across the three fibrinogen genes and
plasma fibrinogen levels: the Coronary Artery Risk Development in Young
Adults (CARDIA) study’, J. Thromb. Haemost. 4, 1279–1287.
Reiner, A. P., Wurfel, M. M., Lange, L. A., Carlson, C. S., Nord, A. S., Carty,
C. L., Rieder, M. J., Desmarais, C., Jenny, N. S., Iribarren, C., Walston, J. D.,
Williams, O. D., Nickerson, D. A. & Jarvik, G. P. (2008b), ‘Polymorphisms of
223
the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers
of systemic inflammation’, Arterioscler. Thromb. Vasc. Biol. 28, 1407–1412.
Reinhart, W. H. (2003), ‘Fibrinogen–marker or mediator of vascular disease?’,
Vasc Med 8, 211–216.
Riddle, D. R., Sonntag, W. E. & Lichtenwalner, R. J. (2003), ‘Microvascular
plasticity in aging’, Ageing Res. Rev. 2, 149–168.
Ridker, P. M. (2003), ‘Clinical application of C-reactive protein for cardiovascular
disease detection and prevention’, Circulation 107, 363–369.
Riese, H., Vrijkotte, T. G., Meijer, P., Kluft, C. & de Geus, E. J. (2002), ‘Diag-
nostic strategies for C-reactive protein’, BMC Cardiovasc Disord 2, 9.
Ritchie, K. & Lovestone, S. (2002), ‘The dementias’, Lancet 360, 1759–1766.
Román, G. C. (2004), ‘Brain hypoperfusion: a critical factor in vascular demen-
tia’, Neurol. Res. 26, 454–458.
Rontu, R., Ojala, P., Hervonen, A., Goebeler, S., Karhunen, P. J., Nikkilä,
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van der Wiel, A., Frölich, M., Macfarlane, P. W., Blauw, G. J. & Westendorp,
R. G. (2003), ‘Interaction of atherosclerosis and inflammation in elderly sub-
jects with poor cognitive function’, Neurology 61, 1695–1701.
van Oijen, M., Cheung, E. Y., Geluk, C. E., Hofman, A., Koudstaal, P. J.,
Breteler, M. M. & de Maat, M. P. (2008), ‘Haplotypes of the fibrinogen gene and
cerebral small vessel disease: the Rotterdam scan study’, J. Neurol. Neurosurg.
Psychiatr. 79, 799–803.
van Oijen, M., de Maat, M. P., Kardys, I., de Jong, F. J., Hofman, A., Koudstaal,
P. J., Witteman, J. C. & Breteler, M. M. (2007), ‘Polymorphisms and haplo-
types in the C-reactive protein gene and risk of dementia’, Neurobiol. Aging
28, 1361–1366.
van Oijen, M., Witteman, J. C., Hofman, A., Koudstaal, P. J. & Breteler, M. M.
(2005), ‘Fibrinogen is associated with an increased risk of Alzheimer disease
and vascular dementia’, Stroke 36, 2637–2641.
Vermeer, S. E., Prins, N. D., den Heijer, T., Hofman, A., Koudstaal, P. J. &
Breteler, M. M. (2003), ‘Silent brain infarcts and the risk of dementia and
cognitive decline’, N. Engl. J. Med. 348, 1215–1222.
Verschuur, M., de Jong, M., Felida, L., de Maat, M. P. & Vos, H. L. (2005), ‘A
hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for
interleukin 6-induced expression, and its activity is influenced by the adjacent
-148C/T polymorphism’, J. Biol. Chem. 280, 16763–16771.
Verzilli, C., Shah, T., Casas, J. P., Chapman, J., Sandhu, M., Debenham, S. L.,
Boekholdt, M. S., Khaw, K. T., Wareham, N. J., Judson, R., Benjamin, E. J.,
Kathiresan, S., Larson, M. G., Rong, J., Sofat, R., Humphries, S. E., Smeeth,
L., Cavalleri, G., Whittaker, J. C. & Hingorani, A. D. (2008), ‘Bayesian meta-
analysis of genetic association studies with different sets of markers’, Am. J.
Hum. Genet. 82, 859–872.
Visser, M., Bouter, L. M., McQuillan, G. M., Wener, M. H. & Harris, T. B.
(1999), ‘Elevated C-reactive protein levels in overweight and obese adults’,
JAMA 282, 2131–2135.
229
Viviani, B., Bartesaghi, S., Corsini, E., Galli, C. L. & Marinovich, M. (2004),
‘Cytokines role in neurodegenerative events’, Toxicol. Lett. 149, 85–89.
Wang, Q., Hunt, S. C., Xu, Q., Chen, Y. E., Province, M. A., Eckfeldt, J. H.,
Pankow, J. S. & Song, Q. (2006), ‘Association study of CRP gene polymor-
phisms with serum CRP level and cardiovascular risk in the NHLBI Family
Heart Study’, Am. J. Physiol. Heart Circ. Physiol. 291, H2752–2757.
Wechsler, D. (1998a), Wechsler Adult Intelligence Scale (UK), third edn, The
Psychological Corporation: London.
Wechsler, D. (1998b), WMS-III UK: Wechsler memory scale administration and
scoring manual, The Psychological Corporation: London.
Welsh, P., Woodward, M., Rumley, A. & Lowe, G. (2008), ‘Associations of plasma
pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with
cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA
study’, Br. J. Haematol. 141, 852–861.
Wetterling, T., Kanitz, R. D. & Borgis, K. J. (1996), ‘Comparison of different
diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-
AIREN)’, Stroke 27, 30–36.
Weuve, J., Ridker, P. M., Cook, N. R., Buring, J. E. & Grodstein, F. (2006),
‘High-sensitivity C-reactive protein and cognitive function in older women’,
Epidemiology 17, 183–189.
Whalley, L. J. (2002), ‘Brain ageing and dementia: what makes the difference?’,
Br J Psychiatry 181, 369–371.
Whalley, L. J., Deary, I. J., Appleton, C. L. & Starr, J. M. (2004), ‘Cognitive
reserve and the neurobiology of cognitive aging’, Ageing Res. Rev. 3, 369–382.
Williams, G. & Pickup, J. C. (1999), Handbook of Diabetes, second edn, Blackwell
Science.
Wilson, C. J., Cohen, H. J. & Pieper, C. F. (2003), ‘Cross-linked fibrin
degradation products (D-dimer), plasma cytokines, and cognitive decline in
community-dwelling elderly persons’, J Am Geriatr Soc 51, 1374–1381.
Wright, C. B., Sacco, R. L., Rundek, T. R., Delman, J. B., Rabbani, L. E. &
Elkind, M. S. (2006), ‘Interleukin-6 is associated with cognitive function: the
Northern Manhattan Study’, J Stroke Cerebrovasc Dis 15, 34–38.
230
Yaffe, K., Blackwell, T., Whitmer, R. A., Krueger, K. & Barrett Connor, E.
(2006), ‘Glycosylated hemoglobin level and development of mild cognitive im-
pairment or dementia in older women’, J Nutr Health Aging 10, 293–295.
Yaffe, K., Lindquist, K., Penninx, B. W., Simonsick, E. M., Pahor, M.,
Kritchevsky, S., Launer, L., Kuller, L., Rubin, S. & Harris, T. (2003), ‘In-
flammatory markers and cognition in well-functioning African-American and
white elders’, Neurology 61, 76–80.
Yang, Q., Tofler, G. H., Cupples, L. A., Larson, M. G., Feng, D., Lindpaintner,
K., Levy, D., D’Agostino, R. B. & O’Donnell, C. J. (2003), ‘A genome-wide
search for genes affecting circulating fibrinogen levels in the Framingham Heart
Study’, Thromb. Res. 110, 57–64.
Yankner, B. A., Lu, T. & Loerch, P. (2008), ‘The aging brain’, Annu Rev Pathol
3, 41–66.
Yao, S. T., Hobbs, J. T. & Irvine, W. T. (1969), ‘Ankle systolic pressure measure-
ments in arterial disease affecting the lower extremities’, Br J Surg 56, 676–679.
Yasojima, K., Schwab, C., McGeer, E. G. & McGeer, P. L. (2001), ‘Generation
of C-reactive protein and complement components in atherosclerotic plaques’,
Am. J. Pathol. 158, 1039–1051.
Yeh, E. T. (2005), ‘A new perspective on the biology of C-reactive protein’, Circ.
Res. 97, 609–611.
Yu, H. & Rifai, N. (2000), ‘High-sensitivity C-reactive protein and atherosclerosis:
from theory to therapy’, Clin. Biochem. 33, 601–610.
Yudkin, J. S., Stehouwer, C. D., Emeis, J. J. & Coppack, S. W. (1999), ‘C-reactive
protein in healthy subjects: associations with obesity, insulin resistance, and
endothelial dysfunction: a potential role for cytokines originating from adipose
tissue?’, Arterioscler. Thromb. Vasc. Biol. 19, 972–978.
Zee, R. Y. & Ridker, P. M. (2002), ‘Polymorphism in the human C-reactive
protein (CRP) gene, plasma concentrations of CRP, and the risk of future
arterial thrombosis’, Atherosclerosis 162, 217–219.
Zhang, Y. X., Cliff, W. J., Schoefl, G. I. & Higgins, G. (1999), ‘Coronary C-
reactive protein distribution: its relation to development of atherosclerosis’,
Atherosclerosis 145, 375–379.
231
Zigmond, A. S. & Snaith, R. P. (1983), ‘The hospital anxiety and depression
scale’, Acta Psychiatr Scand 67, 361–370.
Zouki, C., Beauchamp, M., Baron, C. & Filep, J. G. (1997), ‘Prevention of In
vitro neutrophil adhesion to endothelial cells through shedding of L-selectin
by C-reactive protein and peptides derived from C-reactive protein’, J. Clin.
Invest. 100, 522–529.
Zouki, C., Haas, B., Chan, J. S., Potempa, L. A. & Filep, J. G. (2001), ‘Loss
of pentameric symmetry of C-reactive protein is associated with promotion of






lm(formula = fAVLT ~ Age + Sex + APOE, data = AAA)
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 100.97284 4.62311 21.841 <2e-16 ***
Age -0.52492 0.06048 -8.679 <2e-16 ***
SexM -7.73929 0.87143 -8.881 <2e-16 ***
APOEe2e3 1.85050 2.63195 0.703 0.482
APOEe2e4 -1.23080 3.55942 -0.346 0.730
APOEe3e3 -0.27416 2.42319 -0.113 0.910
APOEe3e4 -0.69777 2.51362 -0.278 0.781
APOEe4e4 -3.62035 3.75895 -0.963 0.336
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
### RAVENS ###
lm(formula = fRAVENS ~ Age + Sex + APOE, data = AAA)
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 63.35087 2.58461 24.511 < 2e-16 ***
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Age -0.43507 0.03404 -12.780 < 2e-16 ***
SexM 1.65709 0.48174 3.440 0.000597 ***
APOEe2e3 1.08932 1.44103 0.756 0.449805
APOEe2e4 -0.98802 1.95303 -0.506 0.613005
APOEe3e3 0.49080 1.32249 0.371 0.710599
APOEe3e4 -0.04059 1.37600 -0.030 0.976468
APOEe4e4 -2.34450 2.04319 -1.147 0.251363
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
### VFT ###
lm(formula = fVFT ~ fAge + Sex + APOE, data = AAA)
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 45.19938 3.67556 12.297 <2e-16 ***
fAge -0.10930 0.04837 -2.260 0.0240 *
SexM -0.58830 0.69684 -0.844 0.3987
APOEe2e3 0.55757 2.06981 0.269 0.7877
APOEe2e4 -0.19963 2.75584 -0.072 0.9423
APOEe3e3 0.05874 1.89907 0.031 0.9753
APOEe3e4 -0.77910 1.97300 -0.395 0.6930
APOEe4e4 1.94960 3.03687 0.642 0.5210
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
### DST ###
lm(formula = fDST ~ fAge + Sex + APOE, data = AAA)
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 83.09313 3.00751 27.629 < 2e-16 ***
fAge -0.63158 0.03932 -16.062 < 2e-16 ***
SexM -4.40919 0.56763 -7.768 1.38e-14 ***
APOEe2e3 1.91114 1.71171 1.117 0.264
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APOEe2e4 1.78532 2.27392 0.785 0.432
APOEe3e3 0.99043 1.57463 0.629 0.529
APOEe3e4 0.30485 1.63404 0.187 0.852
APOEe4e4 -2.14914 2.45146 -0.877 0.381
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
### TMT ###
lm(formula = log(fTMT) ~ fAge + Sex + APOE, data = AAA)
Residuals:
Min 1Q Median 3Q Max
-1.05805 -0.27184 -0.03239 0.23173 2.08397
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 3.296244 0.110924 29.716 < 2e-16 ***
fAge 0.018896 0.001455 12.989 < 2e-16 ***
SexM 0.083966 0.020947 4.009 6.38e-05 ***
APOEe2e3 -0.054276 0.062954 -0.862 0.389
APOEe2e4 0.095416 0.084144 1.134 0.257
APOEe3e3 0.026141 0.057878 0.452 0.652
APOEe3e4 0.041574 0.060101 0.692 0.489
APOEe4e4 0.041150 0.090052 0.457 0.648
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
### g ###
lm(formula = follow-up.g ~ Age + Sex + APOE, data = AAA)
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 3.406544 0.284548 11.972 < 2e-16 ***
fAge -0.050255 0.003744 -13.423 < 2e-16 ***
SexM -0.270226 0.053028 -5.096 3.91e-07 ***
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APOEe2e3 0.186092 0.159237 1.169 0.243
APOEe2e4 -0.104824 0.214190 -0.489 0.625
APOEe3e3 0.053004 0.146581 0.362 0.718
APOEe3e4 -0.003060 0.152422 -0.020 0.984
APOEe4e4 -0.185932 0.226567 -0.821 0.412
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
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Appendix B
JAGS code for Bayesian
Mendelian randomisation
## Remove all objects from the current R environment
rm(list=ls())
## Load the genetics library
library(genetics)
## Load the snpMatrix library
library(snpMatrix)
#############################################################
## AAA Trial dataset - CRP
#############################################################
## Read the AAA Trial data from a text file
data <- read.table("AAA.txt", header=T)
## Convert the four CRP SNP data into genotypes
genotypes <- data[,21:24]
## Should check that pairs of alleles are ordered alphabetically
## Factor levels are ordered alphabetically
## Re-writes the genotypes as integers with either 0, 1, or 2
## copies of the first (alphabetically) allele and prints the
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## Hardy-Weinberg p-value for each of the SNPs.
for(col in 1:dim(genotypes)[2]) {
cat(dimnames(genotypes)[[2]][col], table(genotypes[, col]))




## Choose SNPs and remove those out of Hardy-Weinberg equilibrium
g <- as.matrix( genotypes[, dimnames(genotypes)[[2]]])
## The mean of the genotypes -- a number between 0 and 2
g.bar <- apply(g, 2, mean, na.rm=TRUE)
## The total number of SNPs
T <- dim(g)[2]
## The number of cases
N <- dim(data)[1]
## The outcome variable, general intelligence
y <- data$follow.g - 1
## Age at follow-up
age <- data$fAge
## Age centred about zero
age <- age - mean(age, na.rm=TRUE)
## Sex, re-written as integers
sex <- as.integer(data$Sex)
## Mean sex i.e. proportion of men in the study
sex.bar <- mean(sex, na.rm=TRUE)
## The intermediate variable, log of baseline CRP, which is standardised
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x <- log(data$bCRP)
x.bar <- mean(x, na.rm=TRUE)
x.sd <- sd(x, na.rm=TRUE)
x <- x - x.bar
x <- x / x.sd
## Plausible measurement precision for x
tau.xmeas <- 4
## The variance of the ratio of causal:crude evidence for an
## association between CRP and g was set to 25, which corresponds
## to a precision of 1/25 = 0.04
tau.theta <- 0.04
## Writes the list of variables to the file crpdata.R
dump(c("N", "y", "x", "age", "sex", "sex.bar", "T", "g", "g.bar",
"tau.xmeas", "tau.theta"),
file="crpdata.R")
## Prints the number of genotypes typed for each SNP
nogenotypes <- logical(N)
for(i in 1:N) {
nogenotypes[i] <- !sum(as.integer(!is.na(genotypes[i, ])))
}
cat("Number genotyped", dim(genotypes[!nogenotypes, ])[1], "\n")
## Standard regression analyses
## CRP and ’g’ on genotype
for(locus in (1:dim(genotypes)[2])) {
cat("\nRegression of x and y on", dimnames(genotypes)[[2]][locus], "\n")
print(summary.glm(glm(x ~ age + sex + genotypes[, locus],
family="gaussian"))$coefficients[4, ])




## Regression of ’g’ on CRP
cat("\nRegression of y on x\n")
print(summary.glm(glm(y ~ age + sex + x,
family="gaussian"))$coefficients[4, ])
#############################################################
## The model - built in JAGS
## Observed data: Continuous outcome y (’g’), intermediate phenotype x
## (plasma CRP), SNP genotype g (CRP SNPs).
## Unmeasured confounder c (age and sex) has effects on both x and y.
model{
## Coefficients for regression of x on g
## Diffuse Gaussian priors for regression coefficients
## Diffuse Gamma prior on tau.x, the precision of plasma CRP
## Beta prior on locus provides weight towards heterozygotes
beta0.x ~ dnorm(0, 0.001);
for(locus in 1:T) {
beta.gx[locus] ~ dnorm(0, 0.001);
phi[locus] ~ dbeta(0.5, 0.5);
}
beta.sex.x ~ dnorm(0, 0.001);
beta.age.x ~ dnorm(0, 0.001);
tau.x ~ dgamma(0.01, 0.01);
## Coefficients for regression of y on resid.x -- diffuse Gaussian priors
beta0.y ~ dnorm(0, 0.001);
beta.ry ~ dnorm(0, 0.001);
beta.sex.y ~ dnorm(0, 0.001);
beta.age.y ~ dnorm(0, 0.001);
theta ~ dnorm(0, tau.theta);
## Beta prior on allele freq
phi.ns ~ dbeta(0.5, 0.5);
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## Beta prior on sex ratio
phi.sex ~ dbeta(1, 1);
## Gaussian prior on age with Gamma prior for precision
mu.age ~ dnorm(0, 0.001);
tau.age ~ dgamma(0.001, 0.001);
## Gamma prior for precision of ’g’
tau.y ~ dgamma(0.001, 0.001);
## Each genotype allele is Binomially distributed
for(i in 1:N) {
for(locus in 1:T) {
g[i, locus] ~ dbin(phi[locus], 2);
}
## Sex follows a Bernoulli distribution
sex[i] ~ dbern(phi.sex);
## Age follows a Normal distribution
age[i] ~ dnorm(mu.age, tau.age);
## A beta weight for the genotypes, which combines information
## from all SNPs typed
beta.gxg[i] <- sum(beta.gx * (g[i, ] - g.bar));
## Effect of genotype and confounder on intermediate phenotype
mu.x[i] <- beta0.x +
beta.sex.x * (sex[i] - sex.bar) + beta.age.x * age[i] +
beta.gxg[i];
## True value of intermediate phenotype
xlatent[i] ~ dnorm(mu.x[i], tau.x);
## xmeas is measurement precision
x[i] ~ dnorm(xlatent[i], tau.xmeas);
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## Random effect on x includes confounder
resid.x[i] <- x[i] - mu.x[i];
## Regression of y on resid.x under H0
mu.y[i] <- beta0.y +
beta.sex.y * (sex[i] - sex.bar) + beta.age.y * age[i] +
beta.ry * (theta * mu.x[i] + resid.x[i]);




## Commands to run the model in JAGS and notification of the parameters





parameters in init1.txt, chain(1)


















## A function to calculate the log likelihood function for theta.
loglikFromSamplesN <- function(mu=0, sigmasq, x.samples, bwspec=0.25) {
## prior N(mu, sigmasq), posterior samples x.samples
## log likelihood = log (posterior weighted by inverse of prior density)
## invprior <- exp(0.5* (x.samples - mu)^2 / sigmasq) *
## sqrt(2 * pi * sigmasq)
invprior <- 1/ dnorm(x.samples, mean=mu, sd=sqrt(sigmasq))
invsum <- 1 / sum(invprior)
invprior <- invsum * invprior
d <- density(x.samples, weights=invprior, bw=bwspec)
x <- d[[1]]
logL <- log(d[[2]])
## Scale logL to have value zero at first positive value of x
## FIXME - use interpolation





## Generate initial values from two chains to reduce probability of













cat("Time elapsed", Sys.time() - t0, "\n")
## Collate the output from the MCMC
s.instrumental <- mcmc.list(read.coda("CODAchain1.txt", "CODAindex.txt"),
read.coda("CODAchain2.txt", "CODAindex.txt"))







## Log likelihood function for theta













## Calculate and plot likelihood function
sigmasq <- 1 / tau.theta # prior variance
theta.samples <- data.frame(s.instrumental[[1]])$theta
z <- loglikFromSamplesN(0, sigmasq, theta.samples, 0.25)
pdf("thetalik.pdf")
plot(z[, 1], z[, 2], type="l",
xlab="Ratio causal / crude effect of \nintermediate phenotype on outcome",














Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
AVLT -0.004 (0.98) 1254 0.040 (1.05) 607 -0.220 (0.93) 89
RAVENS 0.021 (0.99) 1204 -0.044 (1.02) 601 0.015 (1.01) 85
VFT -0.023 (0.99) 1276 0.009 (1.00) 628 0.253 (1.07) 93
DST 0.010 (0.98) 1295 -0.037 (1.05) 639 0.110 (0.96) 93
ln(TMT) -0.017 (1.00) 1287 0.037 (1.01) 625 -0.021 (0.87) 94
g 0.010 (0.98) 1146 -0.026 (1.04) 567 0.035 (0.96) 83
rs2070016
CC CT TT
Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
AVLT -0.019 (1.00) 40 -0.047 (1.02) 495 0.017 (0.99) 1422
RAVENS -0.162 (0.84) 39 0.021 (1.01) 474 -0.003 (1.00) 1384
VFT 0.025 (1.05) 42 0.030 (1.07) 502 -0.011 (0.98) 1458
DST -0.275 (1.01) 45 -0.011 (1.00) 506 0.012 (1.00) 1482
ln(TMT) 0.217 (0.91) 45 0.016 (1.05) 506 -0.012 (0.98) 1461
g -0.168 (1.02) 35 -0.005 (1.02) 453 0.006 (0.99) 1314
rs4220
AA GA GG
Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
AVLT -0.038 (1.07) 53 -0.028 (1.01) 551 0.013 (0.99) 1338
RAVENS -0.130 (0.87) 51 0.048 (1.02) 528 -0.014 (1.00) 1303
VFT -0.161 (0.86) 53 0.071 (1.06) 561 -0.023 (0.98) 1373
DST -0.242 (1.02) 57 0.017 (1.01) 567 0.003 (0.99) 1394
ln(TMT) 0.213 (0.92) 57 -0.019 (1.05) 561 -0.001 (0.98) 1379
g -0.154 (1.04) 47 0.045 (1.03) 504 -0.012 (0.99) 1236
rs2227412
AA GA GG
Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
AVLT -0.009 (0.98) 1291 0.037 (1.04) 581 -0.139 (0.94) 71
RAVENS 0.026 (0.99) 1246 -0.051 (1.02) 570 -0.041 (1.00) 67
VFT -0.023 (1.01) 1315 0.025 (0.98) 601 0.210 (1.08) 74
DST 0.026 (0.99) 1335 -0.063 (1.03) 610 0.053 (0.98) 74
ln(TMT) -0.015 (1.02) 1324 0.027 (0.99) 599 0.048 (0.81) 75
g 0.017 (0.99) 1181 -0.037 (1.03) 544 -0.0003 (0.95) 65






Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
MR -0.003 (0.99) 19 0.068 (1.01) 241 -0.023 (1.00) 725
LNS 0.039 (0.73) 19 0.054 (0.96) 254 -0.020 (1.02) 718
VFT -0.181 (0.79) 20 0.043 (0.94) 255 -0.010 (1.02) 727
DST -0.002 (1.24) 20 0.022 (0.94) 253 -0.007 (1.01) 727
ln(TMT) 0.284 (1.06) 20 0.004 (0.97) 253 -0.009 (1.01) 722
FACES -0.222 (0.83) 20 0.055 (1.02) 253 -0.013 (1.00) 728
LM 0.073 (0.96) 20 -0.027 (1.01) 252 0.007 (1.00) 720
g -0.084 (0.92) 19 0.019 (0.98) 247 -0.005 (1.01) 699
rs4220
AA GA GG
Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
MR -0.111 (0.93) 27 0.038 (0.99) 280 -0.011 (1.01) 686
LNS -0.192 (0.83) 27 0.047 (1.00) 282 -0.012 (1.01) 680
VFT -0.260 (0.79) 27 0.054 (0.97) 285 -0.012 (1.02) 689
DST 0.036 (0.99) 27 -0.027 (0.95) 284 0.010 (1.02) 687
ln(TMT) 0.118 (0.88) 27 0.065 (0.99) 283 -0.031 (1.01) 683
FACES -0.067 (1.11) 27 -0.025 (0.99) 284 0.013 (1.00) 689
LM -0.233 (0.96) 27 -0.005 (0.99) 281 0.011 (1.01) 683
g -0.234 (0.77) 27 -0.007 (0.95) 274 0.012 (1.03) 661
rs2227412
AA GA GG
Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
MR 0.055 (0.99) 705 -0.138 (1.03) 279 -0.019 (0.93) 30
LNS 0.049 (1.00) 702 -0.140 (0.98) 277 0.133 (1.02) 31
VFT 0.074 (0.99) 710 -0.175 (1.00) 281 -0.112 (1.04) 31
DST 0.077 (0.97) 711 -0.219 (1.03) 277 0.204 (1.17) 31
ln(TMT) -0.053 (0.99) 707 0.147 (1.01) 277 -0.112 (1.06) 30
FACES 0.042 (0.97) 709 -0.103 (1.07) 281 -0.015 (1.01) 31
LM 0.018 (1.01) 703 -0.061 (0.98) 278 0.146 (1.04) 31
g 0.075 (0.97) 686 -0.207 (1.04) 268 0.143 (1.04) 29






Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
MR 0.072 (0.91) 17 -0.080 (1.02) 237 0.022 (1.00) 791
LNS 0.575 (1.12) 17 -0.093 (1.07) 235 0.015 (0.97) 786
VFT -0.051 (0.89) 17 -0.026 (1.00) 237 0.009 (1.00) 791
DST -0.095 (0.88) 17 -0.032 (0.99) 237 0.012 (1.01) 790
LM 0.241 (0.74) 17 -0.070 (0.99) 236 0.016 (1.01) 794
g 0.223 (0.83) 17 -0.089 (1.03) 235 0.022 (0.99) 778
rs4220
AA GA GG
Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
MR 0.225 (0.80) 25 -0.077 (1.04) 274 0.020 (0.99) 754
LNS 0.159 (0.91) 25 -0.055 (1.04) 272 0.015 (0.99) 749
VFT -0.005 (1.05) 25 -0.040 (1.01) 274 0.015 (0.99) 754
DST 0.082 (0.83) 25 -0.084 (0.98) 273 0.028 (1.01) 754
LM -0.034 (0.80) 25 -0.111 (1.01) 274 0.042 (1.00) 756
g 0.124 (0.74) 25 -0.117 (1.03) 271 0.039 (1.00) 742
rs2227412
AA GA GG
Cognitive Test mean (s.d.) n mean (s.d.) n mean (s.d.) n
MR 0.019 (1.00) 704 -0.026 (1.00) 300 -0.166 (1.04) 35
LNS 0.009 (1.02) 699 -0.018 (0.96) 299 -0.019 (1.01) 34
VFT -0.033 (0.99) 702 0.075 (1.00) 302 0.019 (1.11) 35
DST 0.003 (1.00) 704 -0.002 (0.99) 299 -0.041 (1.08) 35
LM 0.020 (0.99) 704 -0.017 (1.02) 302 -0.246 (0.97) 35
g 0.010 (0.99) 694 -0.013 (1.01) 296 -0.082 (1.04) 34
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